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SUMMARY 
Ataxia telangiectasia and Rad3-related (ATR) is a central regulator of the mammalian DNA 
damage response. ATR is essential for survival, but hypomorphic mutations in ATR are 
associated with a subset of Seckel syndrome (ATR-S), a human condition characterised by 
microcephaly and severe growth retardation. I used patient-derived cell lines, as well as siRNA 
ATR inhibition to evaluate the impact of ATR deficiency in skeletal development (osteogenesis 
and chondrogenesis). The expression of chondroinduction-specific markers was also assessed and 
found impaired in ATR-S and PCNT-S patient-derived primary fibroblasts. I also found signs of 
insulin/PI3K/mTOR signalling deregulation in both ATR as well as PCNT deficient cells. A 
checkpoint defect in a disorder with a primary defect in mTOR pathway function, Donohue 
Syndrome, was also uncovered, establishing a link between defects in insulin/mTOR signalling 
with deregulation of the DNA damage response/checkpoint machinery, possibly via the glycogen 
synthase kinase 3β, GSK3 β, in human patient cells. I characterized cellular functional aspects of 
a novel microcephalic disorder, Microcephaly-Capillary Malformation Syndrome (MIC-CAP), 
caused by mutations in the endosome-associated deubiquitinase enzyme STAMBP. MIC-CAP 
cells exhibit compromised RAS-MAPK and PI3K-AKT pathway signalling, and defective ATR-
dependent DDR, a common feature of microcephalic disorders. I also characterized aspects of 
PI3K-AKT signalling in two megalencephaly disorders harbouring novel mutations in core 
components of this pathway. Finally, I evaluated aspects of mTOR pathway function in cells from 
a genomic disorder caused by copy-number variation of 1q21.1. 
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2 
 
Introduction  
Perturbation of organism size, growth and development, and the mechanisms 
that regulate it, are of key understanding in human disease. Primordial dwarfism is a 
term that designates a group of human disorders displaying extreme global growth 
failure, which usually also manifests with proportionally reduced (or even smaller) 
head size (microcephaly) (McKusick 1955; Rauch et al. 2008). Severe microcephaly 
is defined as occipitofrontal circumference (OFC) 3 standard deviations or more 
below the norm for the age and gender (Verloes et al. 2004; Woods 2004). 
Microcephalic primordial dwarfism (MPD) is then a group of autosomal recessive 
conditions (subtypes described in 1.2) that couples acute intrauterine and postnatal 
growth retardation with severe microcephaly and mental retardation.  
Organ and organismal size is effectively determined by cell number and volume 
(Conlon and Raff 1999). Some of the mechanisms that regulate organism growth will 
also be discussed further below. 
In this thesis, I will present several distinct though interwoven stories concerning 
the interaction between aspects of the DNA damage response (DDR), cell cycle 
checkpoint control and mTOR pathway function using cell lines form various human 
disorders including MPD, megalencephaly disorders and metabolic disorders. 
Collectively, this data highlights the importance of the functional crosstalk between 
these distinct pathways for normal human development. But first, I will provide 
some background on the origin of microcephaly and related human disorders to 
overview their aetiology and molecular pathologies 
  
1.1 Mammalian brain development  
 
Reduced head size is the reflection of reduced cerebral cortex volume, likely 
linked to impaired neural cell proliferation and/or increased apoptosis during early 
embryogenesis. Several classes of neuroprogenitor cells undergo rapid and sustained 
cellular proliferation, migration and differentiation at the foetal neural tube: 
neuroepithelial cells (NE), radial-glial cells and basal (or intermediate) progenitors 
(Thornton et al. 2009). The totality of neurons produced during the development of 
the CNS is determined by type and number of cell divisions undergone by these 
progenitor cells. NE cells are the original progenitor cells, extending from the basal 
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lamina to the apical ventricular layer. NE cells divide symmetrically laterally to 
generate more progenitor cells, or asymmetrically to originate the other 
“downstream” types of progenitor cells. Both symmetric and asymmetric divisions of 
the all these types of progenitor cells give rise to the neurons (Huttner et al. 2005; 
Götz et al. 2005).  
NE cell are polarized along the apical-basal axis in the neural epithelium, 
with the nucleus migrating between the surfaces. S-phase occurs with the nucleus 
located near the basal lamina, which then migrates towards the apical surface where 
mitosis occurs. The apical-basal polarity in the neuroepithelium is important for the 
establishment of the cleavage plan for symmetric and asymmetric cell divisions 
(Huttner et al. 2005; O'Driscoll et al. 2008).  
 
 
Figure 1.1 Symmetric vs asymmetric progenitor cell division. 
Orientation of the mitotic spindle is perpendicular to the apical-basal axis during symmetric cell 
division, with the resulting cleavage plan intersecting the apical PM. A deviation in the orientation of 
the mitotic spindle gives rise to an asymmetric cell division, with only one of the daughter cells 
inheriting the apical PM region. 
 
The apical plasma membrane of NE cells is attached by adherens junctions to 
the apical surface. Asymmetric cell division would result in apical cells constituents 
being inherited by one daughter cells, and basal constituents by the other, giving rise 
to one other progenitor cell and a neuron. An unequal inheritance of polarized cell 
constituents such as the apical PM means that both symmetric as well as asymmetric 
cell divisions can derive from a perpendicular cleavage plan. The correct orientation 
of the mitotic spindle is therefore crucial during neurogenesis, and highly regulated. 
The number of rounds of symmetric proliferative divisions undergone by NE cells 
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determines the ultimate number of neurons. As neurogenesis progresses, increased 
asymmetric divisions means that only one daughter cell inherits the apical PM and 
remains a NE cell, while the other becomes either a basal progenitor, a radial-glial 
cell or a neuron (S. Zhang et al. 2007; Götz et al. 2005; Huttner et al. 2005).  
 Additionally, cell cycle length plays a role in proliferative vs differentiating 
cell divisions. Longer cell cycles have been associated with differentiating divisions, 
while for example shortening of G1 phase has been linked to an increase in 
proliferative divisions (O'Driscoll et al. 2008). Reduced neuroprogenitor proliferative 
capacity is a likely cause of microcephaly. 
 
1.1.1 Primary microcephaly 
 
Reduction of brain size in MPD is similar to that observed in autosomal 
recessive primary microcephaly (MCPH). MCPH patients exhibit significantly 
prenatal brain size reduction, but not usually associated with pronounced alterations 
in the brain architecture (Poulton et al. 2011). This suggests that defective 
neurogenic proliferation could underlie the microcephaly seen in MCPH. These 
patients have mild to moderate mental retardation, but do not share other clinical 
features typical of MPD, such as severe growth retardation and skeletal abnormalities 
(Woods 2004).  
Several susceptibility loci have been linked to primary microcephaly to date 
(Table 1), and all the MCPH proteins identified so far associate with the centrosome 
(Thornton et al. 2009).  
 
Table 1.1 Primary microcephaly loci. 
(adapted from Thornton and Woods 2009) 
locus OMIM Chromosome location Gene  
MCPH1 251200 8p23 Microcephalin (MCPH1) 
MCPH2 604317 19q12 WDR62 
MCPH3 604804 9q33.3 CDK5RAP2/CEP215 
MCPH4 604321 15q21.1 CEP152 
MCPH5 608716 1q31 ASPM 
MCPH6 608393 13q12.2 CENPJ 
MCPH7 612703 1p32 STIL 
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MCPH1 encodes a BRCT domain containing protein that functions in cell cycle 
progression and also in the DNA damage response, both mechanisms that are known 
to affect neurogenesis. MCPH1 is required for the recruitment of DDR proteins 
(Doxsey, et al. 2005; X. Wu et al. 2009), and a defective G2/M checkpoint activation 
has also been observed in MCPH1 patient derived cells (Alderton et al. 2006). 
Studies have shown that MCPH1 and PCNT are responsible for the recruitment of 
the checkpoint kinase CHK1 to the centrosome, and loss of MCHP1 would result in 
premature entry into mitosis (Tibelius et al. 2009). ASPM (Abnormal Spindle 
Microcephaly Associated) localizes to mitotic spindle poles and is involved in 
spindle organization/positioning (Higgins et al. 2010), being highly expressed during 
the period of rapid proliferative expansion of the cerebral cortex in the mouse 
(Pulvers et al. 2010). CENPJ is required for centriole biogenesis, and loss of 
centrioles results in spindle malformation and defective chromosome segregation 
(Bond et al. 2005). The study of MCPH genes has highlighted the importance of 
centrosome function and spindle formation in the development of microcephaly, with 
impacts on other mechanisms such as defects in the DDR. 
 
1.2 MPD disorders 
 
Microcephalic primordial dwarfism encompasses a range of single-gene 
autosomal recessive disorders, which include Seckel-syndrome (SS), microcephalic 
osteodysplastic primordial dwarfism type II (MOPDII) and Meier-Gorlin syndrome 
(MGS). Disproportionally reduced brain size distinguishes MPD from other forms of 
dwarfism. 
 
1.2.1 Seckel syndrome 
 
A group of patients was described by Helmut Seckel in 1960 as “bird-
headed” or “nanocephalic” dwarfs, due to their characteristic facial features (Figure 
1.2) (Q. Wang et al. 2004; Seckel 1960). The term Seckel syndrome (OMIM 
210600) is now used to encompass unspecified and heterogeneous forms of 
microcephalic primordial dwarfism characterized by intrauterine and postnatal 
growth retardation, proportionate dwarfism, severe microcephaly (OFC -4 to -14SD) 
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and mental retardation, in addition to the typical facial features (Knoblich 2010; 
Majewski et al. 1982). Abnormalities associated with SS also include extremely 
delayed skeletal maturation with retarded ossification resulting in skeletal 
abnormalities (Jackman et al. 2003; Børglum et al. 2001); Acanthosis nigricans, a 
hyperpigmentation of the skin commonly caused by insulin resistance has also been 
reported in SS. The association of SS with cancer is not clear, but some cases have 
been reported  (Faivre et al. 2002; Butler et al. 1987). 
Consistent with the heterogeneity of the clinical features, a number of 
genomic susceptibility loci associated with SS have been identified to date. 
 The first locus was mapped to chromosome 3q22.1-q24 (Sckl1) where the 
disease was found to be caused by a mutation in the gene encoding the apical DDR 
protein ataxia-telangiectasia and RAD3-related (ATR) (Diviani et al. 2000; 
O'Driscoll et al. 2003). The single synonymous 2101A→G transition was shown to 
affect splicing efficiency resulting in low levels of ATR protein (Figure 1.2). Patient 
cell lines exhibited defects in the ATR-dependent DDR, such as impaired H2AX 
phosphorylation in response to UV irradiation (J. Kim et al. 2008; O'Driscoll et al. 
2003). Interestingly, microcephalin (MCPH1), the first causative gene linked with 
primary microcephaly, is also associated with defective ATR pathway function 
(Alderton et al. 2006).  
Mutations in the gene coding for the ATR interacting protein, ATRIP (ataxia-
telangiectasia and RAD3-related-interacting protein), phenocopy ATR loss (Tibelius 
et al. 2009; Ogi et al. 2012). Cells from an ATRIP-mutated SS patient also exhibit 
reduced ATR expression (due to lack of ATR/ATRIP co-stabilization) and impaired 
ATR-dependent DDR (S. Zhang et al. 2007; Ogi et al. 2012).  
Other SS-causing genetic defects identified include CENPJ and CEP152 
(Table 1.2). CENPJ (Centromere protein J; also known as CPAP) is a centrosomal 
protein with roles in spindle assembly/disassembly and centriole duplication, 
important for maintenance of centrosome integrity and cell cycle control (Chen et al. 
2006). CENPJ interacts with Pericentrin (PCNT), mutated in the SS-related 
MOPDII. CEP152 (centrosomal protein 152) is a scaffolding protein, component of 
the pericentriolar material, involved in recruitment of proteins to the centrosome. 
CEP152 interacts also with the Polo-like kinase, PLK4 and CENPJ. CEP152 
mutations have also been observed in primary microcephaly (Guernsey et al. 2010), 
as well as mutations in CEP63 (Sir et al. 2011). CEP63 is required for CDK1 
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localization to the centrosome (Löffler et al. 2011). Cep 63
-/-
 in DT40 cells results in 
mitotic spindle defects (Sir et al. 2011). 
Mutations in CtIP (CTBP-interacting protein), a protein involved in end-
resection at DSBs have also been identified in SS (Qvist et al. 2011). CtIP has an 
established role in DNA repair (Delaval and Doxsey 2010; Sartori et al. 2007), 
interacting with the MRN complex at sites of DSBs.  Loss of CtIP function in 
processing DSBs leads to a reduction of RPA-coated ssDNA regions and 
consequently compromised ATR activation (Qvist et al. 2011). A novel association 
between Seckel syndrome and the centrosomal protein ninein (NIN) was recently 
found (Dauber et al. 2012). 
 ATR knockdown is embryonic lethal. A mouse model of SS has been 
generated, incorporating the original Seckel syndrome ATR-splicing mutation 
(O'Driscoll et al. 2003) (Figure 1.2). The ATR-SS mouse exhibits all the hallmarks 
of SS, including the severe growth retardation and microcephaly with micrognathia 
(Murga et al. 2009). Elevated apoptosis was observed during embryogenesis in this 
model, as a consequence of increased replicative stress-induced DNA damage that 
results from ATR depletion (Murga et al. 2009). Notably, the authors noted a 
supressed Insulin-like Growth Factor-1/Growth hormone axis in the ATR-SS mouse, 
which could also have an impact on the growth retardation phenotype. Moreover, 
conditional Atr knockdown in adult mice results in depletion of a high percentage of 
proliferating cells and an age-related phenotype (Ruzankina et al. 2007). 
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Figure 1.2 ATR-Seckel Syndrome. 
a) SS patients show markedly reduced stature and microcephaly, with characteristic „bird-headed‟ 
profile (inset) with receding forehead, micrognathia, prominent teeth, microtia (small ears). b) 
pronounced skeletal abnormalities are also a feature of SS. c) western blot showing the reduced ATR 
protein expression in ATR-SS patient  cells (O'Driscoll et al. 2003). d) “humanized” ATR-Seckel 
mouse, incorporating the human ATR hypomorfic mutation, recapitulates SS clinical features (X. 
Yang et al. 2008; Murga et al. 2009). 
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1.2.2 MOPDII 
 
Microcephalic Osteodysplastic Primordial Dwarfism-type II (MOPDII) is a 
defined form of MPD, clinically similar to SS but regarded as a separate entity 
(Majewski and Goecke 1982). Distinguishing features include disproportionally 
shorter limbs, distinct skeletal features and microcephaly that progresses postnatally 
(Hall et al. 2004), accompanied by milder mental retardation. A risk of neurovascular 
problems (moyamoya disease) has been associated with MOPDII (Bober et al. 2010), 
with the life-threatening development of brain aneurysms and seizures (J. G. Hall et 
al. 2004). Additionally, MOPDII individuals develop insulin resistance during 
childhood (with acanthosis nigricans) and type II diabetes (Huang-Doran et al. 
2011).  
Mutations in the gene encoding pericentrin (PCNT) - a key structural 
centrosomal protein involved in spindle assembly during mitosis - have been 
identified in MOPDII (Griffith et al. 2008). PCNT mutations have been previously 
associated with patients clinically diagnosed as Seckel syndrome. Over- and mis-
diagnosis of SS has led to some confusion in the literature (Thompson and Pembrey 
1985), and the current opinion is now that the PCNT-Seckel patients reported are in 
fact MOPDII patients. For sake of simplicity I will use the term PCNT-S in this 
thesis to refer to PCNT-mutated MDP. Importantly, cells from PCNT-mutated Seckel 
syndrome/MOPDII patients are also defective in ATR-dependent DNA damage 
signaling, and PCNT knockdown results in compromised ATR-dependent checkpoint 
activation (Griffith et al. 2008).  
 
1.2.3 Meier-Gorlin syndrome 
 
Meier-gorlin syndrome (MGS), also known as “ear, patella and short stature” 
syndrome, is defined by absent or hypoplastic patellae (knee caps) and marked 
microtia (small ears) (Bongers et al. 2001). MGS patients have microcephaly with 
mild intellectual disability, growth failure and skeletal abnormalities (Faqeih, Sakati, 
and Teebi 2005). Mutations in the pre-replication complex components have recently 
been found in a group of MGS patients. Mutated MGS genes include ORC1, ORC4, 
ORC6, CDC6 and CDT1 . These mutations suggest a link between defective DNA 
replication (in this case origin licensing) and MPD.  Interestingly, ORC1 defective 
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MGS-patient derived cell lines also exhibit defects in the ATR-dependent signalling 
response to DNA damage (Sarah Walker, GDSC). 
 
Table 1.2 Genes mutated in MPD. 
Gene OMIM MPD Gene function 
ATR; ATRIP 210600 Seckel Master regulator of DDR 
CENPJ/CPAP 613676 Seckel Centriole biogenesis 
CEP152 613823 Seckel Centriole biogenesis; genome stability 
CEP63 614728 Seckel Centrosome function 
RBBP8(CtIP) 606744 Seckel DNA DSB resection 
NIN 614851 Seckel Centrosome function; microtubule organization 
PCNT 210720 MOPDII 
Component of pericentriolar material; scaffold 
for signaling molecules 
ORC1,ORC4,ORC6, 
CTD1, CDC6 
224690  613800 
613800  613804 
613805 
MGS 
Components of pre-replication complex; 
licensing of replication origins 
IGF1  IGF1 deficiency Endocrine/paracrine growth hormone 
U4atac 210710 MOPDI Spliceosome component 
 
Finally, Netchine and colleagues recently described an extremely rare 
syndrome caused by homozygous mutations in IGF-1 (Insulin-like Growth Factor-1) 
(Netchine et al. 2011).  The clinical presentation of IGF-1 mutated patients is 
extremely similar to other MPD types, including intrauterine and postnatal growth 
retardation, microcephaly and mental retardation. Sensorial deafness is a specific 
trait of this disorder. Additionally, insulin resistance, partial gonadal dysfunction and 
osteoporosis have also been observed in IGF-1 deficient patients (Netchine et al. 
2011). This supports a role for IGF-1 in neuronal development and growth. The 
authors suggest that recombinant IGF-1 therapy is likely beneficial to the 
management of this disorder. There are indications that growth hormone (GH) 
therapy in Seckel syndrome children had a positive effect on final height, associated 
with increased serum-levels of insulin-like growth factors (Guertin et al. 2006; 
Birkebaek et al. 2011). 
 
The intersection between ATR signaling and centrosomal proteins appears to 
be a recurrent theme in MDP. Overall, MPD-causative mutations seem to affect the 
efficiency of cell cycle progression, resulting in reduced cell number generated 
during development, in particular during neurogenesis, and consequently giving rise 
to small brain and body size. 
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1.3 DNA damage response  
 
Microcephaly is a common feature of many disorders associated with defective 
DNA damage response (DDR) (O'Driscoll and Jeggo 2008). An efficient DDR is 
therefore crucial during normal brain development. 
Maintenance of genomic stability and the faithful transmission of the 
information held within the DNA during cellular division is an essential function 
carried out by the cell cycle and the DDR machineries. Cells are susceptible to 
numerous agents that can cause damage to the DNA, both endogenous as well as 
exogenous. Reactive oxygen species (ROS), generated during normal metabolism, 
induce base and sugar lesions that can result in single stranded and double stranded 
DNA breaks (SSBs; DSBs) (Cooke et al. 2003; Cadet et al. 2003 ). DNA damage 
resulting from hydrolysis and methylation can also occur during normal cellular 
processes (DeBont 2004). DNA DSBs also occur during V(D)J recombination in 
developing B and T cells (Jeggo et al. 1995). Depending on cell cycle context (i.e. 
the presence of a homologous sister) DSBs are repaired by non-homologous end-
joining (NHEJ) in mammalian cells, and/or homologous recombination (HR) 
(Sargent et al. 1997). External agents such as ionizing radiation (IR) directly induce 
complex breaks in the genome, including DSBs. Additionally, exposure to UV 
radiation results in bulky lesions, including pyrimidine dimers, whose processing 
generates regions of ssDNA. UV-induced dimers also perturb the normal progression 
of replication and transcription complexes. Finally, chemicals such as the 
Ribonucleotide Reductase inhibitor hydroxyurea (HU), which causes replication fork 
arrest, can also result in DNA breaks (Sakano et al. 2001).  
DNA damage is a major source of mutagenesis, carcinogenesis and ageing. As 
such, cells have evolved complex and highly regulated mechanisms of detecting 
DNA damage, and either elicit the repair response, involving cell cycle arrest; or 
alternatively activate the programed cell death pathway, in order to prevent 
accumulation of mutations and proliferation of damaged cells. 
 The DDR is the coordination of DNA damage sensors, signal transducers, 
mediators and effector proteins (Harper et al. 2007; Zhou et al. 2000). 
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Figure 1.3 General outline of the DNA damage response signal-transduction pathway. DNA 
damage is detected by sensor proteins which then activate ATM/ATR. These transducers in turn 
signal to downstream effectors leading to either cell cycle arrest or apoptosis. 
 
The principal regulators of the DDR are the DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs), Ataxia telangiectasia mutated (ATM) and Ataxia 
telangiectasia and Rad3 related (ATR), which are members of the 
phosphatidylinositol 3-kinase like kinases (PIKKs) family of protein kinases. Other 
PIKKs include the mammalian target of rapamycin (mTOR), the suppressor of 
morphogenesis in genitalia (SMG1) and transformation/transcription domain-
associated protein (TTRAP) (Lempiäinen et al. 2009). The ATR and ATM kinases 
preferentially phosphorylate substrates with a consensus SQ/TQ motif, where a 
serine or threonine residue is followed by a glutamine (Shechter et al. 2004a). 
 
 
Figure 1.4 The PIKK family of kinases. The FATC (FRAP-ATM-TTRAP), SQ/TQ-directed protein 
kinase, PIKK-regulatory (PRD) and FAT-C (FAT-C terminal) domains of homology are indicated. 
The amino terminal region contains multiple HEAT (Huntington, Elongation factor 3, A subunit of 
protein phosphatase, TOR1) repeats (adapted from Derheimer et al. 2010). 
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The ATM and DNA-PKcs kinases are activated by DSBs, resulting for example 
from IR-induced damage. DNA-PKcs associates with Ku70-Ku80, forming the 
DNA-PK complex, which allows its recruitment to sites of DSB and DNA-PKcs 
activation. DNA-PKcs is important for NHEJ, a main DSB repair pathway (Burma 
and Chen 2004). 
ATM activation occurs early following DSB formation, via interaction with the 
Mre11-Rad50-Nbs1 (MRN) complex (Bakkenist and Kastan 2003), which is the 
initial sensor of the DNA damage. ATM is a primary transducer of the cellular 
response to DSBs, and activation of ATM-dependent cell cycle checkpoints can 
mediate cell cycle arrest, via some of the key ATM substrates: the checkpoint kinase 
2 (CHK2), p53, p21. ATM is mutated in the neurodegenerative disorder Ataxia 
telangiectasia (A-T; OMIM 208900), which is associated with cancer predisposition 
(O'Driscoll and Jeggo 2006). A-T patient cells are sensitive to killing by IR and 
agents that induce DSBs, and exhibit defective cell cycle checkpoint activation 
(Riballo et al. 2004).  
 
 
1.4 ATR activation/ ATR-dependent signaling 
ATR, together with ATM, constitute the two key apical regulators of the 
mammalian DDR and cell cycle checkpoint pathways.  
ATR is activated by regions of single-stranded DNA (ssDNA), generated during 
normal replication or replication-fork stalling in S-phase, or as an intermediate in 
DNA repair pathways like the nucleotide excision repair (NER) and homologous 
recombination (HR) pathways (Byun et al. 2005). ATR can also be activated by 
persistent DSBs in late S-phase or G2, in an ATM-dependent manner, following 
resection to generate single-stranded regions of DNA (de Klein et al. 2000; Ward, 
Minn, and Chen 2004; Brown and Baltimore 2000; Byun et al. 2005). 
ATR exists in the cells in a stable complex with the ATR-interacting protein 
(ATRIP), and the expression of each protein is dependent on the other (Lawlor et al. 
2002; Cortez et al. 2001). The structure that effectively activates ATR is a region of 
RPA (Replication-protein A)-coated ssDNA, next to a region of dsDNA with a 5‟ 
end (Chalhoub et al. 2009; Cimprich and Cortez 2008). These structures are formed 
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normally during normal replication, or as a consequence of replication fork stalling 
(Zou et al. 2003). RPA-coated ssDNA is also an intermediate of repair pathways 
such as NER, and therefore ATR-dependent signaling is not just required in 
replicating cells but throughout the cell cycle as part of the DDR (O'Driscoll et al. 
2003). The heterotrimeric RPA complex is composed of three subunits (RPA1-3) and 
promotes ssDNA stabilization, with important roles during replication as well as the 
assembly of signaling complexes onto sites of DNA damage. ATRIP is recruited to 
single stranded regions of DNA through its affinity for RPA, thus localizing ATR to 
sites of DNA damage/replication fork stalling. UV radiation elicits the NER pathway 
to remove the damage caused by the pyrimidine dimers. This results in the formation 
of RPA-coated ssDNA intermediates during the repair process, which activate ATR 
signaling. ATR-deficient cells are therefore sensitive to UV and replication inhibitors 
(O'Driscoll et al.2003). ATR can also be activated by IR in an ATM dependent 
manner.     
Chromatin-bound RAD9/RAD1/HUS1 (9-1-1 complex), recruited to sites of 
DNA damage under regulation of the RAD17/RFC2-5 complex (RSR), facilitates 
ATR activation and ATR-mediated substrate phosphorylation (Bermudez et al. 2003; 
You et al. 2002) (Figure 1.5). 
 
15 
 
 
Figure 1.5 Model for ATR recruitment and activation.  ssDNA (generated during DNA synthesis; 
or at resected double-strand DNA breaks for example), rapidly becomes coated with the stabilizing 
protein RPA, providing the signal that initiates an ATR-dependent response. RPA recruits ATRIP, 
which exists in a complex with ATR, localizing the kinase to the sites of DNA lesion. Additionally, 
RPA recruits Rad17, which loads the 9-1-1 complex. This steps are important to then recruit TopBP1, 
which activates ATR.  
 
Recruitment of the RAD17/RFC2-5 complex to chromatin at DNA ends and 
junctions of ssDNA and dsDNA, is dependent on RPA, and independent of the ATR-
ATRIP complex (Planchon et al. 2008; Zou et al.2002). Other factors that have been 
implicated in promoting activation of the ATR-ATRIP complex include the MRN 
complex and TopBP1. DNA topoisomerase II binding protein 1 (TopBP1) is 
recruited to sites of DNA damage via interaction with RAD9 ( Martin et al. 2008; 
Greer et al. 2003), and its interaction with ATR-ATRIP is thought to stimulate ATR 
activation (Puc et al. 2005; Mordes et al. 2008). TopBP1 promotes ATR 
autophosphorylation at Threonine 1989, thought to mediate full activation of the 
ATR kinase (S. Liu et al. 2011).  
However, association of ATR-ATRIP to chromatin is not absolutely essential for 
ATR signaling. Disruption of the RPA and DNA-binding domains in ATRIP mutants 
did not impede ATR-mediated CHK1 phosphorylation in X. laevis (Ball et al.2005). 
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Both ATR and ATM respond to DNA damage sensors by phosphorylating an 
array of independent as well as overlapping substrates that coordinate cell cycle 
progression with DNA repair, chromatin remodeling, or apoptosis. This implies there 
is a level of functional redundancy between the kinases. However, unlike ATM, 
ATR is absolutely required for cell viability. Atr knockout in mice results in early 
(pregastrulation) embryonic death, whereas Atr
+/−
 mice display a decrease in 
longevity, with an increase in the incidence of tumors, including histiocytic 
sarcomas, lymphomas and sebaceous gland adenomas (Brown et al. 2000). 
Accordingly, chromosomal fragmentation is seen in ATR
-/-
 cultured blastocysts. 
Conversely, ATM
-/- 
mice are viable (Y. Xu et al. 1996). This suggests a fundamental 
role for ATR-dependent signaling in cellular homeostasis that cannot be 
complemented by ATM. 
Mouse models have been generated in order to investigate the consequences of 
ATR depletion. Atr knockdown in the adult mouse, using recombinant Cre 
technology, revealed an age-related phenotype, and stem cell depletion in tissues 
with high replicative capacity, with little impact on brain tissue (Ruzankina et al. 
2007). Age-related features such as hair greying, kyphosis and osteoporosis were 
also observed in this model.  
In a different approach, a mouse model was developed incorporating the human 
ATR-Seckel syndrome splicing mutation  (ATR
S/S
), first described by O´Driscoll and 
coleagues (O'Driscoll et al. 2003). ATR
S/S 
mice were born at sub-mendelian ratios, 
and importantly, faithfully reproduced the clinical features manifested in the human 
syndrome. These include severe growth retardation and microcephaly with receding 
forehead and micrognathia. ATR
S/S 
mice also exhibit signs of premature ageing and 
have reduced longevity, compared to control littermates (Murga et al. 2009). 
Additionally, signs of embryonic replicative stress were observed in this model, 
suggested by increased activation of DDR processes, such as H2AX 
phosphorylation, 53BP1 foci formation and breakages in the chromosomes; and 
elevated apoptosis observed in ATR
S/S
 mouse embryonic tissues (Dummler et al. 
2007; Murga et al. 2009). More recently, Atr deletion in the mouse nervous system 
revealed a selective impact on certain progenitor cells during neurogenesis, with 
particularly decreased cellularity in the brain cortex and corpus callosum (Lee et al. 
2012). Increased DDR was also observed, and the effects were attributed to high 
replicative stress in these rapidly proliferating cell populations.  
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1.4.1. Key ATR substrates in the DDR 
Activated ATR can phosphorylate a number of downstream targets to 
modulate checkpoint activation, DNA repair and apoptosis (Figure 1.5). These 
include H2AX, CHK1, p53, BRCA1, NBS1.  Large-scale proteomics analysis has 
revealed a high number of novel substrates for ATR and/or ATM in response to 
DNA damage, vastly increasing the scope of pathways linked to the DDR (Matsuoka 
et al. 2007). Although the biological significance of these novel interactions is yet 
unknown, it is noteworthy that a number of these novel substrates are components of 
the insulin-mTOR network. 
While the list of ATR and ATM substrates keeps increasing, I‟ll give here an 
overview of some of the key mediators of the ATR-dependent signaling in the DDR.   
 
 
 H2AX:  
Histone H2A variant X (H2AX) is a highly conserved variant of the core 
histone H2A. Phosphorylation of H2AX on Ser139 (γH2AX) is an early step in 
the DDR, which can be mediated by ATM, DNA-PK and/or ATR in response to 
various types of DNA damage (Easton et al. 2005; Fernandez-Capetillo et al. 
2003). An extended region of γH2AX is then formed along the chromatin, 
surrounding the sites of DNA damage, which facilitates the association of the 
repair and checkpoint machineries (Rogakou et al. 1999; Unal et al. 2004). 
γH2AX is generated in an ATR-dependent manner in response to damage caused 
by UV exposure or HU treatment, resulting in the formation of foci at replication 
forks during S phase (Ward and Chen 2001). γH2AX foci also co-localize with 
many DDR proteins, such as BRCA1, 53BP1, MDC1, RAD51, NBS1 and the 
MRN complex (Fernandez-Capetillo, Celeste, and Nussenzweig 2003). γH2AX 
is therefore important for maintenance of genome stability. This is further 
highlighted by the elevated chromosomal instability, DDR defects and growth 
defects observed in H2AX
-/-
 mice (Altomare and Testa 2005; Bassing et al. 2002; 
Celeste et al. 2003). 
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 CHK1 
The checkpoint kinase CHK1 is an essential Ser/Thr kinase, related to CHK2. 
Both CHK1 and CHK2 are coordinators of the signaling pathways that mediate 
intra-S and G2/M checkpoint activation (see section 1.4.2 of the Introduction), 
but CHK2 function does not compensate for CHK1 loss (Hirao et al. 2002). This 
could be related to an essential role for CHK1 in fork stability during DNA 
replication, associated with ATR activation (Sørensen et al. 2003; Sørensen et al. 
2005). CHK1 is activated by ATR (or ATM)-mediated phosphorylation on 
Ser317 and Ser345, both in unperturbed cell cycles as well as in response to 
DNA damage. CHK1 activation can also be reinforced by autophosphorylation 
(Clarke et al. 2005). Chromatin association and activation of CHK1 requires 
ATR-ATRIP dependent phosphorylation of the 9-1-1 complex, RAD17 and 
BRCA1 (Soliman 2005; Ball et al. 2005; Byun et al. 2005; J. Kobayashi 2004; 
Zou et al.2002; You et al. 2002). 
The mediator protein Claspin is a component of the replication machinery 
that interacts with RPA and RAD17 (Land et al.2007; Lee et al. 2005; Wang et 
al. 2006). CHK1 binding to Claspin facilitates ATR-mediated CHK1 activation 
(Hudson et al. 2002; Kumagai et al. 2000). The Claspin-mediated CHK1 
activation is also promoted by interaction with Tipin (Timeless-interacting 
protein)/Timeless complexes and Tipin/Claspin complexes at RPA-coated 
ssDNA regions. 
Activated CHK1 dissociates from the chromatin, and localizes to the 
cytoplasm and centrosomes (Mendoza et al. 2011; Niida et al. 2007). Notably, 
CHK1 retention at the centrosome reduces CDK1 activation and therefore 
modulates entry into mitosis (Manning et al. 2003; Krämer et al. 2004) (Section 
1.5 of the Introduction). 
Similar to ATR, Chk1
-/-
 mice are embryonic lethal (Manning et al. 2005; Q. 
Liu et al. 2000). Ser345 phosphorylation of CHK1 seems to have an 
indispensable function in cell metabolism, as its ablation in cultured cells proves 
lethal, as opposed to Ser317 mutant lines (Wilsker et al. 2008). 
 
 
 
19 
 
 p53 
The tumor suppressor p53 is a transcription factor that modulates pathways 
leading to either growth arrest or apoptosis (Meek et al. 2004). p53-responsive 
genes are involved in activation of cell cycle checkpoints, DNA repair and 
apoptosis.  
After DNA damage, ATR (or ATM) directly phosphorylates p53, which is 
also targeted by CHK1/CHK2, promoting its dissociation from MDM2, a 
ubiquitin ligase that normally binds p53 and targets it for nuclear export and 
proteasomal degradation. MDM2 is also a p53-responsive gene, thus operating 
on a negative feedback loop. Modulation of the MDM2/p53 loop, p53 
biochemical activity and/or the cellular environment, determine the p53-response 
outcome. Cell cycle arrest-promoting p53 targets include p21, a cyclin-dependent 
kinase (CDK) inhibitor. This results in an arrest in G1, via suppression of cyclin 
E-associated CDK2 activity. Conversely, p53-mediated programmed cell death 
involves the BH3-only protein PUMA (p53 upregulated modulator of apoptosis), 
the BH domain proteins Bcl-2-associated protein X (BAX) and Bcl-2 
antagonist/killer (BAK) (Reinhardt et al. 2012). This is a powerful tumor 
suppressor pathway that normally impedes deregulated proliferation of 
damaged/transformed cells.  
 
 53BP1  
p53-interacting protein 1 (53BP1) is a p53 activating mediator protein with 
roles during replication, and is rapidly recruited to sites of DNA damage (Hay et 
al. 2004; Harper et al. 2007). Association of 53BP1 with γH2AX provides 
scaffolding to concentrate DDR proteins to sites of DNA damage (Sakasai et al. 
2008). 53BP1 is phosphorylated by ATM and serves to amplify ATM signal at 
DSBs, via accumulation of the MRN complex (Noon et al. 2010). 53BP1 plays a 
role in inititation and maintenance of the G2/M checkpoint in response to IR 
(Shibata et al. 2010). 
The function of 53BP1 in the ATR-dependent DDR is less understood. UV or 
HU-treatment induce 53BP1 phosphorylation by ATR (Magnuson et al. 2012; 
Jowsey et al. 2007). 53BP1 foci formation during replication arrest in S-phase 
depend on both ATR and CHK1 function (Ruvinsky et al. 2006; Sengupta et al. 
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2004). At the replication fork, 53BP1 is involved in recruitment of Bloom kinase 
(BLM), and interacts with RAD51 in a CHK1-dependent mode to affect HR 
(Miron et al. 2001; Tripathi et al. 2008). 53BP1 is also thought to amplify ATR 
signaling in UV-induced checkpoint activation (Laplante et al. 2009; Stiff et al. 
2008). 
 
 
 BRCA1 
BRCA1 was originally identified as a susceptibility gene for familial breast 
and ovarian cancer (Futreal et al. 1994). Since then, an essential role for BRCA1 
in development has been established, as BRCA1 deficiency is embryonic lethal 
(Gowen et al. 1996). BRCA1 is a large protein with established functions in the 
DDR and tumor suppression, interacting with a host of DNA repair and 
checkpoint proteins, including CtIP and the MRN complex (involved in DNA 
end resection)(Yun et al. 2009a), BARD1 and TopBP1 (replication-associated 
damage response) (Greenberg et al. 2006), and recruitment of RAD51 to sites of 
DNA damage (Yun et al. 2009b). These interactions are mediated by C-terminal 
repeat domains, termed BRCT domains (Manke et al. 2003; Cantor et al. 2001).  
BRCA1 contains an SQ/TQ cluster, which is phosphorylated by ATR/ATM, and 
CHK1/CHK2 (Foray et al. 2003; Li et al. 2000; Lee et al. 2000). BRCA1 is 
required for the ATR/ATM –mediated phosphorylation of some of its targets in 
response to DNA damage, such as p53, CHK1, CHK2 and NBS1 (Foray et al. 
2003; Yarden et al. 2002). Additionally, BRCA1 expression is modulated by p53 
(Arizti et al. 2000). p53 and BRCA1 appear to regulate transcription from an 
overlapping set of target genes in response to DNA damage. For example, 
BRCA1 facilitation of p53 phosphorylation promotes transcription of the CDK 
inhibitor, p21, which activates and maintains checkpoint arrest at the G2/M 
border (Fabbro et al. 2008; Siliciano et al. 1997). Cells deficient in BRCA1 
exhibit defects in G2/M activation after IR-induced DNA damage (Sabatini et al. 
2006; Xu et al. 1999). Additionally, disruption of BRCA1-ATRIP interaction 
also leads to G2/M checkpoint defects (Venere et al. 2007). 
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1.4.2 ATR-dependent cell cycle checkpoints 
Cell cycle checkpoints are surveillance mechanisms that convey transient 
arrests at discreet phases of the cell cycle that concede time for repair of damaged 
DNA (Sancar et al. 2004). Alternatively, the outcome of checkpoint activation may 
be programed cell death if the damage is deemed too severe. These arrests are 
activated in response to cellular stress, and work to prevent genomic instability and 
accumulation of damaged DNA.  
ATR signaling can activate multiple checkpoint arrests, namely during S-
phase, but also at the G2/M transition, of which I will give a brief outline. 
 
 
 
 
 The intra S-phase checkpoint 
ATR mediates an S-phase arrest in response to replication stress. ssDNA 
regions are generated normally during replication, where low-level ATR 
activation is thought to also have a role (Sørensen et al. 2004; Shechter et al. 
2004b) (section 1.4.3). However, prevention of normal replication fork 
progression can occur when a DNA polymerase encounters a block or DNA 
lesion, causing replication fork stalling. This must be overcome to allow 
completion of DNA replication. MCM helicase-mediated unwinding of the DNA 
at sites of replication fork stalling generates long stretches of ssDNA regions, 
which are recognized by RPA, which recruits ATR-ATRIP. This signal amplifies 
ATR-CHK1 activation and downstream signaling (Plas et al. 2009; Paulsen et al. 
2007), which contribute to downregulation of DNA replication as well as 
replication fork stabilization. Activation of ATR and CHK1 mediates 
downstream phosphorylation of CDC25A, targeting it for degradation involving 
the SKP1/Cullin/F-box (SCF) complex (Rowinsky 2004; Busino et al. 2003). 
This prevents CDC25A dependent removal of the inhibitory phosphorylation on 
CDK2 (threonine 14 and tyrosine 15 residues). Inhibition of CDK2/Cyclin (A or 
E) complexes downregulates DNA replication by reducing the association of 
CDC45 with the pre-replication complexes (Guba et al. 2002; Méndez et al. 
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2000; Costanzo et al. 2000). Inhibition of DNA synthesis delays S-phase 
progression and allows stabilization of replication fork structures. 
ATR also phosphorylates BLM in response to stalled replication forks, and 
this phosphorylation is required for recovery from HU-induced replication blocks 
(Sengupta et al. 2004). 
 
 
 
 The G2/M checkpoint 
The G2/M checkpoint orchestrates a cell cycle arrest that prevents the cells 
from entering mitosis when harboring DNA damage. Much like the intra-S 
checkpoint, G2/M arrest arises from the coordinated action of multiple pathways 
to regulate the activation/inactivation of the CDK1-Cyclin B1 complex, also 
termed the mitosis promoting factor (MPF) (Porter et al. 2003). During normal 
cell cycle progression, the expression of Cyclin B1 is highly regulated, and it 
peaks in G2 phase (Lindqvist et al. 2009). This restricts the formation of the MPF 
complex at other stages of the cell cycle. Phosphorylated Cyclin B1 concentrates 
at the centrosomes in late G2 (Jackman et al. 2003; Toyoshima et al. 1998). 
Activation of the MPF requires phosphorylation of CDK1 on Thr161. This is 
mediated by the CDK-activating kinase (CAK) when a threshold level of MPF is 
reached (Tassan et al. 1994) (Figure 1.5). The subsequent proteolysis of CyclinB 
drives mitotic exit and reentry into prophase (Kapuy et al. 2009). 
The CDC25 dual-specificity phosphatases mediate removal of the inhibitory 
Thr14 and Tyr15 phosphorylations on CDK1, a step required for CDK1 
activation (Mailand et al. 2002). Thr14 and Tyr15 phosphorylation of CDK1 is 
mediated by the Myt1 and Wee1 kinases, respectively. The Polo-like kinase 1 
(PLK1) also phosphorylates Wee1 and Myt1, resulting in Wee1 degradation 
(Watanabe et al. 2004) and Myt1 inhibition (Nakajima et al. 2003). Aurora A 
kinase and co-factor Bora are also involved in PLK1 phosphorylation and 
activation (Seki et al. 2008; Lindqvist et al.2009). 
The CDC25 phosphatases are therefore key regulators of mitotic entry, where 
a fine balance between mitosis-inhibitory and activating signals determines the 
final outcome for the cell. There are three mammalian CDC25 homologues - 
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CDC25A, CDC25B and CDC25C – that have both unique and overlapping 
functions (Mailand et al. 2002). CDC25A activity is required to maintain the 
threshold of CDK1 activity necessary for promoting mitosis; and this role is 
further supported by CDC25B and CDC25C function.  In turn CDK1 activation 
is also thought to mediate CDC25A stabilization, CDC25C activation, and 
CDC25B localization (Schmitt et al. 2006). Threshold-dependent activation of 
CDK1-Cyclin B1 therefore promotes a positive feedback activation loop. 
(Lindqvist, Rodríguez-Bravo, and Medema 2009). In CDC25A overexpressing 
cells CDK1 kinase activity is increased and the transition from G2 into mitosis is 
accelerated (Timofeev et al. 2010). Conversely, CDC25A is specifically 
degraded/inhibited after DNA damage, resulting in mitotic arrest (Schmitt et al. 
2006; Boutros et al. 2006) and this can be mediated by ATR/CHK1-dependent 
signaling, depending on the nature of the damage. 
 
 
 
Figure 1.6 CDK1-CyclinB levels control entry into mitosis. 
 
UV radiation and replication inhibitors can induce ATR-mediated G2/M 
arrest. Activated CHK1 phosphorylates CDC25A on Serines 76 and 123 
(Donzelli et al. 2004; Zhao et al. 2002; Jin et al. 2008). CDC25A 
phosphorylation at these and other sites promotes its SCF-mediated 
ubiquitination and degradation (Busino et al. 2003). CHK1 can also 
phosphorylate CDC25C and promote its nuclear export (Peng et al. 1997); and 
Aurora A inhibition of CDC25B in response to DNA damage is also CHK1 
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dependent (Cazales et al. 2005). The result of all these actions is the sustained 
downregulation of CDK1/Cyclin B complex activation, which prevents entry into 
mitosis (Figure 1.6). ATR/CHK1 signaling therefore plays a key role in 
regulation of CDC25 phosphatase inhibition following certain types of DNA 
damage, resulting in mitotic arrest to allow time for repair.  
Other checkpoints, including spindle assembly, have also been associated 
with ATR-dependent function (Smith et al. 2009). 
 
 
 
 
Figure 1.7 ATR-dependent G2/M checkpoint. 
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1.4.3 ATR signaling and replication 
Both ATR/CHK1‟s absence is invariably lethal suggesting their essential 
involvement in unperturbed cell cycles (Cortez et al. 2001; Niida et al. 2007). A role 
for ATR in normal fork progression during DNA replication has been described, 
through modulation of origin firing. Single-stranded DNA is generated in normal 
replication forks during helicase progression and synthesis and joining of Okazaki 
fragments. ATR-ATRIP is attracted to RPA-bound ssDNA and activates CHK1, 
preventing late firing of origins of replication, by inhibiting the S-phase kinases 
CDK2 and CDC7. Thus, in every S-phase ATR is necessary to regulate the firing of 
origins of replication, stabilize replication forks and prevent early onset of mitosis 
(Shechter et al. 2004a; Paulsen and Cimprich 2007).  
Accordingly, ATR-Seckel patient derived cells show reduced 
phosphorylation of H2AX and CHK1; reduced stabilization of replication forks after 
(aphidicolin-induced) replication fork stalling; and failure to undertake G2/M arrest 
(Alderton et al. 2004). 
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1.5 The centrosome  
A number of ATR pathway components and other DDR proteins localize to the 
centrosome ( Zhang et al. 2007). 
The centrosome is a cellular organelle formed by the two centrioles and 
surrounding pericentriolar material (PCM), which is the main microtubule 
organization center in metazoan cells. The centrosome takes part in efficient cell 
cycle regulation (Hinchcliffe et al. 2001; Mikule et al. 2007; Matsumoto and Maller 
2004), involved in processes such as spindle organization and orientation and 
accurate chromosome segregation during mitosis, although it is not essential (Doxsey 
et al. 2005).  Centrosomal duplication is synchronized with initiation of DNA 
replication and each daughter cell should receive one functional centrosome after 
mitosis. Defects in centrosome maturation are associated with inability to form 
adequate bipolar spindles, or formation of monopolar spindles which can lead to 
polyplody or failure to undergo cytokinesis (Doxsey et al. 2005; Shinmura et al. 
2007; Uetake et al. 2004). Aberrant centrosomes have been linked to aneuploidy in 
cancer (Wang et al. 2004). Centrosomal function is thought to be essential during 
neurogenesis to maintain the proper balance between symmetric and asymmetric cell 
divisions, a determining factor in the regulation of brain size (Knoblich et al. 2010). 
Additionally, the centrosome is involved in aspect of the cell cycle checkpoints. 
The CDK1-CyclinB complex is initially activated at the centrosome (Jackman et al. 
2003), and the checkpoint kinase CHK1 has also been shown to accumulate at the 
centrosome in response to DNA damage and disruption of CHK1 centrosomal 
localization leads to G2/M checkpoint defects (Krämer et al. 2004; Löffler et al. 
2007). 
 
1.5.1 Pericentrin  
The large conserved coiled-coil protein pericentrin (or kendrin) acts as an 
anchoring protein for a number of regulatory molecules and is an integral component 
of the pericentriolar material (PCM). Well described pericentrin interacting partners 
include the microtubule component γ-tubulin, the kinases PKA (Diviani et al. 2000), 
PKCβ (J. Kim et al. 2008) and BCR-ABL (Patel et al. 2009) and the checkpoint 
kinase 1 Chk1 (Tibelius et al. 2009).   
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At the centrosome PCNT has been shown to have a role in the ATR-
dependent checkpoint signaling (Zhang et al. 2007). Centrosome-associated CHK1 
prevents/delays the transition from G2 to mitosis by inhibiting CDC25 activation of 
CyclinB-Cdk1 complexes, which accumulate at the centrosome during interphase 
(Delaval et al. 2010; Krämer et al. 2004). Current evidence suggests that pericentrin 
disruption would lead to loss of centrosomal CHK1, resulting in impaired G2/M 
checkpoint activation after DNA damage and premature entry into mitosis (Tibelius 
et al. 2009; Krämer et al. 2004). The subsequent accumulation of damaged DNA 
could eventually lead to mitotic arrest and cell death (Delaval et al. 2010).  
This could lead to a reduction of total cellularity which would explain the 
severe dwarfism and microcephaly observed in humans and mice harboring PCNT 
mutations, supporting a role for impaired checkpoint signalling in primordial 
dwarfism (Microcephalic Osteodysplastic Primordial Dwarfism Type-II; MOPDII). 
Aditionally, disruption of microtubule nucleation/organization function due to loss of 
γ-tubulin from the spindle poles can also result in spindle dysfunction during mitosis 
(Zimmerman et al. 2004). Aberrant spindle orientation could result in an imbalance 
between symmetric vs assymetric divisions and thus impair the balance of progenitor 
cells/differentiating cells during embryogenesis. Not only the deregulation of 
assymetric divisions in the neuroepithelion (Wang et al. 2009) could contribute to the 
observed microcephaly, but the reduced total cellularity could also explain the short 
stature observed in PCNT-mutated primordial dwarfism.  
 
Figure 1.8 Model of pericentrin’s role in the ATR-dependent G2/M checkpoint. 
(adapted from Griffith 2008) 
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1.6 Cellular pathways that regulate growth 
 
The development and growth of organisms requires the intricately coordinated 
action of a number of signaling pathways with impact on the size and patterning of 
cells, organs and organism. Established examples include the insulin/mTOR pathway 
and the MAPK pathway, of which I will here provide a concise overview. Other 
important growth-regulating signaling cascades involve the morphogens Wnt 
(Wingless) and TGF-β (Transforming growth factor) superfamily. 
 
1.6.1 mTOR pathway and its role in growth/development 
 
 The mammalian target of rapamycin (mTOR) is a serine/threonine protein 
kinase belonging to the phosphatidylinositol 3-kinase-related-kinase family (PIKK). 
mTOR is a key component of a signaling pathway that integrates inputs from 
nutrients and growth factors to regulate translation, cell growth and cell proliferation 
(Hay et al. 2004; Wullschleger et al. 2006; Martin et al. 2005). 
Multiple extracellular signals impact on mTOR activation, such as insulin 
and growth factors (e.g. platelet derived growth factor (PDGF), insulin-like growth 
factors 1 and 2 (IGF-1/IGF-2))(Yang et al. 2008). Additionally, mTOR has also a 
role in sensing nutrient availability, energy levels and redox status in the cell (Yang 
et al. 2008; Land et al. 2007). When appropriate nutrients and growth stimuli are 
present, the mTOR pathway promotes cell growth by increasing ribosome biogenesis 
and protein synthesis. On the contrary, when nutrients are limiting, or in the presence 
of other kinds of stress, the cells suppress protein synthesis and promote nutrient 
recycling (autophagy) via mTOR signaling (Martin et al. 2005).   
Extensive animal studies have supported the requirement of TOR function 
during development and growth. TOR deletion in C. elegans and D. melanogaster 
results in developmental arrest (Jia et al. 2004; Yang et al. 2007). In mammalian 
cells, growth to appropriate cell size requires mTOR and PI3K-dependent signals 
(Laplante et al. 2012). Additionally, homozygous Tor
-/-
 mouse embryos die shortly 
after implantation due to impaired cell proliferation (Murakami et al. 2004).   
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1.6.2 mTOR complexes 1 and 2 
 
The mTOR protein kinase functions in most eukaryotic cells as the catalytic 
subunit of two distinct multi-protein complexes, named mTOR complexes 1 and 2 
(mTORC1; mTORC2) (Kim et al. 2002; Laplante et al. 2009). The rapamycin-
sensitive mTORC1 is composed of mTOR, the associated proteins RAPTOR 
(regulatory-associated protein of mTOR), mLST8 (also known as GβL), and also 
PRAS40 and DEPTOR (DEP domain-containing mTOR-interacting protein). 
mTORC2 also contains the catalytic subunit mTOR, mLST8/GβL, plus two different 
proteins - RICTOR (rapamycin-insensitive companion of mTOR) and mSin1 (also 
known as mitogen-activated-protein-kinase-associated protein1) (Figure 1.9).  
 
 
Figure 1.9 The mammalian TOR complexes, mTORC1 and mTORC2. 
mTORC1 comprises the mTOR catalytic subunit in association with RAPTOR and mLST8 (also 
known as GβL), and the newly identified PRAS40 and DEPTOR. mTORC2 contains instead of 
RAPTOR a protein called RICTOR, but also other subunits such as mLST8 and mSin1. 
 
mTORC2, which is for the most rapamycin insensitive, mediates signaling to 
downstream targets such as the protein kinase C α (PKCα), and is an important 
regulator of the cytoskeleton. mTORC2 is involved in modulation of cell 
proliferation and survival through an array of downstream substrates, including the 
transcription factors FOXO and MDM2, a regulator of p53 (Guertin et al. 2006). 
mTORC2 has also been shown to phosphorylate AKT on Ser473, facilitating AKT 
phosphorylation on Thr308 by the phosphoinositide dependent protein kinase-1 
(PDK1).  
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Through its interaction with AKT, mTORC2 can also act as an upstream 
regulator of mTORC1 (Soliman 2005; Martin et al. 2005).  
The mTORC1 complex has been more extensively researched. Its activity is 
stimulated by extracellular and intracellular signals that inform on the nutritional 
status of the cell or the organism. mTORC1 thus integrates different signals that 
include insulin and growth factors via outer membrane bound receptor tyrosine 
kinases (RTKs) , and amino acids and oxidative stress, via internal sensors such as 
the RAS homolog enriched in brain (Rheb) protein and the AMP-activated protein 
kinase (AMPK) (Martin et al. 2005).   
Amino acid - induced mTORC1 activation involves the RAS-related GTPase 
(RAG) family of proteins. In the presence of amino acids, active RAG heterodimers 
interact with RAPTOR, and promote mTORC1 activation (Martin et al.2005).  
mTORC1 mediates the insulin/IGF response via a signaling cascade 
involving the insulin receptor substrate (IRS), the phosphoinositide 3-kinase (PI3K), 
PDK1, AKT, the tuberous sclerosis complex (TSC1-TSC2) and Rheb (Figure 1.9). 
Rheb  is a ubiquitously expressed small GTPase which in its GTP bound state 
directly binds to and activates mTORC1. However, nucleotide-free Rheb inhibits 
mTORC1, thus playing an essential role in mTORC1 signaling. Overexpression of 
Rheb can sustain mTORC1 activity in the absence of growth factor signaling (Martin 
et al. 2005; Kim et al. 2002; Shah et al. 2004). 
mTORC1 can also be activated via the RAS-RAF-ERK1/2 pathway, 
downstream of receptor tyrosine kinases. Activated ERK1/2 (extracellular-signal-
regulated kinases) inhibits the TSC1-TSC2 complex, the central negative regulator of 
mTORC1.  Additionally,  mTORC1 can integrate information of the levels of 
cellular energy (via AMPK) as well as hypoxia, by mechanisms also involving 
regulation of the TSC1-TSC2 complex activity, as described below (Land et al. 
2007; Brugarolas et al. 2004).  
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Figure 1.10 The insulin/mTOR signaling network involves negative feedback mechanisms and 
cross-talk with the PI3K/AKT and RAS/MAPK pathways. 
Ligand binding induces phosphorylation of IRS-1 resulting in recruitment of the p110 catalytic 
subunit of PI3K. AKT phosporylates and inhibits TSC1/TSC2 function, leading to mTOR activation. 
Through 4E-BP1, rapamycin-sensitive mTORC1 drives cell growth and proliferation by enhancing 
eIF4E-mediated mRNA translation. S6K1 activation by mTOR leads to IRS-1 phosphorylation and 
proteasomal degradation. 
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1.6.3 Key regulators of mTORC1 
 
1.6.3.1 PI3K 
The phosphatidylinositol 3-kinases (PI3K) are enzymes that can 
phosphorylate the 3‟-inositol position on a number of membrane-associated 
phosphatidylinositols (PI). The canonical PI3K family is divided into three classes (I 
to III). The main subgroup activated by the receptor tyrosine kinases (RTKs) are the 
Class IA PI3K, whose heterodimers are composed of a catalytic subunit (p110α, 
p110β, or p110δ), and a regulatory subunit  (p85α, p55α, p50α, p85β, or p55γ) 
(Emerling et al. 2011).  
The lipid second messenger phosphatidylinositol 3,4,5 -triphosphate (PIP3) is 
an important activator of signaling pathways that regulate growth and cell survival. 
PI3Ks are activated by G protein-coupled receptors (e.g. RAS) and RTKs such as the 
insulin receptor (Castellano et al.  2011). Upon ligand binding and activation of the 
receptor, activated PI3K can phosphorylate phosphatidylinositol (4,5)-bisphosphate 
(PIP2) to generate PIP3 at the plasma membrane. PIP3 is an important signaling 
molecule. PIP3 accumulation recruits the serine threonine kinases PDK1 and AKT to 
the plasma membrane enabling their activation. Besides AKT, PDK1 also 
phosphorylates the ribosomal protein S6 kinase (S6K) and the Serum/glucocorticoid 
regulated kinase 1 (SGK) (Rintelen et al. 2001; Mora et al. 2004). Germline deletion 
of Pdk1 is embryonic lethal,  whereas hypomorphic Pdk1 mouse mutants are smaller 
in size and have a proportionately reduced organ volume (Lawlor et al. 2002). 
Interestingly, conditional Pdk1 inactivation in the mouse brain causes microcephaly 
(Chalhoub et al. 2009). 
 
1.6.3.2 PTEN 
 
The phosphatase and tensin homolog (PTEN) acts in opposition of PI3K 
activity by dephosphorylating PIP3 and therefore negatively regulating PIP3-
dependent signaling. PTEN functions as a tumor suppressor by inhibiting PI3K/AKT 
signaling, and therefore loss of PTEN results in increased PI3K signaling. PTEN 
deletion is embryonic lethal in mice (Di Cristofano et al. 1998). Mutations in PTEN 
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are associated with cancer predisposition, macrocephaly, and hamartomas in various 
tissues (Chalhoub et al. 2009), such as seen in Cowden‟s Disease.  
Recently, PTEN‟s involvement in the DDR and DNA repair pathways has 
also been described (Ming and He 2012). PTEN has proposed roles in both double 
strand break repair and nucleotide excision repair, involving in this case suppression 
of XPC (Xeroderma pigmentosum, complementation group C) transcription (Ming et 
al. 2011). 
PTEN can localize to the nucleus by several mechanisms (Planchon, Waite, 
and Eng 2008). There, it was shown to suppress Cyclin D activity (Chung et al. 
2006); and interact with RAD51 and CENP-C, which would mediate PTEN‟s 
described involvement in DSB repair (Planchon et al.  2008). 
Importantly, PTEN interacts with CHK1 (Martin et al.  2008); with CHK1 
loss resulting in decreased PTEN phosphorylation and decreased total levels of 
PTEN. Conversely, PTEN depletion impairs CHK1-dependent checkpoint activation, 
resulting from cytoplasmic sequestration of CHK1 (Puc et al. 2005). PTEN 
interaction with p53 has also been observed.  Under certain circumstances, PTEN 
regulates p53 protein levels, and transcriptional activity by modulation of p53‟s 
recruitment to the DNA (Freeman et al. 2003). 
 
1.6.3.3 AKT 
 
Upon receptor activation, AKT is recruited to the cell membrane through its 
affinity with PIP3, where it is phosphorylated by mTORC2 at Ser473 and PDK1 at 
Thr308 (Xu et al. 2012). Once activated, AKT can phosphorylate a number of 
different substrates.  Via its substrates BAD (Bcl-2-associated death promoter) and 
NF-κB ((nuclear factor kappa-light-chain-enhancer of activated B cells), AKT 
inhibits apoptosis and promotes cell survival (Datta et al. 1997; Madrid et al. 2000). 
AKT-dependent inhibitory phosphorylation of the glycogen synthase kinase (GSK-3) 
results in increased glycogen synthesis (Hajduch et al. 2001). AKT also 
phosphorylates PRAS40, preventing it from inhibiting mTORC1 (Vander Haar et al. 
2007). 
AKT exists in 3 different isoforms (AKT 1-3). AKT1 and 2 have similar 
patterns of tissue-specific expression, with AKT2 more highly expressed in insulin-
target tissue like fat and muscle (Dummler et al.  2007). Akt2
 -/-
 mice exhibit a severe 
34 
 
diabetic phenotype (Cho et al. 2001). AKT3 expression is significantly lower than 
that of the other isoforms, with the exception of the brain and testes. Akt3 knockout 
mice exhibit a significant reduction in brain size (Easton et al. 2005).  Interestingly, 
mTOR signaling appears attenuated in the brains of Akt3-/- but not Akt1-/- mice 
(Easton et al. 2005). This suggests that AKT isoform-specific mTOR regulation may 
contribute differently to cell growth regulation in different tissues. Mouse knockout 
models suggest both specific as well as redundant roles for the AKT isoforms in 
growth and metabolism, but a single functional Akt1 allele appears to be sufficient 
for viability in mice (Dummler et al. 2006).  
AKT has also been specifically associated with endochondral ossification 
(Rokutanda et al. 2009). AKT1 seems to have the biggest impact on skeletal 
development.  
AKT activation is a commonly found genetic defect in human cancers such as 
ovarian (40-70%), multiple myeloma (90%), acute myeloid leukemia (Acute myeloid 
leukemia (70%) and thyroid (80–100%) cancer, associated with increased tumour 
cell proliferation, survival and invasiveness (Altomare et al.  2005; Vivanco et al. 
2002). AKT activation was also found in 100% of the cases of anaplastic large-cell 
lymphoma invetsigated (Altomare et al. 2005). 
 
1.6.3.4 The TSC complex 
 
The TSC1-TSC2 tumour suppressors are the central negative regulators of 
mTORC1 activation, receiving signals from a number of kinases including AMP-
activated kinase (AMPK), AKT, RSK1 and ERK and thus integrating the mTOR 
response with a complex network of other signaling pathways (Yang et al. 2007; 
Soliman et al. 2005). TSC1 (or hamartin) acts as a stabilizer of TSC2 (tuberin). 
The TSC1-TSC2 complex acts downstream of PI3K and AKT signaling. 
Active AKT phosphorylates two residues on TSC2 (Ser 939 and Thr1462) thereby 
inhibiting TSC1-TSC2.  This results in release of the TSC1-TSC2 inhibitory effect 
over mTORC1, enabling activation of mTORC1 dowstream signaling. 
AMPK is a sensor for cellular energy, being activated by an increase in the 
AMP:ATP ratio. Active AMPK phosphorylates TSC2 (and RAPTOR) resulting in 
mTORC1 inhibition (Soliman et al. 2005).  
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The TSC1-TSC2 complex mediates mTOR oxygen-sensing function, by a 
mechanism involving the HIF-1α -regulated expression of REDD1, which activates 
TSC1-TSC2 (Land and Tee 2007).
 
The mTOR pathway is a positive regulator of 
HIF-1α, with evidence for regulation at the level of transcription, translation and 
protein stability (Hudson et al. 2002). 
The TSC1-TSC2 complex also responds to ERK signaling, via RSK, which 
directly phosphorylates and inhibits TSC1-TSC2 (Mendoza et al. 2011). 
The GAP (GTPase activating protein) domain in TSC2 stimulates the GTPase 
activity of Rheb. Activated TSC1-TSC2 increases the conversion of  Rheb-GTP to 
Rheb-GDP.  In its GTP-bound form, Rheb acts as an activator of mTORC1 
(Manning and Cantley 2003).  
TSC1, TSC2 mutations cause the severe disorder tuberous sclerosis, 
characterized by the development of benign tumors (hamartomas) in many tissues.  
TSC-deficiency causes increase in cell growth and proliferation due to lack of 
TSC-dependent mTORC1 inhibition. This desensitizes the cells from extracellular 
signals, such as growth factor signaling, thus encouraging cell proliferation even 
when conditions are unfavorable. However, feedback inhibition from mTORC1 to 
AKT has been shown to limit cell growth in TSC-defective tumors (Manning et al. 
2005). Overexpression of Tsc1 and Tsc2 results in reduced cell and organ size (Potter 
et al. 2001). This effect was shown to counteracted by S6k overexpression in 
Drosophila (Huang et al. 2008; Radimerski et al. 2002). 
 
1.6.4 Downstream targets of mTORC1  
 
The mTORC1 pathway regulates cell growth and size through downstream 
effectors by phosphorylating substrates such as the regulators of translation 4EBP1 
(eukaryotic initiation factor 4E (eIF4E)-binding protein 1) and the ribosomal p70 S6 
kinases (S6K1 and S6K2) (Hay et al. 2004). 
mTORC1 inhibits 4E-BP1 by phosphorylation at multiple sites. In its non-
phosphorylated state, 4E-BP1 is bound to eIF4E. Upon phosphorylation by 
mTORC1, 4E-BP1 releases its inhibitory effect over eIF4E, allowing it to bind to 5‟-
capped mRNAs and promote translation initiation (Bhandari et al. 2001; Gingras et 
al. 2001). 
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The S6K serine\threonine protein kinases are able to phosphorylate the S6 
ribosomal protein, a component of the 40S ribosome, stimulating initiation of protein 
synthesis. S6K1 is directly phosphorylated by mTORC1 on two residues, Thr389 and 
Ser371. Additionally, PDK1 has also been shown to directly phosphorylate S6K1 on 
Thr229. S6K1 activity seems to require coordinated phosphorylation at these 3 sites 
by mTORC1 and PDK1 (Magnuson et al. 2012).  
Other identified S6K1 substrates implicate S6K1 activity in other processes, 
such as mRNA processing (via SKAR and CBP80), initiation of cap-dependent 
translation (via PDCD4, eIF4B and co-ordination with 4EBP1) and elongation (via 
eEF2 kinase); and nascent protein folding (via CCTβ). In addition, S6K1 is linked to 
cell survival (via BAD, Mdm2, and GSK3) (Ruvinsky et al. 2006).  
S6k1 null mice have reduced body and cell size, whereas the combined S6k1 
and S6k2 knockout mice die perinatally. In D. melanogaster, dS6K inactivation 
causes severe developmental delay (pronounced body and organ size) and lethality 
(Miron et al. 2001).   
Other important mTORC1 substrates include the transcription factor YY1 
(Yin Yang1) and PGC-1α (peroxisome-proliferator-activated receptor coactivator -
1α) involved in expression of mitochondrial genes (Laplante and Sabatini 2009); the 
signal transducer and activator of transcription 3 (STAT3) (Zha et al. 2011); the 
hypoxia-inducible factor HIF-1α, and SGK1 (serum and glucocorticoid-inducible 
kinase 1) which regulates progression through cell cycle via p27 (potentially 
regulated also via mTORC2) (Land et al. 2007; Hong et al. 2008).  
 
1.6.4.1 mTOR feedback regulation loops 
 
Feedback loops are important players in the regulation of mTOR signaling. 
Signaling from S6K1 is known to inhibit the insulin receptor substrate (IRS-1) by 
directly phosphorylating a number on inhibitory sites on IRS-1 (Wan et al. 2007; 
Briaud et al. 2005). IRS-1 phosphorylation on Serine 636 and Serine 639 promotes 
its proteasomal degradation, resulting in reduced signaling from the insulin/IGF 
receptor down to PI3K and its effectors. This negative feedback loop from S6K is 
known to down-regulate insulin signaling and may be involved in acquired insulin 
resistance in type II diabetes and obesity, as a result of sustained mTORC1 activation 
(Zick 2005). S6K1 signaling also represses IRS-1 gene expression. S6K is also 
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involved in a positive feedback loop where it phosphorylates RICTOR at T1135, 
leading to AKT phosphorylation on Ser473 (Treins et al. 2010).  
Additionally, mTORC1 can also phosphorylate the growth factor receptor–
bound protein 10 (Grb10) resulting in feedback inhibition of PI3K signaling (Yu et 
al. 2011). 
 
 
1.6.5 mTOR and human disease 
 
Inappropriate mTOR pathway signaling is a known contributing factor to 
various human pathologies, notably cancer (Figure 1.11; Tables 1.3 and 1.4).  
The mTOR pathway signaling is hyperactive in many cancers, particularly 
those associated with high PI3K signaling or with mutations in the PTEN tumor 
suppressor (Sabatini et al. 2006). Loss of PTEN function is associated with an array 
of cancer types including among others, thyroid, melanoma, ovarian, breast, brain 
and renal carcinomas. Amplified AKT and PI3K signaling is also a common feature 
of certain cancers (Table 1.3), and interestingly, BCR–ABL translocation and the 
amplification of genes encoding HER-2 or the epidermal growth factor receptor 
(EGFR) have also been show to activate PI3K signaling (Guertin and Sabatini 2005; 
Dazert and Hall 2011). 
 
Table 1.3 Oncogenes and tumor suppressor genes in the mTOR pathway. 
(adapted from Dazert 2011) 
 
 Most frequent types of cancer 
Oncogene   
EGFR Glioblastoma; lung cancer; peritoneal cancer 
HER2 Breast cancer; Ovarian cancer; Gastric cancer 
PIK3CA Breast cancer; head and neck squamous cell carcinoma; endometrial cancer 
AKT Head and neck squamous cell carcinoma; pancreatic cancer; ovarian cancer 
RAS Pancreatic cancer; thyroid cancer; colorectal cancer 
RAF Melanoma; thyroid cancer; ovarian cancer 
Tumor suppressor   
PTEN Glioblastoma; endometrial cancer; melanoma  
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The use of the mTOR inhibitor rapamycin and its analogs (“rapalogs”) has 
been widely investigated as a therapeutic tool for the treatment/management of 
tumors as well as other mTOR associated diseases (Plas and Thomas 2009). Studies 
have suggested that rapamycin treatment may be particularly effective in cancers 
associated with PTEN-inactivation; and a very positive response to rapamycin has 
been seen in particular in mantle-cell lymphoma (associated with Cyclin-D1 
overexpression) (Rowinsky et al. 2004). 
 
 
Table 1.4 Tumor-prone syndromes associated with mTOR signaling. 
(adapted from Guertin et al. 2005) 
Disease  Genetic defect Pathology  
Tuberous sclerosis complex 
(TSC) 
TSC1/TSC2 Multiple hamartomas 
LAM 
(lymphangioleiomyomatosis) 
TSC2 Abnormal lung cell proliferation  
Cowden’s disease PTEN Hamartomatous tumor syndrome; 
macrocephaly 
Proteus syndrome PTEN; AKT1 Hamartomatous tumor syndrome; overgrowth 
Lhermite-Duclos disease PTEN Hamartomatous tumor syndrome 
Peutz-Jehgers syndrome STK11/LKB1 gastrointestinal harmatoma tumor syndrome; 
(STK11 is an AMPK regulator, which 
modulates TSC2 function) 
HCM (familial hyperthrophic 
cardiomyopathy) 
AMPK Myocardial hyperthrophy 
 
Interestingly, rapamycin has also been shown to suppress angiogenesis (Guba 
et al. 2002). This has been linked to mTORC1‟s role in the regulation of HIF-1α. An 
hypoxic microenvironment is often found in tumors, resulting in increased levels of 
HIF-1α which in turn promotes the expression of the vascular endothelial growth 
factor (VEGF), involved in blood vessel formation (Bernardi et al. 2006; Hudson et 
al. 2002). Consistently, rapamycin treatment has proven useful in the management of 
Kaposi‟s sarcoma, which is characterized by elevated VEGF signaling and strong 
vascularization (Campistol et al. 2004; Stallone et al. 2005), as well as tumors 
associated with loss of the Von Hippel-Lindau (VHL) tumor suppressor, a negative 
regulator of HIF-1α (Thomas et al. 2006; Guertin et al. 2007).  
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Defects in mTOR are also known to underlie major growth defects, organ 
hypertrophy, diabetes, obesity and ageing (Dann et al. 2007; Dazert et al. 2011). As 
such, mTOR is a potential crucial therapeutic target for certain disorders associated 
with inappropriate cell or tissue growth; as well as graft rejection problems during 
transplants (rapamycin is an potent immunosuppressor). 
 
 
Figure 1.11  mTOR signaling in human disease. 
(from Dazert 2011) 
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1.6.5.1 mTOR function in the brain 
 mTOR signaling has been implicated in several neurological disorders. 
These include Alzheimer‟s, Parkinson‟s and Huntington‟s disease, epilepsy and 
tuberous sclerosis, as well as a high number of brain tumors (Garelick and Kennedy 
2011).   
mTOR is expressed during early brain development, where it is involved in 
neuronal survival and differentiation, axon formation and synaptogenesis. The 
kinases PI3K and AKT are also important for neuronal migration and cortical 
lamination (Segarra et al. 2006). Conditional PTEN deletion in mouse neurons, 
associated with hyperactivation of mTOR pathway, results in macrocephaly, 
neuronal hypertrophy and other neuronal deficiencies (Kwon et al. 2001), and PTEN 
loss-of-function has also been observed in autism syndromes associated with 
macrocephaly (Butler et al. 2005).  
TOR function in the adult CNS is important for synaptic plasticity, memory 
function, and control of food uptake (Garelick and Kennedy 2011; Tang et al. 2002). 
Increased mTOR activity in the hypothalamus suppresses food uptake and body 
weight (Cota et al. 2006), and chronic increased mTOR activity has been associated 
with metabolic disorders and homeostatic deregulation. In Chapter 7 I will present 
data on a human megalencephaly disorder caused by novel genetic defects in PI3K-
AKT-mTOR pathway components. 
 
1.6.5.2 Insulin/mTOR signaling and skeletal development. 
 
Chronic hyperinsulinaemia results in mTORC1-dependent activation of S6K, 
which will inhibit insulin signaling at the cell membrane via the S6K-IRS feedback 
loop (Zick 2005; Ueno et al. 2005). As a result, PI3K and AKT are not properly 
activated leading to decreased glucose uptake. This mechanism is linked to the 
development of type II diabetes, and mice lacking S6k1 exhibit enhanced insulin 
sensitivity (Um et al. 2006). 
The role of insulin/IGF signaling in growth and development has been widely 
researched (Oldham and Hafen 2003; Tamemoto et al. 1994). Inr knockout in 
Drosophila melanogaster, for example, results in a significantly reduced body size 
(Oldham and Hafen 2003). 
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Notably, although the occurrence of diabetes is not clear for Seckel 
Syndrome patients, unpublished evidence suggests it. Acanthosis nigricans, a 
hyperpigmentation of the skin commonly caused by insulin resistance, has been 
observed in Seckel syndrome patients. The ATR-Seckel mouse also has a depressed 
insulin-dependent-transcriptional axis (Murga et al. 2009). ATM defects are also 
known to affect insulin-dependent signaling and A-T patients have diabetes mellitus, 
indicating insensitivity to insulin signaling (Bar et al. 1978; Morrell et al. 1986).  
 
Interestingly, the mTOR/AKT pathway has been shown to regulate the 
processes of endochondral ossification and skeletal growth, where the insulin 
pathway has a pivotal role (Phornphutkul et al. 2006). Links between insulin/mTOR 
pathway signaling and skeletal development will be further discussed in Chapter 4. 
 
 
1.6.6 RAS/MAPK pathway and its role in growth/development 
 
 The RAS/mitogen activated protein kinase (MAPK) pathway is an important 
regulator of cell growth and differentiation during normal development.  
 Activated RTK‟s function as docking sites for a number of intracellular 
proteins, including the SH2-domain containing SHC, SHP-2 and GRB2 (Lowenstein 
et al. 1992). The subsequent recruitment of SOS promotes activation of RAS (from 
inactive GDP-bound to active GTP-bound). RAS-GTP promotes signaling via the 
MAPK pathway, which includes the kinases RAF, MEK and ERK. ERK dependent 
phosphorylation of cytoplasmic as well as nuclear substrates (including cell cycle 
regulators) mediates cell proliferation (F. Chang et al. 2003). Some of ERK1/2 
targets include the ribosomal protein S6 kinases (RSKs), mitogen- and stress-
activated protein kinases (MSKs), and ternary complex factors (TCFs). Additionally, 
ERK signaling regulates the activation of mTORC1 via the phosphorylation and 
inactivation of TCS2 (Sunayama et al. 2010; Ma et al. 2005). 
Germline mutations in RAS/MAPK pathway components have significant 
impact on development and are responsible for a class of developmental syndromes, 
aptly named „RASopathies‟ (Table 1.5) usually associated with cardio-vascular 
abnormalities and neurocognitive delay, as well as growth problems (Tidyman et al. 
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2009; Tidyman et al. 2008; Cesarini et al. 2009). Most of these mutations result in 
increased Ras/MAPK signaling. Additionally, there is an increased risk of 
developing cancer. RAS somatic mutations alone have been observed in around 20% 
of all malignancies (Tidyman et al. 2009). 
 
 
Table 1.5  Genetic syndromes of the RAS-MAPK pathway. 
(adapted from Tidyman et al.  2009) 
Syndrome RAS-MAPK pathway gene 
Noonan PTPN11; SOS1; RAF1; KRAS; 
LEOPARD PTPN1; RAF1 
Hereditary gingival fibromatosis 1 SOS1 
Neurofibromatosis 1 NF1 
Capillary malformation-arteriovenous  
malformation 
RASA1 
Costello HRAS 
Autoimmune lymphoproliferative NRAS 
Cardio-facio-cutaneous BRAF; MAP2K1;MAP2K2;KRAS 
Legius SPRED1 
 
 
Despite the substantial knowledge that already exists of signaling pathways 
that govern growth, how organ and organism size is determined remains in large part 
unknown, and could benefit from the study of human growth disorders. 
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1.7 Aims 
 
In the work presented in this thesis I investigate the consequences of 
defective ATR-dependent function, in particular how defects in this pathway 
manifest in the specific set of clinical features observed in forms of microcephalic 
primordial dwarfism. For this purpose, specific cell culture differentiation assays 
were designed and implemented using standard model cell culture systems, but also 
employing de-differentiation of patient-derived fibroblasts. My novel findings help 
establish a previously unsuspected role for ATR function in differentiation processes, 
specifically its involvement in skeletogenesis via chondrogenesis.  
Clinical features linked to ATR-signaling deficiency include microcephaly 
and severe growth retardation, and the insulin/mTOR pathway is a crucial regulator 
of growth and developmental processes. As such, and in view of the significant 
overlap existing between these seemingly unrelated pathways, I used cells derived 
from long recognized and novel human disorders to investigate the functional 
interplay between the ATR-dependent DDR and the mTOR pathway.  
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Chapter Two 
Materials and methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
2.1 Chemicals and equipment 
 
Unless otherwise stated, all chemicals were obtained from Fisher Scientific, 
Invitrogen or Sigma, and all enzymes from New England Biolabs or Roche. Cell 
culture media was obtained from Gibco Invitrogen Cell Culture and cell culture flasks, 
cryotubes and dishes from Nunc. Protein gels and western blots were carried out using 
the Biorad Mini-PROTEAN III gell system. 
 
2.2. Mammalian cell culture 
2.2.1 Cell culture conditions 
All cell lines were grown in a humidified atmosphere at 37ºC with 5% CO2. 
Cells were passaged every 2-4 days to maintain a logarithmic growth phase.  
Adherent cells were washed once with PBS and incubated in trypsin solution 
(250mg/ml in PBS) at 37ºC until detached. Cells were then washed with fresh culture 
medium, pelleted by centrifugation at 2000g for 2 min and re-suspended in an 
appropriate volume of fresh culture medium. 
Lymphoblastoid cell lines (LBLs) were cultured in RPMI 1640 (Dutch 
modification medium without L-glutamine) supplemented with 15% fetal calf serum 
(FCS), 2mM L-glutamine, 500U/ml penicillin, 50g/ml streptomycin (referred to as 
complete RPMI1640 medium). Primary fibroblast cell lines were cultured in MEM 
supplemented with 15% fetal calf serum (FCS), 2mM L-glutamine, 500U/ml 
penicillin, 50g/ml streptomycin (referred to as complete MEM medium). MG63 
cells were cultured in MEM supplemented with 10% fetal calf serum (FCS), 2mM L-
glutamine, 500U/ml penicillin, 50g/ml streptomycin. T98G glioblastoma cells were 
cultured in MEM supplemented with 10% fetal calf serum (FCS), 2mM L-glutamine, 
500U/ml penicillin, 50g/ml streptomycin, 1% non-essential amino acids (NEEA), 
1% sodium pyruvate.  
For long-term storage, cells were pelleted and re-suspended in culture 
medium containing 10% DMSO. 2ml aliquots containing approximately 5X10
6
 cells 
were transferred to cryotubes and cooled slowly to -80ºC before being stored in 
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liquid nitrogen. Cell lines were thawed rapidly in a 37ºC water bath and re-
suspended in 20mls of complete medium. 
2.2.2 Cell lines 
 
Table 2.1 Mammalian cell lines used in this study. 
Cell line Source/reference 
Fibroblasts  
1BR.3 (WT) GDSC cell bank 
FO2-98 (ATR; ATR-S) (O'Driscoll et al. 2003)  
ASB (PCNT
E220X-/-
; PCNT-S) (Griffith et al. 2008)  
42552 (PCNT
 C1990fs-/-
; PCNT-S) (Griffith et al. 2008)  
(ORC1 mut; MGS) (Bicknell, Walker, et al. 2011)  
CL10-0031 (IFT43 mut; Sensenbrenner 
Syndrome) 
A kind gift from Prof. H Brunner (Nijmegen, The 
Netherlands); (Arts et al. 2011)  
Lymphoblastoid lines (LBLs)  
AG87 (WT) GDSC cell bank 
DK0064 (ATR
A2102G
; ATR-S) (O'Driscoll et al. 2003)  
CV1559 (PCNT
E220X-/-
; PCNT-S) (Griffith et al. 2008) 
GM10080 (PTEN p.Glu261Ter; CD) Coriell Cell Repository (USA) 
GM16378 (INSR mut; DS) Coriell Cell Repository (USA) 
CAO133 (DS) A kind gift from Dr. R Semple (Cambridge, UK) 
48608/P3.1 (STAMBP
125A>G/532C>T
; MIC-CAP) Dr. Kym Boycott (Ottawa, Canada) 
LR07-155a1/P1.2 (STAMBP
299T>A/1270C>T
; 
MIC-CAP) 
Dr. Kym Boycott (Ottawa, Canada) 
P5.1 (STAMBP mut; MIC-CAP) Dr. Kym Boycott (Ottawa, Canada) 
LR04-078/P7.1 (STAMBP
112C>T
; MIC-CAP) Dr. Kym Boycott (Ottawa, Canada) 
LR08-018 (AKT3 
1391C>T
; MCAP/MPPH) (Rivière et al. 2012)  
LR00-016a1 (PIK3R2
1117G>A
; MPPH) (Rivière et al. 2012) 
LR05-204 (PIK3CA
1359_1361 
del; MPPH) (Rivière et al. 2012)  
LR09-006 (PIK3CA
2740G>A
; MCAP) (Rivière et al. 2012) 
02-22 (1q21.1 Dup) (Harvard et al. 2011) 
09-103 (1q21.1Del) (Harvard et al. 2011) 
Other  
MG-63 (human osteosarcoma) American Type Culture Collection (ATCC) 
T98G  (human glioblastoma) GDSC cell bank 
C2C12 (murine myoblasts) A kind gift from Prof. S Morley (Sussex, UK) 
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2.3 Differentiation assays 
2.3.1 Osteoinduction 
MG-63 osteosarcoma cells were cultured in different reported osteogenic 
mediums, containing: 
a) 5, 10 or 20µM of piceatannol, added to proliferating cells for a period 
of up to 3 weeks. Adapted from (J.-K. Chang et al. 2006).  
b) 4µg/ml dexamethasone; 100µM ascorbate; 10µM β-
glycerophosphate (Mineralizing medium, MM), added to both 
confluent and proliferating cells. Adapted from (J. R. J. Adams, 
Sander, and Byers 2006)  
and assessed at various time points for the induction of osteogenic-specific markers.    
 
2.3.2 Detection of mineralization 
Osteocyte-derived mineral deposition was assessed by Alizarin Red S (ARS) 
incorporation, which stains calcium-rich deposits in cells in culture. ARS recovery 
by acetic acid extraction was followed by semiquantification of staining measured by 
colorimetric detection at 405nm. Detection and quantification of mineralization was 
performed as described in (Gregory et al. 2004). 
 
2.3.3 Chondroinduction 
 Patient-derived hTERT immortalized fibroblasts were chondroinduced (de-
differenciated) by seeding in micromass culture (2X10
5
 cells/ml) onto 24 well plates 
coated with the chondrogenic proteoglycan aggrecan (A1960, Sigma-Aldrich). 
Plates were prepared using 20μg of aggrecan/well, dried slowly overnight at around 
37
º
C. Adapted from (French et al. 2004). 
 Aggregate sizes were measured using light microscope images (40X 
magnification) using Adobe®Photoshop® (arbitrary units, lower cut-off point at the 
single cell size approximately). 
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2.3.4 Measurement of sulfated gylcosaminoglycan (GAGs)  
 The synthesis of chondrocyte-specific sulfated GAGs was determined using 
the dimethylmethylene blue (DBM) assay. Chondroinduced fibroblasts, cultured on 
aggrecan-coated plates as described above, were analyzed for the excretion of 
sulfated GAGs at 24h and 72h post-induction. The culture media from each 
individual well was removed and cleared of cells by centrifugation. DMB solution 
was prepared as described in (Carroll 1987). Sulfated GAG quantities were 
determined by comparison with a calibration curve of chondroitin sulfate solutions 
(in full media) used as standard. Semiquantification of staining was measured by 
colorimetric detection at 525nm. Adapted from (Barbosa et al. 2003). 
 
 
2.4 siRNA mediated knockdowns 
 Logarithmically growing cells were trypsinized and 5x10
5
 cells seeded onto 
wells on 6-well plates/small 2cm dishes in 2ml of medium. The oligonucleotides 
used were ON-TARGET plus SMARTpool siRNA, fom Dharmacon (Table 2.2). 
Cells were transfected using METAFECTENE® PRO (Cambio) transfection reagent 
according to manufacturer‟s instructions. Cells were analysed at 24h post-
transfection with repeat transfections done at 24h or 48h when necessary. The 
control oligonucleotide was ON-TARGETplus siCONTROL Non-targeting siRNA 
(Dharmacon). 
 
 
Table 2.2 siRNA oligos 
Target Cell line Oligo ref/NCBI accession number 
ATR 1BR.3 L-003202-00-0005; NM_001184 
PCNT 1BR.3 L-012172-00-0005; NM_006031 
Pcnt C2C12 L-062315-01-0005; NM_008787 
INSR MG-63 L-003014-00-0005; NM_000208 
GSK-3β MG-63 L-003010-00-0010; NM_002093 
STAMBP T98G L-012202-00-0005; NM_006463 /NM_201647/ NM_213622 
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2.5 STAMBP lentiviral complementation  
 STAMBP-deficient MIC-CAP LBLs were complemented using Precision 
LentiORF viral particles, carrying the pLOC lentiviral vector incorporating Human 
STAMBP (cat no. OHS5901-101004516; clone ID PLOHS_100005246) from 
ThermoScientific. The infection was performed according to the manufacturer‟s 
instructions, and infected cells selected using Blasticidin. Successfully infected LBL 
cultures were determined by STAMBP immunoblotting. 
 
2.6 Protein extracts 
 
Whole cell extracts (WCE) 
Cell pellets were washed 2X in PBS and either stored at -20°C or directly lysed 
in 50-100μL of lysis buffer: 
a) IP extracts: cells were resuspended in 50-100μL IP buffer (50mM Tris.HCl 
pH7.5, 150mM NaCl, 2mM EDTA, 2mM EGTA, 50mM NaF, 25mM β-
glycerolphosphate, 0.1mM sodium orthovanadate, 0.2% Triton-X100, 
0.3% Igepal, protease inhibitor cocktail (Roche)) and incubated on ice for 
1hr, prior to either clearing by centrifugation or sonication. 
b) Urea extracts : cells were lysed in urea buffer (9M urea, 50mM Tris-HCl 
pH7.5, 10mM β-mercaptoethanol) and directly sonicated. 
Cell lysates were centrifuged for 5 min at 13000 rpm at 4°C. The supernatant was 
transferred to a clean, cold eppendorf tube. The protein concentration was then 
determined using Bradford Protein Assay reagent (Bio-Rad Laboratories) at a UV 
absorbance of 595nm. Extracts were either stored at -80°C or directly boiled in 2x 
SDS loading buffer (5% SDS, 10% Glycerol, 10% β-mercaptoethanol, 125mM Tris-
HCL pH6.8 and 0.2% bromophenol blue) and loaded onto SDS-PAGE gels. 
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2.7 CDC5A stability assay 
Cells were either untreated or irradiated with 10J/m
2
/s U and then incubated 
in complete medium with 100g/ml cycloheximide (CHX) for up to 4hrs. Cells were 
pelleted and resuspended in WCE extraction buffer in the continued presence of 
CHX. 50g WCEs were resolved by SDS-PAGE and western blotted with anti-
CDC25A antibodies (Alderton et al., 2006). 
 
2.8 PAGE/Western-blotting 
 
 Whole cell extracts (50g, unless otherwise stated) were denatured by 
heating at 90°C for 10 mins in SDS loading buffer (50mM Tris pH6.8, 2% (w/v) 
SDS, 10% (v/v) glycerol, 0.1% (w/v) bromophenol blue) and separated alongside 
molecular weight markers (Precision Plus Protein Prestained Dual Colour Standards, 
BioRad) by SDS-PAGE (Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis). 6% to 15% acrylamide gels, with a 4% stack, were resolved at 100-
160V in running buffer (25mM Tris-HCl, 250mM Glycine, 0.1% (w/v) SDS) using 
Mini-PROTEAN 3 apparatus (Bio-Rad).  
 Gels were transferred onto PVDF membranes (Immun-Blot® PVDF 
membranes for protein blotting, Bio-Rad) using a Trans-blot SD Semi-Dry Transfer 
Cell (Bio-Rad) in semi-dry transfer buffer (20% methanol, 30mM Tris-HCl, 200mM 
Glycine 0.03% SDS) for 1-1.5 hrs at 20-25V. Membranes were blocked in either 5% 
BSA or 5% non-fat milk in Tris Buffered Saline with 0.1% Tween-20 (TBS-T) for a 
period of 1hr. Membranes were then probed with primary antibody in 5% BSA/TBS-
T overnight at 4°C with shaking. Membranes were washed with TBS-T, 3 times for 
10 mins, and probed with HRP-conjugated secondary antibodies (DABKO) for 1 hr, 
followed by three further TBS-T washes. Labeled proteins were then detected by 
enhanced chemiluminescence (Pierce ECL Detection Reagents; or GE Healthcare 
ECL plus detection reagents). 
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2.9 Indirect Immunofluorescence 
 For indirect immunofluorescence (IF), LBLs were pelleted, swollen in 75nM 
KCl (10 mins) and fixed in 3% PFA, 2% sucrose. Following fixation, the cells were 
either stored in 70% EtOH at 4°C; or resuspended in PBS and immobilized onto 
poly-L-lysine coated slides by cytospinning. Adherent cells were cultured directly on 
cover slides and fixed in 3% PFA, 2% sucrose. Cells were permeabilized by addition 
of 150µl 0.1% Triton 100-X in PBS for 1-2 mins, washed in PBS by dipping 3X and 
blocked for 10 min in 150µl of 5% BSA/PBS. The cells were then incubated for 30 
mins with 150µl of primary antibody in 5% BSA/PBS; washed in PBS by dipping, 
and a second blocking step performed for  10 min in 150µl of 5% BSA/PBS. 150µl 
of secondary antibody in 5% BSA/PBS were then added and the cells incubated for 
30mins in the dark. For nuclear staining, 2ml of DAPI solution were added and 
incubated for 5 mins in the dark. The slides were again washed 3X in PBS and the 
excess liquid was removed.  The slides were then preserved in anti-fading mounting 
media (Vectashield), and analysed using the Zeiss AxioPlan platform and images 
captured using SimplePCI software at constant exposure times. 
 
 
2.10 Immunoprecipitation 
 In a final volume of 150μl, 500μg of WCE in IP extraction buffer (see 2.5) 
were immunoprecipitated with 1-2μg of the appropriate antibody. The mixture was 
agitated for at least 4hrs (to overnight) at 4°C. Protein G/Sepharose beads suspended 
in IP buffer were then for at least 1hr at 4°C. with constant agitation. After 
centrifugation at 4°C for 5 mins, the supernatant was discarded and the 
immunoprecipitate washed 3X with 300μl IP buffer. The immunoprecipitates were 
resuspended in 30-50 μl IP extraction buffer and 50 μl of 2X SDS loading buffer. 
The mixture was boiled for 10 mins to denature and release the bound protein. 
Immunoprecipitates were centrifuged at high speed and the supernatant resolved by 
SDS-PAGE and Western blotting. 
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2.11 Antibodies 
Table 2.3 List of antibodies 
Antibody Company Dilution (WB/IF) 
ATR Santa Cruz Biotechnology 1:300 WB 
53BP1 Bethyl 1/200 IF 
p-Rb S807/811 Cell Signaling 1:1000 WB 
Rb Cell Signaling 1:1000 WB 
PCNT Abcam 1:500 WB 
HIF-1α BD Transduction Laboratories 1:500 WB 
pAKT (Thr308) Cell Signaling 1:1000 WB 
pAKT (Ser473) Cell Signaling 1:1000 WB 
AKT Cell Signaling 1:1000 WB 
pS6K (Ser371) Cell Signaling 1:500 WB 
pGSK-3β Cell Signaling 1:1000 WB 
GSK-3β Cell Signaling 1:1000 WB 
p4E-BP1 (Thr37/46) Cell Signaling 1:1000 WB 
4E-BP1 Cell Signaling 1:1000 WB 
pS6 (S240/S244) Cell Signaling 1:1000 WB 
pPDK1 (Ser241) Cell Signaling 1:1000 WB 
pPTEN (Ser380) Cell Signaling 1:1000 WB 
pTSC2 (Thr1462) Cell Signaling 1:1000 WB 
TSC2 Cell Signaling 1:1000 WB 
pC-RAF (Ser259) Cell Signaling 1:1000 WB 
pPI3K p85 (Tyr458)/p55(Tyr199) Cell Signaling 1:500 WB 
PI3K p110α Cell Signaling 1:1000 WB 
PI3K p110β Cell Signaling 1:1000 WB 
PI3K p110γ Cell Signaling 1:1000 WB 
PI3K p85 Cell Signaling 1:1000 WB 
Insulin Rβ Cell Signaling 1:500 WB 
pCHK1 (S345) Cell Signaling 1:500 WB 
pCHK1 (Ser280) Cell Signaling 1:500 WB 
pCDK1 (Y15) Cell Signaling 1:500 WB 
CDC25A NeoMarkers 1:300 WB 
STAMBP Santa Cruz Biotechnology 1:1000 WB 
Α-FK2 (Ub) Enzo Lifesciences 1:100 IF 
LC3A Cell Signaling  1:500 WB / 1:100 IF 
Caspase 3 Cell Signaling 1:500 WB 
pC-RAF (S338) Cell Signaling 1:1000 WB 
pERK1/2 (T202/Y204) Cell Signaling 1:1000 WB 
ERK1/2 Cell Signaling 1:1000 WB 
MEK1/2 Cell Signaling 1:1000 WB 
AMPK-β2 Cell Signaling 1:1000 WB 
AMPK-β1 Cell Signaling 1:1000 WB 
pAMPKα (T172) Cell Signaling 1:1000 WB 
AMPKα Cell Signaling 1:1000 WB 
pACC (S79) Cell Signaling 1:1000 WB 
ACC Cell Signaling 1:1000 WB 
pRAPTOR (S792) Cell Signaling 1:1000 WB 
PIP3 MBL 1:100 IF 
AKT3 (62A8) Abcam 1:500 WB 
PCNA Santa Cruz Biotechnology 1:500 WB 
DNA Polimerase α (POL1A) Santa Cruz Biotechnology 1:200 WB 
MCM2 Santa Cruz Biotechnology 1:1500 WB 
β-tubulin Santa Cruz Biotechnology 1:2000 WB 
Anti-(rabbit/mouse/goat) HRP 
conjugated secondary antibody 
DAKO 1:2000 
53 
 
2.12 HU-induced 53BP1 foci formation 
 LBLs were untreated or treated with 5mM Hydroxyurea for 2hr. Cells were 
then washed once in PBS and slides prepared using a cytospin. Cells were fixed in 
3% PFA, 2% Sucrose for ten minutes followed by extensive PBS washing. Slides 
were then stained using the standard immunofluorescence technique described above 
using an anti-53BP1 primary antibody. Cells with > 5 53BP1 foci were counted as 
positive and the percentage of positive cells was assessed for each cell line.  
 
2.13 G2/M checkpoint assay  
 Exponentially growing LBLs were washed with PBS and irradiated with 
7J/m
2 
UV-C or 3gy IR. Cells were then cultured in the presence of Colcemid for a 
further four hours in complete medium before harvesting, or for 24hr in complete 
medium with the addition of 1.5M Nocodazole (Sigma). Cells were pelleted, 
swollen in 75mM KCL for 10 minutes and then fixed in 3%PFA, 2% sucrose for 15 
mins. Cell nuclei were stained with DAPI and the cells were transferred into poly-L-
Lysine coated slides (by cytospinning) and mounted using an anti-fading solution 
(Vectashield). The mitotic index was then determined for each cell line by counting 
at least 500 cells. A decrease in the number of mitotic cells was taken as indicative of 
activation of the G2/M checkpoint. 
UV irradiation was performed using a UV-C source (0.5J/m
2/s). γ irradiation 
was performed with a 
137
Cs source at a dose rate of ~2Gy/min. 
 
2.14 Annexin-V apoptosis assay 
 For annexin V-apoptosis assessment I used the Single Channel Annexin V 
Apoptosis Kit (Alexa Fluor-488 conjugated anti-Annexin V with Sytox Green) from 
Life Technologies LTD (Paisley, UK) according to manufacturer‟s instructions.  
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2.15 Autophagy flux analysis 
 WT and patient LBLs were treated with the autophagy inhibitor Bafilomycin 
A1 for 2h to monitor autophagy flux. The cells were then harvested, and the urea 
WCE resolved by Western blotting and analyzed for the presence of the full length 
(LC3-I) and cleaved (LC3-II) forms of the autophagosome marker LC3A. 
Calculation of the LC3-II/LC3-I ratio gives an indication of the autophagy flux in the 
cells, and between the LBL lines. 
 
 
2.16 RAS activation assay  
 Active RAS was detected using the RAS Activation Assay Kit from 
Millipore, according to the manufacturer‟s instructions. Fresh lysates from 
exponentially growing or serum-starved LBLs (MIC-CAP) were washed and cleared 
as per instruction in the appropriated buffers, and incubated with RAF-1 RBD 
Agarose, for the RAS-Pull-Down. The agarose beads were pelleted, washed, and 
resuspended in 40μl SDS-PAGE buffer before boiling and separated by SDS-PAGE. 
 
 
2.17 Mitochondrial function 
 Analysis of mitochondrial function and mitochondrial mass in WT and 
patient LBLs was performed using the MitoTracker® dyes (Invitrogen) according to 
the manufacturer‟s instructions. Different mitochondrion selective probes were used. 
MitoTracker Red, for analysis of mitochondrial membrane potential; MitoSox, for 
detection of superoxide formation: and MitoGreen, which indicates total 
mitochondrial mass in the cells. The cells were incubated with the appropriate dyes 
as indicated, and fluorescence intensity was determined by FACS analysis. 
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2.18 Semi-quantitative RT-PCR 
 Semi-quantitative RT-PCR (24-28 cycles) was performed using the 
ProtoScript® AMV LongAmp® Taq RT-PCR Kit (New England Biolabs) using the 
primer sets indicated below. 
 
Table 2.4 List of primers for RT-PCR. 
Name Primer sequence Tm (°C) 
Osteocalcin 
Forward: 5‟ – ATGAGAGCCCTCACACTCCTC – 3‟ 
Reverse: 5‟ – GCCGTAGAAGCGCCGATAGGC – 3‟ 
60 
Collagen I 
Forward 5‟ – CATCTCCCCTTCGTTTTTGA – 3‟ 
Reverse: 5‟ – CTGTGGAGGAGGGTTTCAGA – 3‟ 
53 
SOX9 
Forward: 5‟ – GAACGCACATCAAGACGGAG – 3‟ 
Reverse: 5‟ – TCTCGTTGATTTCGCTGCTC – 3‟ 
58 
VEGFA 
Forward: 5´-GTCTTGGGTGCATTGGAGCC- 3‟ 
Reverse: 5‟ – CCTCGGCTTGTCACATDTGC – 3‟ 
55 
ELP4 
Forward: 5´- AAGAGGATCCTGCCAACATTT - 3 
Reverse: 5‟ – AGGATTGGATCCATCAAATCC – 3‟ 
60 
 
 
 
 
2.19 Agarose gel electrophoresis 
 Agarose gels were made up at the required percentage (w/v) depending on 
fragment size, by dissolving Ultrapure Electrophoresis Grade Agarose (Invitrogen) in 
1XTAE buffer (0.4 Tris acetate, 1mM EDTA). The mixture was heated with frequent 
mixing until dissolved, and after cool down ethidium bromide was added to a final 
concentration of 0.3μg/ml. The samples were prepared in loading buffer and 
subjected to electrophoresis in 1XTAE buffer. Samples were run alongside a 1K 
DNA ladder (Invitrogen) as size marker, and DNA was visualized using a UV 
transiluminator. 
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2.20 Quantitative RT-PCR (qRT-PCR) 
 qRT-PCR analysis for expression of chondrogenic markers was carried out 
using the QuantiFast SYBR Green PCR Kit (Qiagen) and the QuantiTect Primers 
listed below (Table 2.5). 
 
Table 6 List of primers for qRT-PCR. 
Name  Primer reference (QuantiTect, Qiagen) 
COL1A1 (NM_000088) Hs_COL1A1_1_SG  (cat no. QT00037793) 
SOX9 (NM_000346) Hs_SOX9_1_SG (cat no. QT00001498) 
VEGFA (NM_001025366) Hs_VEGFA_6_SG (cat no. QT01682072) 
GAPDH (NM_002046) Hs_GAPDH_1_SG (cat no. QT00079247) 
 
 Reactions containing 12.5μl SYBR Green PCR Master Mix, 2.5μl 10XPrimer 
assay mix, 5μl RNAse-free water and 5μl template cDNA to a final volume of 25μl 
were prepared in duplicate. Cycling was carried out using the Stratagene Mx3005 
QPCR System. Cycling conditions: reactions were heated to 95°C for 5 minutes, 
followed by 40 cycles of 95°C for 10 seconds and 60°C for 30 seconds. Reactions 
were then heated up to 95°C for a further 1 minute and incubated at 55°C for 30 
seconds. 
 Relative expression levels were calculated using the Ct (threshold cycle) 
values for the various conditions. The fold upregulation/downregulation following 
chondroinduction was calculated using the formula: 2e
-ΓCt
, with Ct= Ct(COL1A1, 
VEGFA or SOX9)-Ct(GAPDH). 
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Chapter Three 
Results I: The impact of defective ATR function on 
skeletogenesis 
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3.1 Introduction 
The main clinical features observed in Seckel syndrome (SS) are the 
profound dwarfism/growth retardation, and a disproportionate impact on 
skeletogenesis (osteogenesis and chondrogenesis). Some authors have proposed 
Seckel syndrome as a chondrodysplasia (Rodríguez et al. 1982). Impaired ATR 
signaling appears to be a feature of SS patient cell lines (Griffith et al. 2008), and 
mutations in ATR were the first genetic defect identified in Seckel Syndrome 
(O'Driscoll et al. 2003). The index case exhibited skeletal abnormalities, including 
thoracic kyphosis, narrow iliac blades, coxa valga, subluxation of the hips, 
micrognathia and multiple ivory epiphysis of the hands. Indeed overt skeletal 
abnormalities (kyphosis, osteoporosis, micrognathia) are a feature of a humanized 
mouse model of ATR-mutated Seckel Syndrome (Murga et al. 2009). 
I wanted to investigate whether these are simply „cell autonomous‟ effects of 
loss of ATR since ATR is essential for cell division and survival, or whether ATR-
signaling is specifically required for skeletogenesis and growth.  
A role for ATR (and ATM) in regulating a spectrum of cellular processes 
beyond the DNA damage response (DDR) has been suggested. Recently, two large-
scale proteomic studies have identified hundreds of proteins phosphorylated by ATM 
or ATR in response to DNA damage (Matsuoka et al. 2007; Stokes et al. 2007), but 
the significance of these phosphorylations is yet unclear. Many of these substrates 
are involved in protein modification, transcriptional regulation, and developmental 
processes. In particular, the exploration of ATR‟s role in these processes has been 
hampered by its absolute requirement for survival in mice (Brown and Baltimore 
2000). Ruzankina et al. have recently shown that mosaic ATR deletion in adult mice 
results in depletion of a high percentage of proliferating cells and an age-related 
phenotype including skeletal degeneration (Ruzankina et al. 2007). 
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3.1.1 Skeletogenesis 
The formation and development of the skeleton is the result of tightly 
regulated differentiation and interaction between its three main constituting cell 
types: chondrocytes (which form cartilage); osteoblasts (deposit bone extracellular 
matrix) and osteoclasts (bone resorption). Whereas chondrocytes and osteoblasts are 
of mesenchymal origin, osteoclasts derive from the monocyte-macrophage cell 
lineage (Goldring et al. 2006). The activity, proliferation and differentiation of bone 
cells is carefully coordinated during embryogenesis, as bone is formed, and later in 
adult life in the process of bone remodeling. Migration of cells to the site of future 
bone formation is followed by cellular condensations that result of epithelial-
mesenchymal interactions and finally differentiation of chondrocytes and osteoblasts 
(Ducy and Karsenty 1998). Several bone morphogenetics proteins (BMPs) have a 
role in the formation and shaping of mesenchymal condensations (Karsenty et al. 
2008). In mammals, bone development occurs by two distinct mechanisms. 
Intramembranous ossification is the result of direct condensation of mesenchymal 
cells and accounts for a small number of skeletal elements, such as the flat bones of 
the skull and medial clavicles. Endochondral ossification generates the majority of 
bones and utilizes an initial cartilage template, on which osteoblasts differentiate to 
form endochondral bone (Figure 3.1.1) (Karsenty et al. 2008; Provot and Schipani 
2005). 
Chondrogenesis is the process that results in the formation of the cartilage 
intermediate. During endochondral bone development, chondrocyte differentiation 
takes place in the epiphysial growth plate (GP) at the extremities of long bones 
(Provot and Schipani 2007). Deposition of cartilage specific extracellular matrix 
(ECM) accompanies chondrocyte unidirectional proliferation, followed by 
hypertrophy, calcification, and ultimately cell death. Round proliferative 
chondrocytes develop along the longitudinal axis of the bone in a columnar layer and 
express collagen type II (Karsenty et al. 2008). The cells then gradually stop dividing 
and increase in size while becoming surrounded by the ECM. Differentiation into 
postmitotic hypertrophic cells (expressing primarily collagen type X) is accompanied 
by mineralization of the surrounding matrix (Goldring et al. 2006).  
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Figure 3.1.1  Mechanisms of bone formation. 
Endochondral ossification requires the formation of a cartilage template, which is later replaced by 
bone, and is the mechanism by which the majority of the skeleton is formed. Bones of the skull are 
formed directly via intramembranous ossification without the use of a cartilage template. 
 
 
Hypertrophic chondrocytes eventually die by apoptosis and are replaced by 
mineralized bone via vascular invasion, which allows recruitment of osteoclasts and 
osteoblasts, and consequent resorbtion of cartilagineous matrix and replacement with 
bone-specific matrix. Collagenous fibers and glycosaminoglycans (GAGs) such as 
chondroitin sulfate, hyaluronic acid (HA) and keratan sulfate, are the main organic 
components of the bone intercellular matrix, in addition to osteoblast proteins 
osteocalcin and osteopontin. 70% of the bone‟s dry weight consists of inorganic 
matter: Ca
2+
 phosphate (around 85%), CaCO2 (10%), Ca and Mg fluorides (5%) 
(Provot and Schipani 2007; Provot and Schipani 2005; Zuscik et al. 2008; Adams, et 
al. 2007).  
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3.1.2. Regulation of chondrogenesis 
The sequential stages of chondrogenesis and endochondral ossification 
involve a precise pattern of gene expression, under regulation of a number of 
transcription factors, as well as other signaling molecules such as growth and 
differentiation factors, as depicted in Figure 3.1.2. In the early stages, condensing 
mesenchyme already expresses ECM and cell adhesion molecules such as the IIa 
splice form of collagen II (COL2A), N-cadherin and tenascin C, as well as the 
important nuclear transcription factor SRY-box 9 (SOX9) (Karsenty et al. 2008). 
Non-hyperthrophic proliferating chondrocytes then start expressing the IIb form of 
collagen II (colIIb) and aggrecan, as well as collagen type XI and cartilage-derived 
retinoic-acid sensitive protein (CD-RAP), under SOX9 regulation (Karsenty et al. 
2008). Aggrecan is the main ECM proteoglycan produced by chondrocytes, highly 
upregulated during chondrocyte differentiation and maturation. It interacts with 
hyaluronan filaments to form aggregates involving the cell-surface receptor CD44. 
An aggrecan core mutation has been identified in the homozygous nanomelic chick, 
resulting in extreme micromelia (i.e. disproportionately short limbs) with reduced 
head and trunk size and other major skeletal abnormalities (Schwartz et al. 1993). 
SOX9 positively regulates proliferation and differentiation of non-
hypertrophic chondrocytes, and negatively regulates hypertrophy, being excluded 
from mature chondrocytes. SOX5 and SOX6 can bind to and increase SOX9 
transactivation function. SOX9 haploinsufficiency causes Campomelic Dysplasia, a 
rare human disorder of severely impaired skeletal development (Foster et al. 1996). 
Upon withdrawal from the cell cycle, hypertrophic chondrocytes stop expressing 
collagen type II and instead express collagen type X and alkaline phosphatase 
(Karsenty et al. 2008). The runt-domain transcription factor, Runx2 is the main 
osteoblast differentiation factor, expressed at high levels in cells of the osteoblast 
lineage and in the adjacent perichondrium, where it regulates the expression of many 
genes that determine the osteoblast phenotype, including osteocalcin, an osteoblast-
derived hormone expressed only in fully differentiated osteoblasts (Komori et al. 
2008). Runx2 deficient mice show complete absence of bone formation and in vitro 
Runx2 gene expression promotes an osteoblast-specific gene pattern expression. 
Runx2 is also transiently expressed in prehypertrophic chondrocytes and has been 
shown to induce the expression of hypertrophic markers, like collagen type X, and is 
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required for mineralization of the cartilage matrix. Additionally, Runx2 is required 
for vascular invasion of cartilage, by means of activation of the vascular endothelial 
growth factor (VEGF) promoter (Karsenty et al. 2008; Komori et al.2008; Lee et al. 
2012).  
 
 
 
 
 
Figure 3.1.2 Endochondral bone formation. 
a) Cellular organization of the fetal growth plate. b) Sequence of events of chondrogenesis during the 
development of long bones: different stages and accompanying patterns of growth and differentiation 
factors (above the arrows), transcription factors (below the arrows) and extracellular matrix proteins 
involved (adapted from Zuscik et al. 2008). 
 
 
 
a) 
b) 
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3.1.3. Hypoxia and VEGF expression in the fetal GP 
The observation that the mammalian chondrocyte growth plate (GP) is highly 
hypoxic has led to the development of a new model of control of chondrocyte 
survival and differentiation, involving the hypoxia inducible factor, HIF-1α (Provot 
and Schipani 2005; Schipani et al. 2001; Provot and Schipani 2007). HIF-1 is a 
heterodimer composed of HIF-1α and HIF-1β, the latter of which is constitutively 
expressed whilst the former is stabilized under low oxygen conditions. 
 
 
Figure 3.1.3 HIF-1 regulation under normoxic versus hypoxic conditions. 
The hypoxia-inducible factor, HIF-1 operates as a transcription switch during regulation of oxygen 
homeostasis. Under normoxia the von Hippel-Lindau tumor suppressor protein (VHL) targets HIF-1α 
for rapid ubiquitination and degradation by the proteasome. Under hypoxic conditions however, HIF-
1α is free to form a heterodimer with HIF-1β, and the HIF-1 complex then recognizes and binds to the 
promoter of genes that mediate the hypoxia response,  such as the gene encoding VEGF required for 
angiogenesis. 
 
Under normoxic conditions, the ubiquitin ligase von Hippel-Lindau (VHL) 
targets the highly unstable HIF-1α subunit to proteasome degradation (Figure 3.1.3). 
On the other hand, under hypoxia HIF-1α is free to translocate to the nucleus where 
it activates the transcription of specific genes, including the hypoxic responsive 
elements (HRE), which include genes involved in glucose metabolism, angiogenic 
factors such as VEGF, cell cycle proteins and apoptotic factors. HIF-1α is 
fundamental for the survival of hypoxic chondrocytes (Schipani et al. 2001). 
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Significant cell death is observed in HIF-1α-deficient chondrocytes in the hypoxic 
center of the cartilage anlage, prior to hypertrophic differentiation, partly due to HIF-
1α regulation of VEGF expression in this region (Figure 3.1.4) (Provot and Schipani 
2005; Schipani et al. 2001; Provot and Schipani 2007; Schipani 2006). 
 
 
 
Figure 3  Hypoxia and VEGF expression in the fetal growth plate. 
 
HIF-1α controls VEGF expression in the hypoxic areas, whereas VEGF accumulation in the late 
hypertrophic chondrocytes is Runx2-regulated (adapted from Schipani 2006; Stiehl et al. 2002). 
 
 Other HIF-1α targets are probably involved in the observed cell death of 
HIF-1α-deficient growth plates, as VEGF-deficiency alone does not cause the same 
severe phenotype. HIF-1α has also been shown to inhibit chondrocyte proliferation 
(Schipani et al. 2001) and stimulate ECM production with an increase in collagen 
type II accumulation. HIF-1α dependent hypocellularity and decreased growth rate 
are the cause of dwarfism in mice with VHL deficient chondrocytes (Schipani 2006).  
Other factors besides hypoxia may be involved in regulation of HIF-1α 
function in chondrocytes, and indeed peptides such as insulin and interleukin-1 (IL-
1) can also activate HIF-1α under normoxic conditions, associated with PI3K/AKT 
pathway activation (Stiehl et al. 2002). In the context of chondrogenesis, a role for 
insulin and the insulin-like growth factor-I (IGF-I) has also been established, where 
at physiological concentrations they can induce chondrocyte differentiation in vitro 
(Phornphutkul et al. 2006).  
A link to ATR-pathway function and HIF is provided by the fact that the 
ATR damage-response pathway has been recently shown to be activated by stalled 
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replication forks that result from hypoxia-induced S-phase arrest, involving 
phosphorylation of H2AX and accumulation of the tumour suppressor p53 
(Hammond et al. 2002). 
In this chapter I investigated the effect of impaired ATR function on 
osteogenesis and chondrogenesis using distinct model cell systems combining ATR-
knockdown and patient-derived material in the attempt to understand the extreme 
skeletal phenotype observed in ATR-signaling deficient Seckel Syndrome patients. 
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3.2 Results 
3.2.1 The effect of ATR deficiency on osteoinduction of MG63 cells 
To assess the impact of ATR deficiency/impaired ATR function on 
osteogenic differentiation, we used an established cell system in osteoinduction 
studies, the human MG-63 osteosarcoma cell line, considered to be an 
undifferentiated osteogenic progenitor cell type. These cells are known to 
differentiate into mature osteoblasts in culture following treatment with “osteogenic” 
medium. The differentiation medium contains a source of phosphate, ascorbic acid, 
and dexamethasone which induces synthesis of osteoid in MG-63 cells (Adams et 
al.2006)(see materials and methods). Recently, the polyphenol piceatannol was 
shown to induce differentiation in MG-63 cells associated with increase in bone 
morphogenetic protein 2 (BMP2), resulting in enhanced expression of alkaline 
phosphatase and osteocalcin (Chang et al. 2006).  
Stable ATR knockdown was previously introduced in the MG-63 cells 
following transduction using the Expression Arrest
TM
 pSM2 Retroviral shRNAmir 
system (Open Biosystems) (Figure 3.2.1a), and different strategies were tested to 
induce in these cells the expression of an osteoblast phenotype. This model line 
exhibited ˃90% knockdown of ATR protein whilst remaining viable.  
Differentiation was monitored by analysis of expression of markers of 
osteoblast-like cells, such as increased expression of osteocalcin, Runx2 and collagen 
I. MG-63 cells osteodifferentiation was first observed after prolonged (2 weeks) 
treatment with piceatannol, with the induction of expression of osteocalcin detected 
by semi-quantitative RT-PCR (Figure 3.2.1). A basal level of osteocalcin was 
detected in the control cells not unexpectedly since we are working with 
osteosarcoma cells. Surprisingly, the biggest increase in osteocalcin expression was 
detected in cells kept in confluence, in normal medium (MEM 10% FCS), and at 
more reduced time points, just after 24-48h after reaching confluence.  
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 Figure 3.2.1.  Different strategies tested to induce osteodifferentiation in MG63 cells. 
MG63 control (WT) and ATR knockdown (ATR siRNA) cells were cultured in two different 
osteogenic supplemented media; 20µM of piceatannol (pic) alone or dexamethasone/ascorbate/β-
glycerophosphate (mineralizing medium, MM), and split every 2-3 days for a period of 2 weeks. a) 
Western blot analysis confirming ATR knockdown (˃90%) in MG63 cells following siRNA. MCM2 
levels were used for protein loading control. b) Expression of bone cell specific marker osteocalcin 
was assessed by semi-quantitative RT-PCR. Unexpectedly, exponential growing ATR siRNA cells 
appeared to express significant levels of osteocalcin compared to WT suggestive of premature 
engagement of osteogenesis here. Furthermore, upon piceatannol (pic) treatment levels appeared 
higher than those induced in WT. MM supplement was found to be a very poor inducer of osteocalcin 
expression. c) Mineralization was assayed by ARS quantification for the different culture conditions. I 
observed low levels of mineralization under these conditions, for both WT or ATR siRNA cells, with 
the ATR siRNA cells producing slightly more mineral than the WT. 
 
 
The development of an osteoblast-like phenotype under these conditions was 
further confirmed by increased expression of a second marker of bone 
differentiation, collagen I (Figure 3.2.2). The pattern of expression of both 
osteogenic markers was identical between WT and ATR siRNA cells under these 
conditions. 
No expression of either marker was detected after treatment with the 
mineralizing medium (MM), and their increase after piceatannol induction was 
 b) 
a) 
c) 
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moderate when compared to the effect of simply growing the cells to confluence. 
The induction was sustained and detected up to 3 weeks of keeping the cells in 
confluence (Figure 3.2.2), with no apparent impact of ATR knockdown upon the 
expression of bone markers under these conditions, suggesting that at least in the 
earlier stages of osteogenesis ATR inhibition does not compromise osteogenesis. 
 
 
Figure 3.2.2 Kinetic expression of bone differentiation markers in confluent MG-63 WT and 
ATR siRNA cells. 
Time dependent effect of confluence on osteogenesis was assessed in MG-63 WT and ATR siRNA. 
Confluent WT and ATR siRNA MG63 cells start expressing the osteogenic specific markers 
osteocalcin and collagen I after 24h in confluence. Total RNA was extracted after the appointed times 
and osteocalcin and collagen I expression was detected by semi-quantitative RT-PCR. The expression 
the housekeeping gene Elp4, component of RNA PolII holoenzyme, was used as an input control.  
 
 
The later stages of bone formation require mineralization of osteoblasts, by 
accumulation of Ca
2+
 and inorganic phosphate, required for the formation of the 
bone main inorganic component, hydroxyapatite. Induction of mineralization has 
been observed in cultured cell lines after treatment with osteogenic medium 
containing a source of inorganic phosphate. In particular, MG-63 cells can be 
induced to mineralize both after piceatannol treatment (Chang et al. 2006) as well as 
in medium supplemented with a source of phosphate, ascorbic acid, and 
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dexamethasone (MM) (Adams et al. 2006). Mineral deposition can be assessed by a 
number of means including Von Kossa staining and Alizarin Red S (ARS) 
incorporation (Gregory et al. 2004). Both techniques were used to test mineralization 
in our system. 
No mineral deposition was observed in von Kossa-stained monolayers of 
MG-63 cells grown both in the untreated as well as in the mineralizing medium with 
piceatannol, likely due to the short incubation times used (data not shown). However, 
Alizarin Red S staining revealed the formation of a mineralized layer in the cells 
cultured in osteogenic medium. At 2 weeks post-osteoinduction there was no 
detectable mineralization in exponentially growing cells, both untreated or stimulated 
with piceatannol/MM. However, the cultures kept in confluence showed an increase 
in ARS staining, indicating initialization of mineralization (Figure 3.2.3a). Moreover, 
the accumulation of mineral by the differentiating osteoblasts increased over time in 
culture as shown in Figure 3.2.3b. Quantitative analysis of ARS staining revealed 
that the cells treated with the osteogenic supplements produced more mineral than 
the untreated cells, particularly for the later time-points tested  (Figure 3.2.3.c).  
The level of ARS staining was overall significantly higher in the ATR siRNA 
MG-63 cells grown in mineralizing medium, with an accentuated decrease observed 
after 3 weeks. The mechanistic basis of this decrease is unclear but could imply a 
problem with maintenance of the osteogenic status following ATR siRNA in these 
cells. This could be consistent with the osteoporosis observed in various mouse 
models of ATR-deficiency. It must be taken in consideration that some cell death 
was observed in these cells after 3 weeks growth in confluent monolayer. By 
extending this study up to 8 weeks we observed that mineralization in the WT cells 
increases continuously over time. The ATR knockdown cells seemed to be producing 
more mineral initially, but at the later time points they fall below the WT cells 
significantly. Overall this data seem to indicate that initiation of osteogenesis is not 
defective after ATR inhibition, as both WT and ATR siRNA MG-63 cells are able to 
reach the final stages of osteoblast differentiation and mineralize. However, there is 
some modest evidence for a problem with maintenance of differentiation in the 
context of ATR knockdown, which would be consistent with the osteoporosis 
observed following ATR knockdown in adult mice (Ruzankina et al. 2007). 
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Figure 3.2.3 Bone mineral production in WT and ATR siRNA MG63 cells. 
Accumulation of mineral can be observed in MG63 cells after 8 weeks osteoinduction in mineralizing 
medium (MM) as determined by alizarin red (ARS) staining. a) WT and ATR siRNA cells visualized 
under light microscope after ARS staining after 8 weeks osteoiduction, and b) Time-course 
production of mineral, in the presence of MM, assayed by ARS acid extraction. ATR inhibition did 
not prevent initiation of mineralization, but appeared to have impacted on the ability to maintain the 
differentiated status. c) ARS quantification of MG63 after 8 weeks osteoiduction, in the presence 
(MM) or absence (unt) of bone mineralizing medium evidencing a mineralizing problem in the ATR 
siRNA cells.  Data shows the mean variation between 2 replicated cultures, with error bars 
representing ±SD. 
a) 
b) 
c) 
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A cartilage template is required for the formation of the majority of the 
bones, during endochondral ossification. If chondrogenesis is compromised, it will 
consequently affect the formation of the skeleton. This could also account for the 
cartilage deficiencies observed in Seckel syndrome. I therefore investigated 
specifically the chondrogenesis process in the context of ATR deficiency in an 
independent model differentiation cell system to determine the requirements for ATR 
herein.  
 
 
3.2.2 Chondroinduction of human dermal fibroblasts and the impact 
of ATR/PCNT deficiency in chondrogenesis. 
Fibroblasts and chondrocytes share a mesenchymal origin, and it has 
previously been demonstrated that fibroblasts can be induced to de-differentiate, and 
re-differentiate along the chondrocyte lineage, under specific culture conditions 
when seeded onto a chondrogenic matrix (French et al. 2004). In this environment, 
the cells lose their elongated fibroblast-like morphology and acquire a spherical 
phenotype. Dramatic biochemical changes accompany these alterations in 
morphology. This is evidenced by inhibition or total loss of synthesis of proteins 
characteristic of an undifferentiated mesenchymal cell phenotype (e.g. type I 
collagen), and increased synthesis of chondrocyte-specific markers, such as type II 
collagen, SOX9 and aggrecan. In a further attempt to gain insight into the potential 
role of defective ATR-function in disrupting normal skeletal development in Seckel 
syndrome, the role of ATR-signaling during chondrogenesis was investigated. 
Clinically relevant primary fibroblasts derived from an ATR-Seckel 
syndrome patient (FO2-92) as well as PCNT-Seckel (ASB) patient-derived cells 
were used in this study. Mutation in PCNT is the most common cause of MPD and is 
also associated with functional ATR-pathway defects. We developed and 
characterized an in vitro chondroinduction system for human dermal fibroblasts, 
based on French et al. (French et al. 2004). To induce chondrogenic differentiation, 
the cells were seeded at high density on aggrecan-coated wells (see materials and 
methods), and chondrogenic differentiation was monitored over time. 
Chondroinduction in culture is associated with agglomeration of single cells into 
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large aggregates upon exposure to the chondrogenic matrix. When seeded on the 
aggrecan matrix, both WT and patient cells formed aggregates that grew in 
suspension in the culture medium, as early as 2h after plating (Figure 3.2.4a). A first 
indication of a potential defect in chondroinduction in the ATR-S and PCNT-S cells 
arose with the observation that the Seckel cell aggregates appeared to be generally 
smaller than the WT. Measurement of the aggregate sizes confirmed this observation 
(Figure 3.2.4b).  
Because chondrogenesis involves exit from the cell cycle, and maintenance 
of the hypertrophic state, cells need to efficiently arrest proliferation during 
chondroinduction. Considering ATR‟s role in cell cycle checkpoint activation and 
DNA replication, I sought to determine whether chondroinduction in the context of 
ATR-Seckel Syndrome resulted in ordered cell cycle exit and maintenance of this 
exit. Analysis of Retinoblastoma protein (Rb) phosphorylation (Figure 3.2.4c) 
revealed that the cells exit the cell cycle as expected for normal commitment to the 
chondrogenic pathway. Both WT and patient-derived ATR-S fibroblasts stop 
proliferating as early as 15hrs after induction, suggesting commitment to 
chondrogenic differentiation. This tells us that any phenotypes observed are 
uncoupled from ATR‟s role in normal DNA replication. 
Synthesis of sulphated glucosaminoglycans (GAGs) is a typical marker of 
chondrocytic cells (Matsubara et al. 1992). Here, our dermal fibroblasts start 
producing chondrocyte-specific GAGs when cultured in specific concentrations of 
aggrecan (Figure 3.2.5a). Interestingly, significantly reduced synthesis of GAGs by 
the ATR-S cells was observed after aggrecan induction. These results suggest that 
ATR-S cells do not undergo chondroinduction as efficiently as WT fibroblasts, and 
are consistent with smaller aggregate size seen in these cells upon chondroinduction.  
Using semi-quantitative RT-PCR, we analyzed the expression of other 
chondrocyte-specific markers (Figure 3.2.5b). The increased expression of SOX9 
observed in the WT is consistent with chondro-differentiation and cartilage 
formation. In both ATR-S and PCNT-S however, SOX9 expression was not induced, 
or to a much lesser extent. Conversely, collagen type I transcript levels decrease after 
aggrecan treatment, consistent with the acquisition of a non-fibroblastic phenotype.  
We see this in the WT fibroblasts at 48h after chondroinduction, but not as clearly in 
ATR-S and PCNT-S cells. These results indicate that critical aspects of chondrocyte 
differentiation are compromised in Seckel syndrome patient derived cells.  
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Figure 3.2.4 Aggrecan-induced chondroinduction of human dermal fibroblasts. 
a) Phase contrast images (40X) of WT (1BR.3), ATR-S (FO2-98) and PCNT-S (ASB) dermal 
fibroblasts untreated and at 2h, 4h and 24h following addition to aggrecan coated plates. b) Size 
distribution (arbitrary units = a.u.) of aggregates from WT, ATR-S and PCNT-S fibroblasts following 
24hr micromass culture in aggrecan coated plates (n=350 aggregates scored per line) measured using 
Adobe Photoshop from images acquired on the Zeiss Axiovert platform. Larger aggregate size was a 
feature of control fibroblasts following chondroinduction compared to ATR-S and PCNT-S patient 
derived fibroblasts. c) Phosphorylation of Retinoblastoma protein (pRb) detected by Western-blot 
revealed that the cells arrested proliferation following chondroinduction as early as 15hrs following 
chondroinduction, as indictated by the loss of pRb signal. Both WT and ATR siRNA cells exited with 
identical kinetics. 
a)
b)
c)
Wt          ATR-S 
a) 
b) 
c) 
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Figure 3.2.5 Expression of chondrocyte-specific markers in ATR-S and PCNT-S patient 
fibroblasts following chondroinduction. 
Chondrocyte differentiation is accompanied by glycosaminoglycans (GAGs) synthesis which can be 
quantified by dimethylmethylene blue (DMB) assay. a) Lower levels of GAGs are synthesized by 
ATR-S cells growing on aggrecan when compared to WT cells (assay performed previously by Emily 
Outwin). b) SOX9 expression increases during chondroinduction, whereas type I collagen (COL1A1) 
represents a negative marker as differentiated chondrocytes secrete a specific extracellular matrix. 
Consistent with this, SOX9 levels increased while COL1A1 levels decreased in WT cells during 
chondroinduction. In contrast, SOX9 was not induced in either ATR-S or PCNT-S nor did COL1A1 
levels appeared to decrease. Total RNA was extracted after the appointed times and COL1A1 and 
SOX9 expression was detected by semi-quantitative RT-PCR. The expression the housekeeping gene 
Elp4, component of RNA PolII holoenzyme, was used as an input control for RT-PCR.  
 
 
1BR
untreated            2hr                   4hr                  6hr                   24hr
Aggrecan induction (20µg) 
FO2-98
a)
b)
c)
          2hr    4hr             24hr
a) 
b) 
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To further confirm that the phenotypes observed using the patient cells were 
due to ATR and PCNT deficiency, we inhibited ATR or PCNT by siRNA in WT 
fibroblasts (Figure 3.2.6a) and tested the expression of chondrogenic markers in 
these cells by quantitative RT-PCR (Figure 3.2.6). Expression of COL1A1 is not as 
efficiently inhibited following chondroinduction after ATR as well as PCNT 
knockdown, when compared to WT. This data further reinforces my patient-line 
derived data suggesting a potential impairment of effective chondroinduction when 
ATR and PCNT are limiting. 
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Figure 3.2.6 Analysis of COL1A1 mRNA levels after ATR and PCNT knockdown following 
chondroinduction by qRT-PCR. 
a) siRNA mediated ATR and PCNT knockdown in WT (1BR.3) fibroblasts was confirmed by 
western-blot. POL1A (DNA polymerase α p180) levels were used as control for protein loading. 24h 
after siRNA, the cells were seeded on aggrecan coated plates to induce chondrogenesis and harvested 
24h later. The synthesized cDNA was used in quantitative PCR reactions designed to amplify 200bp 
regions of the COL1A1 and GAPDH gene, using the Qiagen Quantifast SYBR Green PCR kit. 
Amplification plots were produced by measuring the SYBR green fluorescence after each 
amplification cycle. A representative amplification plot for COL1A1 b) and GAPDH c) is shown. d) 
Example of a dissociation curve of the PCR product formed for COL1A1,  produced by increasing the 
temperature of the reaction step-wise from 55
o
C to 95
o
C and measuring fluorescence at each increase. 
The experiment was repeated 3 times with samples prepared in triplicate. e) ΓCt values were 
calculated as specified in materials and methods as averages for the three acquisition runs. GAPDH 
mRNA was used as a reference mRNA. Mean values ± standard deviations of the means are shown. 
Consistent with semi-quantitative RT-PCR significantly elevated  levels of COL1A1 were detected in 
ATR and PCNT siRNA cells compared to WT 24h following chondro-induction. This is consistent 
with impaired chondro-induction in these lines. 
 
c) 
b) d) 
e) 
a) 
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3.2.3 HIF-1α/VEGFA expression in ATR-S and PCNT-S cells during 
chondroinduction  
In vivo, the chondrocytic growth plate upon expansion ultimately becomes 
hypoxic (Araldi et al. 2010). An important chondrogenic transcription factor is the 
hypoxia inducible factor, HIF-1α, which induces the expression of a number of genes 
including VEGF. VEGF promotes vascularization enabling the recruitment of 
osteoblasts and osteoclasts to the growth plate (Zelzer et al. 2004; Maes et al. 2012). 
I examined HIF-1α stabilization/expression in control, ATR- and PCNT-Seckel 
syndrome fibroblast following chondroinduction. I found that chondroinduction 
induced expression of HIF-1α in WT cells, under normoxic conditions (Figure 
3.2.7b). Interestingly, I repeatedly observed that aggrecan-induced HIF-1α 
expression appeared to be significantly delayed/reduced in the ATR-S as well as in 
the PCNT-S cells compared to WT. This suggests that impaired ATR function may 
have an impact on the induction of HIF-1α expression in the context of 
chondrogenesis. During normal bone development HIF-1α -induced VEGF 
expression occurs so as to recruit a blood supply to the epiphyseal growth plate 
thereby recruiting osteoblasts onto the cartilage template (Cramer et al. 2004). Using 
semi-quantitative RT-PCR, I found that VEGF expression also increases after 
aggrecan induction in the WT cells, but is not induced in the ATR-S and PCNT-S 
cells (Figure 3.2.7c). This observation further suggests a major problem in regulation 
of the hypoxia response in ATR/PCNT deficient cells, during chondrogenesis. If 
Seckel cell chondrocytes cannot properly induce VEGF expression they may not be 
able to efficiently recruit blood supply to the site of bone formation, which ultimately 
could greatly impair skeletal development via restriction of the growth plate. 
 Hypoxia also results in increased phosphorylation and consequent 
activation of the serine/threonine kinase AKT and p38 mitogen activated protein 
kinase (MAPK), with consequent HIF-1α stabilization. AKT is required for 
regulation of skeletal development, involving the mTOR pathway (Rokutanda et al. 
2009). PI3K/AKT signaling also promotes survival and synthesis of chondrocytic 
matrix in the adult cartilage. Mice lacking both Akt1 and Akt2 genes show severe 
growth deficiency and retarded endochondral ossification (Peng et al. 2003). 
Evidence of AKT inhibition has also been found in human osteoarthritic cartilage 
(Chen et al. 2012). 
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Figure 3.2.7 ATR and PCNT Seckel syndrome fibroblasts exhibit impaired expression of the 
hypoxia-inducible factor, HIF1α, and VEGFA after chondroinduction. 
a) In the fetal growth plate, HIF-1α controls VEGF expression in the hypoxic areas.  b) The total 
levels of HIF-1α were detected by Western blotting at the indicated times after exposure to the 
chondrogenic matrix. ATR-S and PCNT-S cells showed reduced induction of HIF-1α expression, 
compared to WT, under these normoxic conditions. HIF-1α and HIF-1α-dependent VEGFA 
expression by cells treated with CoCl2 (150µM; 24h) was used as a positive control. The expression of 
MCM2 protein, a component of the helicase complex involved in DNA replication, was used as a 
loading control. c) Using semi-quantitative RT-PCR, control fibroblasts showed enhanced levels of 
two VEGFA transcript isoforms (isoforms a and c) post addition to the chondrogenic matrix, which is 
not observed in both ATR- and PCNT-defective cells. The expression the housekeeping gene Elp4, 
component of RNA PolII holoenzyme, was used as input control for RT-PCR.  
 
 
a) 
b) 
c) 
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 I found AKT phosphorylation is induced in this in vitro chondroinduction system 
(Figure 3.2.8c) as early as 4h following aggrecan induction. AKT activation on 
Thr308 is clearly visible in WT cells. Interestingly I found attenuated AKT 
activation in ATR-S cells during chondroinduction suggesting that another important 
programmed chondrogenic event does not occur in these cells (Figure 3.2.8a). AKT 
is activated by phosphorylation at Thr308 by PDK, which is downstream of PI3K 
activation. To confirm this AKT activation upon chondroinduction is PI3K 
dependent, I used a specific PI3K catalytic inhibitor, PI-103. Early chondroinduction 
markers, HIF-1α and VEGFA expression, were not induced in this system in the 
presence of the PI3K inhibitor (Figure 3.2.8b,c). This suggests an important role for 
this pathway in regulating the hypoxia response during chondrogenesis. AKT is 
particularly important in mediating signaling via the insulin receptor. Additionally, 
insulin has been found to stimulate chondrogenic differentiation and activate Hif-1α 
in normoxia, through the PI3K pathway (Stiehl et al. 2002).  
In the next chapter I will investigate the impact of ATR/PCNT deficiency in 
the cellular response to insulin and its potential impact in the process of chondro-
differentiation by examining activation of the PI3K/mTOR pathway in our Seckel 
Syndrome patient derived cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
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Figure 3.2.8 AKT phosphorylation is not induced following chondroinduction of ATR-S cells, 
and in the presence of a PI3K inhibitor. 
Inhibition of PI3Kinase prevents induction of chondrogenic markers following aggrecan-induced 
differentiation. a) Western-blot analysis of cell extracts following short-term chondroinduction 
reveals both HIF1α expression and AKT phosphorylation are not induced in the presence of the 
PI3Kinase inhibitor, in WT fibroblasts. b) Expression of VEGFA is inhibited in WT cells after 
treatment with 150nm of the PI3K-specific inhibitor, PI-103, as determine by semi-quantitative RT-
PCR. The expression the housekeeping gene Elp4, component of RNA PolII holoenzyme, was used as 
an input control for RT-PCR. c) Increased AKT phosphorylation after 72h chondroinduction was 
observed in WT cells but not in ATR-S cells. Protein extracts were analyzed by Western-blot using 
anti-phospho Thr308 of AKT antibody, and β-tubulin for protein loading control.  
 
 
c) 
b) 
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3.2.4 ORC1 Meier-Gorlin syndrome and IFT43 Sensenbrenner 
syndrome fibroblasts exhibit impaired chondrogenesis. 
Recently, mutations in genes involved in replication licensing were identified 
in Seckel Syndrome (SS) and/or Meier-Gorlin Syndrome (MGS) patients. These 
include the origin recognition complex (ORC) proteins ORC1, ORC4, and ORC6, as 
well as pre-replication complex (pre-RC) proteins CDT1 and CDC6 (Bicknell et al. 
2011; Guernsey et al. 2011; Bicknell et al. 2011). 
Both disorders, together with Majewski osteodysplastic primordial dwarfism 
(MOPD) type II, share overlapping clinical features that include accentuated 
microcephaly, severe intrauterine growth retardation and postnatal growth delay 
(Majewski and Goecke 1982; Hall et al. 2004). Various degrees of skeletal 
abnormalities are also observed such as delayed bone age, ivory epiphysis, 
clinodactyly, brachydactily. MGS is also referred to as “ear, patella, short stature 
syndrome" (EPS), due to the characteristic hypoplastic or absent kneecaps (patellae) 
and small ears (the outer ear is a cartilaginous tissue) (Gorlin 1992). Deficiency in 
origin licensing proteins has also been shown to inhibit the formation of primary cilia 
in fibroblasts (Tom Stiff, University of Sussex). The primary cilium plays a central 
role in skeletogenesis, in part by mediating Indian Hedgehog and Wnt signaling 
(Serra 2008; Haycraft et al. 2008). Skeletal defects are also commonly observed in 
ciliopathies, as exemplified by Sensenbrenner Syndrome (cranioectodermal 
dysplasia), a disorder caused by defects in the intraflagellar transport (IFT) 
machinery (Arts et al. 2011). Although impaired replicative capacity may contribute 
to the disease phenotype, these associations prompted me to consider the impact of 
impaired origin licensing machinery in the context of chondrogenesis.  
In this section the efficiency of ORC1-deficient MGS and IFT-43 defective 
Sensenbrenner Syndrome fibroblast to undergo chondroinduction, was investigated. 
The size distribution of chondroinduction derived-aggregates of both ORC1-
defective MGS fibroblasts and IFT43-defective Sensenbrenner Syndrome fibroblasts 
was smaller than those of control wild type (WT) cells after 24hrs culture on the 
chondrogenic matrix (Figure 3.2.9a). However, synthesis of glycosaminoglycans 
(GAGs), a chondrocyte ECM component, was similar in both ORC1 and IFT43 
defective cells, comparable to wild type levels (Figure 3.2.9b). 
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Figure 3.2.9 ORC1 Meier-Gorlin syndrome and IFT43 Sensenbrenner syndrome fibroblasts 
exhibit impaired chondrogenesis. 
a) Phase contrast images (40X) of control (WT) hTERT, ORC1-deficient MGS (ORC1) and IFT43-
mutated Sensenbrenner (IFT43) patient-derived fibroblasts at 0 hr and 24hr following addition to 
aggrecan coated plates. b) Size distribution of aggregates from WT, ORC1 and IFT43 fibroblasts 
following 24hr micromass culture in aggrecan coated plates (n=350 aggregates scored per line) 
measured using Adobe Photoshop from images acquired on the Zeiss Axiovert platform. Larger 
aggregate size was a feature of control fibroblasts following chondroinduction compared to ORC1 and 
IFT43 cells. c) Quantification of glycosaminoglycans (GAGs) synthesis by dimethylmethylene blue 
(DBM) assay showed no difference between levels of GAGs produced by WT or ORC1/IFT43 cells. 
SOX9 expression increases during chondroinduction, whereas type I collagen (COL1A1) represents a 
negative marker as differentiated chondrocytes secrete a specific extracellular matrix. d) SOX9 levels 
increased while COL1A1 levels decreased in WT cells during chondroinduction. Total RNA was 
extracted after the appointed times, and collagen type I and Sox9 expression was detected by semi-
quantitative RT-PCR. The expression the housekeeping gene Elp4, component of RNA PolII 
holoenzyme, was used as an input control for RT-PCR.  
 
 
 
 
COL1A1 expression was also analyzed by semi-quantitative RT-PCR. In WT 
cells I observed a marked decrease in expression of this marker, consistent with 
chondrogenic differentiation, which is also noticeable in IFT-43 cells. ORC1 MGS 
cell, however, fail to inhibit COL1A1 expression to the same extent under these 
conditions (Figure 3.2.9c). SOX9 is also a target of HIF-1α and a key regulator of 
chondrocyte differentiation. I examined SOX9 expression in these fibroblasts upon 
chondroinduction although in this case following 24hrs and 72hrs exposure to the 
chondrogenic matrix (figure 3.2) using semi-quantitative RT-PCR. SOX9 expression 
was found to increase after 24hrs in WT cells. Unexpectedly, aberrantly elevated 
levels of SOX9 were detected in the ORC1-defective MGS cells in the un-induced 
state. The IFT43-defective Sensenbrenner syndrome cells also exhibited some SOX9 
expression in the un-induced cells and could not further induce or indeed maintain 
expression of SOX9 upon chondroinduction. 
Optimal HIF-1α expression was observed in control cells within 2hrs after 
exposure to the chondrogenic matrix (Figure 3.2.10a). 
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Figure 3.2.10 HIF-1α and VEGF induction in ORC1 Meier-Gorlin syndrome and IFT43 
Sensenbrenner syndrome fibroblasts after chondrogenesis. 
a) HIF-1α levels were quantified by Western blotting at the indicated times after exposure to the 
chondrogenic matrix. The expression of MCM2 protein, a component of the helicase complex 
involved in initiation of DNA replication, was used as a loading control. b) Differentiated 
chondrocytes secrete factors that promote vascularization such as VEGFA enabling recruitment of 
osteoblasts to form the trabecular bone. VEGFA secretion was measured by semi-quantitative RT-
PCR up to 4 hrs after induction. ORC1 deficient fibroblasts show elevated basal levels of VEGFA but 
no increase up to 4 hrs unlike the WT cells, in which a marked increase in VEGFA expression is 
observed. We observed a decrease in VEGFA expression in IFT43 fibroblasts. The expression the 
housekeeping gene Elp4, component of RNA PolII holoenzyme, was used as an input control for RT-
PCR. 
 
 Interestingly, both ORC1-defective MGS and IFT43-defective 
Sensenbrenner syndrome cells appeared to have constitutively elevated levels of 
HIF-1α prior to induction relative to WT, but failed to maintain this expression of 
HIF-1α upon chondroinduction. To understand the potential significance or 
consequences of these differences in HIF-1α stabilization kinetics, we examined 
expression of VEGFA (gene encoding VEGF) under these conditions, since it 
represents an important HIF-1α transcriptional target during chondrogenesis. Using 
semi-quantitative RT-PCR a clear induction of VEGFA isoform a was noted in WT 
fibroblasts within 2-4hrs of exposure to the chondrogenic matrix. Both the VEGFA 
isoform c (faster migrating band) and isoform a (slower migrating band), were 
detected. Interestingly, both ORC1-defective MGS and the IFT43-defective 
Sensenbrenner Syndrome cells appear to exhibit VEGFA isoform c expression even 
in the un-induced cells, which, particularly for the Sensenbrenner syndrome cells, 
a) 
b) 
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was not maintained upon chondroinduction. VEGFA expression (isoform c) was not 
induced above background in the ORC1-defective MGS fibroblasts nor was isoform 
a amplified to a comparable extent as in WT cells.  
It was noticeable that both ORC1-defective MGS cells and the IFT43-
defective Sensenbrenner syndrome cells differed from control fibroblasts on four 
endpoints examined as part of the chondroinduction characterisation (aggregate size, 
HIF-1α stabilization, VEGFA and SOX9 induction), but defective ORC1 also differed 
from IFT43 deficiency. ORC1-defective MGS fibroblasts expressed significant 
levels of HIF-1α, VEGFA and SOX9 even in the un-induced cultures suggestive of a 
possible inappropriate engagement with this differentiation process.   
Using qRT-PCR to more closely monitor COL1A1 transcript levels, I 
observed elevated levels in control fibroblasts, partially decreased at 24h following 
addition to chondrogenic matrix and reduced to one fifth of the initial level in control 
WT cells by 72h after chondroinduction. In contrast, ORC1-and IFT43-deficient 
cells endogenous COL1A1 levels were not decreased at 24h and less substantially 
decreased at 72h (2 to 2.5 fold decreased for ORC1-deficient cells) when compared 
to the WT cells (figure 3.2.11). Additionally, SOX9 expression as detected by qRT-
PCR was shown to increase in WT fibroblasts 24h following aggrecan stimulation. 
In the ORC1 deficient cells, the pre-induction state already shows high levels of 
SOX9 transcript, whereas IFT43 cells, by contrast, showed reduced SOX9 levels, 
which only moderately increase following chondroinduction, under the same 
conditions.  
During endochondral bone formation, premature differentiation of immature 
chondrocytes can retard growth plate expansion and result in skeletal abnormalities 
(smaller bones) (Farquharson and Jefferies 2000). A transgenic mouse model of 
ORC1L-patient mutations would be the most appropriate means to formally validate 
this possibility. In summary, following chondroinduction, in our model culture 
system for chondrogenesis, both ORC1-defective MGS patient-derived fibroblast 
and IFT43-defective Sensenbrenner syndrome cells appeared distinct to those of 
control fibroblasts. This is consistent with aberrant inappropriate unregulated 
premature chondrogenic differentiation in these patient-derived cell lines that 
ultimately is not maintained and provides some evidence for the first time that 
chondrogenesis may be impaired/altered in these conditions. This highlights a novel 
link between defects in the origin licensing component ORC1 and programmed 
86 
 
differentiation with specific regard to MGS, and IFT with regard to Sensenbrenner 
Syndrome. 
     
 
   
    
Figure 3.2.11 Analysis of COL1A1 mRNA levels in ORC1 and IFT43 patient cells following 
chondroinduction, by qRT-PCR. 
PCR reactions were carried out using primers designed to amplify regions of the COL1A1 gene  a)  or 
the GAPDH gene, using cDNA as a template. The arrow indicates formation of a 200bp PCR product. 
To check for contamination with genomic DNA, a reaction using the RNA material as template was 
included, as well as a no-template reaction to check for primer contamination. The synthesized cDNA 
was used in quantitative PCR reactions designed to amplify 200bp regions of the COL1A1 and 
GAPDH gene, using the Qiagen Quantifast SYBR Green PCR kit. Amplification plots were produced 
by measuring the SYBR green fluorescence after each amplification cycle. A representative 
amplification plot for COL1A1 b) and GAPDH c) is shown. d) Example of a dissociation curve of the 
PCR product formed for COL1A1, produced by increasing the temperature of the reaction step-wise 
from 55
o
C to 95
o
C and measuring fluorescence at each increase. The experiment was repeated 3 times 
with samples prepared in triplicate. e) ΓCt values were calculated as specified in materials and 
methods as averages for the three acquisition runs. GAPDH mRNA was used as a reference mRNA. 
Mean values ± standard deviations of the means are shown. 
 
a) 
b) 
c) 
d) 
e) 
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Figure 3.2.12 Analysis of SOX9 mRNA levels in ORC1 and IFT43 patient cells following 
chondroinduction, by qRT-PCR. 
PCR reactions were carried out using primers designed to amplify regions of the SOX9 gene or the 
GAPDH gene, using cDNA as template. A representative amplification plot for SOX9 a) and GAPDH 
b) is shown. c) Example of a dissociation curve of the PCR product formed for SOX9,  produced by 
increasing the temperature of the reaction step-wise from 55
o
C to 95
o
C and measuring fluorescence at 
each increase. The experiment was repeated 3 times with samples prepared in triplicate. d) ΓCt values 
were calculated as specified in materials and methods as averages for the three acquisition runs. 
GAPDH mRNA was used as a reference mRNA. Mean values ± standard deviations of the means are 
shown. 
 
 
 
 
 
a) c) 
b) 
d) 
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3.3 Summary 
Severe growth retardation and skeletal defects are key clinical features of 
MPD, including Seckel syndrome, which can be caused by mutations in ATR, as 
well as PCNT, associated with defective ATR-pathway function. ATR is one of the 
apical regulators of the DDR, but novel substrates for ATR (and ATM) have been 
identified in response to DNA damage, which are not directly involved in the DDR 
network.  
In view of the disproportionate impact of impaired ATR signaling on the 
skeletal tissue, exemplified by Seckel syndrome, I investigated if ATR function 
could be specifically required during skeletogenesis. Initiation of osteogenesis was 
not compromised after ATR inhibition, but it had a potential impact on maintenance 
of the differentiated status. Cartilage tissue is required as a template for bone 
development, and therefore defects in chondrogenesis directly impact on the skeletal 
phenotype. Chondroinduction in patient derived ATR-S and PCNT-S cells was less 
efficient than in control WT cells, as assessed by several parameters (aggregate 
formation, synthesis of GAGs, expression of chondrocyte-specific markers). 
Significantly, HIF-1α and VEGFA expression was not induced in ATR-S and PCNT-
S cells during chondroinduction, suggesting a serious problem in the regulation of 
the hypoxia response in these cells. Similarly, activation of PI3K/AKT signaling, 
required for chondrocyte formation, was not efficient in Seckel patient cells.  
 Finally, I provided evidence that ORC1-deficient Meier-Gorlin Syndrome 
(MGS), characterized by microcephaly and skeletal defects, is associated with 
aberrant chondroinduction. Similarly, an IFT43-defect, such as seen in 
Sensenbrenner syndrome, also impacts chondroinduction.  This data suggests a role 
for ORC1 and IFT43 in chondrogenesis. 
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3.4 Discussion 
 
Striking growth retardation and skeletal defects, along with microcephaly, are 
the key clinical features of the Microcephalic Primordial Dwarfism (MPD) Seckel 
Syndrome. A hypomorphic mutation in ATR was the first identified causative 
mutation behind this disorder (O'Driscoll et al. 2003). Mutations in the gene 
encoding the centrosomal protein pericentrin (PCNT) also have been shown to cause 
SS (Griffith et al. 2008). PCNT mutations have also been described in microcephalic 
osteodysplastic primordial dwarfism type II (MOPDII) a related MPD associated 
with a more marked skeletal involvement and asymmetric dwarfism. More recently, 
mutations in ORC1, ORC4, ORC6, CDT1 and CDC6, involved in origin replication 
licencing, have also been identified in Seckel Syndrome and MGS patients (Bicknell, 
Walker, et al. 2011; Guernsey et al. 2011; Bicknell, Bongers, et al. 2011), suggesting 
a link with defective DNA replication and these disorders presentations. Seckel 
Syndrome is a genetically heterogeneous condition associated with defective ATR 
signaling pathway function, even when the causative mutation is not in ATR per se 
(Alderton et al. 2004).  Studies have been done to enlighten the relationship between 
these mutations and the specific phenotypes observed in the patients. Microcephaly 
has been proposed to result from a limiting pool of neuroprogenitor stem cells as a 
result of 1) limited expression and/or 2) elevated apoptosis during brain 
development, as a consequence of imbalanced regulation of mitosis during 
neurogenesis (Mochida and Walsh 2001). PCNT defects potentially affecting spindle 
orientation could result in an imbalance between symmetric versus asymmetric stem 
cell divisions. Not only misregulation of the balance between 
progenitor/differentiating cells in the neuroepithelium could contribute to 
microcephaly, but also diminution of total cellularity could explain the extreme short 
stature observed in primordial dwarfism. The ATR-Seckel mouse model proposes 
that limited ATR function results in accumulation of DNA damage due to replicative 
stress during embryogenesis (Murga et al. 2009). The consequent increase in 
apoptosis during development could account for the clinical features observed in the 
human patients, as well as in the ATR-Seckel mouse. Additionally, conditional ATR 
deletion in adult mice was shown cause depletion of a high percentage of 
proliferating cells in multiple tissue systems (Ruzankina et al. 2007).  
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ATR and ATM are the canonical DNA damage response apical regulators. 
However, a high number of new substrates for ATR/ATM phosphorylation after 
DNA damage have been identified, and some of these are not elements directly 
involved in the DDR network (Matsuoka et al. 2007). This observation potentially 
extends the range of cellular processes regulated by these kinases. 
As such, and in view of the seemingly disproportionate effect of impaired 
ATR signaling on skeletal tissues, as observed in Seckel Syndrome, the question 
arose of whether ATR function could be involved in other aspects of different 
cellular processes, and specifically if ATR function is required for the formation of 
the skeleton during human development. 
Here, I showed that ATR inhibition in MG-63 osteosarcoma cells did not 
prevent initiation of osteoinduction, as indicated by the increase in expression of 
bone specific markers osteocalcin and collagen type I following osteo-induction. 
However, the ability to maintain the differentiated status did appear to be 
compromised following ATR silencing.  
In this osteoinduction model system, some level of cell death was observed 
following initiation of differentiation, in both WT and ATR siRNA cells. In the 
mineralizing conditions however, the ATR siRNA cell cultures seemed to result in 
relatively increased cell death. This observation was not further investigated in this 
study, but could be a potential point of interest, as pathological loss of bone mass 
defines the osteoporosis condition and an aged phenotype (associated with 
osteoporosis) was observed in the conditional ATR knockdown in adult mice 
(Ruzankina et al. 2007). 
A cartilage template is used in the process of formation of the majority of the 
bones in the skeleton (Karsenty 2008), and as such a defect in chondrogenesis could 
directly result in an impaired bone formation/skeletal phenotype, as seen in SS. 
The impact of ATR signaling function on the process of cartilage formation was 
investigated using patient-derived fibroblasts from ATR-S and PCNT-S individuals. 
We optimized here a chondroiduction model system for de-differentiation of human 
fibroblasts, based on a murine cell model previously described. Some indicators 
suggested that chondroinduction is less efficient in ATR-S and PCNT-S cells, in this 
system. The acquisition of a chondrocyte specific round-shaped cell morphology and 
formation of aggregates in suspension was observed following induction, with both 
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SS cell types forming markedly smaller sized aggregates when compared to control 
cells. 
Differentiation was accompanied by synthesis of chondrocyte specific factors 
such as sulphated glycosaminoglycans and the chondrogenic transcription factor 
SOX9, as well as suppression of fibroblastic markers like collagen type I. Notably, 
both ATR-S and PCNT-S derived fibroblasts did not acquire a chondrocyte specific 
phenotype as efficiently as the WT fibroblasts, suggestive of a problem in cartilage 
differentiation in these cells. And importantly, these observed phenotypes are 
uncoupled from the role of ATR in DNA replication, as the cells were shown to have 
exited the cell cycle appropriately upon chondro-differentiation. These observations 
lend me to propose an impact of ATR depletion in aspects of cartilage formation 
which are not associated with replicative stress. 
This observation was further strengthened by siRNA mediated inhibition of 
ATR as well as PCNT, in WT fibroblasts, which resulted in a less efficient inhibition 
of collagen type I expression, compared to control cells, following chondroinduction. 
Another important aspect during chondrocyte differentiation in the fetal 
growth plate is the cellular response to hypoxia observed in that environment (Araldi 
and Schipani 2010). Hypoxia responsive elements are required to promote 
chondrocyte survival. In my system, I found chondroinduction induced normoxic 
expression of HIF-1α in fibroblast cells, after 2-4h post-induction. Moreover, HIF-1α 
expression was delayed/attenuated in the SS patient cells, both ATR-S and PCNT-S. 
This effect was further observed even at 24h after chondroinduction. The small 
diameter of the cell aggregates does not suggest that a hypoxic microenvironment 
can be found in the core of the WT chondrogenic aggregates, but this hypothesis 
needs be further investigated. Expression of the VEGF angiogenic factor, a 
downstream effector from HIF-1α, was correspondingly induced in WT fibroblasts 
under the same conditions, but not induced specifically in ATR-S and PCNT-S cells. 
These combined observations suggest a problem in regulation of the hypoxia 
response in ATR/PCNT deficient cells, in the context of chondrogenesis specifically.  
HIF-1α can be activated under normoxic conditions, following stimulation 
with insulin and interleukin-1, and involving activation of the PI3K/AKT pathway 
(Stiehl et al. 2002).  Also, insulin and IGF-1 have a demonstrated role in 
chondrogenesis, and can induce chondro-differentiation in vitro (Phornphutkul et al. 
2006). 
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The PI3K/AKT signaling pathway can be activated by a large number of 
receptors, including tyrosine receptor kinases such as the insulin receptor and IGF1R 
(insulin-like growth factor 1 receptor) (Laplante and Sabatini 2012). A number of 
cellular functions, including cell differentiation, proliferation and survival, are 
controlled by this pathway in a cell-type specific manner. Chondrocyte hypertrophy 
and survival during cartilage formation requires PI3K/AKT signaling (Rokutanda et 
al. 2009). Additionally, some evidence has been found suggesting regulation of PI3K 
by the cartilage transcription factor Runx2 during this process (Goldring et al.2006). 
Cells from aged and osteoarthritic cartilages produce less collagen and cartilage 
proteoglycan in response to IGF-1, via PI3K/AKT regulation (Chen et al. 2012). 
AKT activation is induced following chondroinduction in my model system, 
in WT fibroblasts.  Notably, ATR-S patient cells failed to induce AKT activation 
under the same conditions. This suggests a major signaling defect involving a key 
signaling pathway in these cells. Phosphorylation on Thr308 of AKT is a PI3K/PDK-
dependent event. Indeed after treatment with a PI3K specific inhibitor, PI-103, 
chondroinduction failed to induce AKT activation in WT cells. Importantly, other 
chondrogenic events such as activation of HIF-1α and VEGF were suppressed after 
PI3K inhibition. This suggests some crucial chondrogenic events are under 
PI3K/AKT pathway regulation, and importantly, these are being mis-regulated in 
ATR-S patient cells. 
A direct link between ATR-pathway function and HIF-1 is provided by the 
fact that the ATR damage-response pathway has been recently shown to be activated 
by stalled replication forks that result from hypoxia-induced S-phase arrest, 
involving phosphorylation of H2AX and accumulation of the tumour suppressor p53 
(Hammond et al. 2002). Interestingly, oxidative stress has also been shown to inhibit 
IGF-dependent induction of chondrocyte proteoglycan and collagen, involving 
changes in regulation of the PI3K/AKT as well as the ERK/MAPK pathways 
(Starkman et al. 2005).  
 In order to try and clarify the mechanism by which ATR (and PCNT) 
deficiencies can have an impact on these seemingly unconnected signaling pathways, 
I investigated in more detail the PI3K/AKT/mTOR signaling response in Seckel 
Syndrome patient cells in the next chapter.  
Finally, defects in origin licensing proteins cause Meier-Gorlin Syndrome 
(MGS) and also Seckel Syndrome (Bicknell et al. 2011; Guernsey et al. 2011; 
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Bicknell et al. 2011). MGS clinical features include microcephaly and bone 
developmental defects. Skeletal defects are also observed in ciliopathies, namely in 
Sensenbrenner syndrome (Arts et al. 2011). In order to understand how deficiency in 
origin licensing proteins may contribute to these specific skeletal phenotypes, I 
investigated the in vitro chondro differentiation of ORC1-deficient MGS, in 
comparison to IFT-43 deficient Sensenbrenner Syndrome patient cells, which are 
defective in IFT.  
I provide evidence for the first time to suggest that defective ORC1 is 
associated with aberrant chondro-induction indicating a role for ORC1 in 
chondrogenesis. Similarly, and for the first time, I provide direct evidence for 
impaired IFT43 in the context of Sensenbrenner syndrome, as also affecting 
chondro-induction. With specific regard to ATR, PCNT and ORC1, it should be 
noted that chondro-induction (and chondrogenesis) involves regulated cell cycle exit. 
Therefore the impact of these genes upon chondro-induction must be independent of 
their roles in cell cycle progression. My data provides a cell-based model to help 
explain the origin of skeletal abnormalities in multiple MPD‟s (Seckel, MOPDII, 
MGS) expanding the impacts of defects in these genes. 
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Chapter Four 
Results II: Insulin-dependent PI3K-AKT-mTOR 
signaling in ATR and PCNT-defected patient –
derived cells 
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4.1 Introduction 
 
Microcephalic primordial dwarfism (MPD), including Seckel Syndrome, is a 
disorder of severe global growth impairment associated with profound 
disproportionate microcephaly. Organism growth and development requires a tightly 
regulated integration of signals from multiple signaling pathways. Key signaling 
pathways involved in the regulation of organ and organism size include the receptor 
tyrosine kinase (RTK)PI3K-AKT-mTOR, and the mitogen-activated protein kinase 
(MAPK) pathway, controlling aspects such as cell mass, cell proliferation and cell 
survival through the regulation of ribosome biosynthesis and global protein 
translation (see Chapter One) (Caron et al. 2010). Growth deregulation is an 
important aspect of many human diseases, including cancer, and a number of 
disorders of growth failure or overgrowth are caused by single gene mutations in the 
RTK-PI3K-AKT-mTOR pathway or the MAPK pathway (Laplante and Sabatini 
2012; Tidyman et al. 2009). 
The currently known genes mutated in microcephalic primordial dwarfism 
(ATR, PCNT, ORC1, CENPJ, CEP152, ORC1, ORC4, ORC6, CDT1, CDC6, U4atac, 
IGF-1) are mainly not components of core growth signaling pathways, but generally 
involved in cell cycle progression (O'Driscoll et al. 2003; Griffith et al. 2008; 
Bicknell, et al. 2011; Guernsey et al. 2011; Bicknell, et al. 2011; Netchine et al. 
2011). Impaired cell division, resulting in reduced cell number, could be one 
hypothesis to explain the global growth failure and reduced organism size.  However, 
mutations in IGF-1 (insulin-like growth factor 1) have also been shown to result in 
primordial microcephalic dwarfism, evidencing that this specific phenotype is 
associated with defective regulation of growth signaling pathways (Netchine et al. 
2011). Seckel Syndrome is associated with defects in ATR-dependent signaling, 
even when the mutated gene is not ATR per se. (Alderton et al. 2004) 
Interestingly, recent studies have found a number of components of the 
insulin/mTOR signaling pathway are substrates for ATR/ATM phosphorylation after 
DNA damage (Matsuoka et al. 2007), suggesting functional links between these 
pathways, although their fundamental biological significance has not been described.  
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Figure 4.1.1  The complex insulin/mTOR signalling involves negative feedback mechanisms and 
cross-talk with the PI3K/AKT and RAS/MAPK pathways. 
Ligand binding induces phosphorylation of IRS-1 resulting in recruitment of the p110 catalytic 
subunit of PI3K. AKT phosporylates and inhibits TSC function, leading to mTOR activation. Through 
4E-BP1, rapamycin-sensitive mTORC1 drives cell growth and proliferation by enhancing eIF4E-
mediated mRNA translation. S6K1 activation by mTOR leads to IRS-1 phosphorylation and 
proteasomal degradation. 
 
 
In this chapter I investigated the insulin-dependent PI3K-AKT-mTOR signal 
transduction in ATR-defective and PCNT-defective Seckel Syndrome cell lines, to 
determine whether impairments of this pathway may underlie the severe dwarfism 
observed in these patients. 
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4.2 Results 
4.2.1 mTORC1-dependent S6K activation is not inhibited by 
rapamycin in ATR-S and PCNT-S cells  
The macrolide rapamycin was first identified as a bacterial anti-fungal agent 
produced by Streptomyces hygroscopicus, identified on Easter Island . It was later 
found to have both immunosuppressive and cell anti-proliferative properties. 
Rapamycin (and its derivatives) is currently used therapeutically for its anticancer 
activity, and as an immunosuppressant for transplant patients (Blagosklonny 2012). 
The primary receptor for rapamycin in the cell is FKBP. The rapamycin-FKBP 
complex binds to and inhibits mTORC1 (Yip et al. 2010). Whereas mTORC1 is 
sensitive to acute rapamycin treatment, mTORC2 is generally considered to be non-
responsive to rapamycin. However, prolonged rapamycin treatment may also 
interfere with mTORC2 function (Sarbassov et al. 2006).  
To investigate mTORC1 function in Seckel Syndrome, I exposed patient-
derived fibroblasts to short, acute rapamycin inhibition. Treatment with rapamycin 
results in rapid loss of S6K phosphorylation. While negatively regulating mTORC1 
downstream substrates, it has been shown that inhibition of mTORC1-dependent 
signaling by rapamycin induces strong activation of AKT, in a negative feedback 
mechanism dependent on S6K/IGF-1R/PI3K.   
 
 
    
Figure 4.2.1. S6K activation is not inhibited by treatment with Rapamycin, in ATR-S and 
PCNT-S cells. 
WT, ATRS and PCNT-S exponentially growing primary cells were treated with 200mM rapamycin 
for a period of 4hours. Protein extracts were analysed by Western-blot using phospho-specific 
antibodies. 
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As expected, the treatment induced the feedback activation of AKT in the 
WT cells, and less markedly, also in Seckel patient fibroblasts. Under these 
conditions however, AKT activation did not impact on phosphorylation of AKT-
dependent substrates such as the glycogen synthase kinase-3β  (GSK3β). 
I found rapamycin did not inhibit mTORC1-dependent S6K phosphorylation 
specifically in the ATR-S and PCNT-S cells unlike WT fibroblasts (Figure 4.2.1). 
Moreover, the endogenous levels of phosphor-S6K appeared abnormally high in both 
ATR-S and PCNT-S, when compared to the WT cells, suggesting that mTORC1 may 
be hyperactive under these conditions. Interestingly, S6K1 defects result in growth 
retardation. 
I then looked at the signaling response to insulin stimulation in ATR-S and 
PCNT-S cells, as S6K continuous feedback inhibition of IRS-1 could result in insulin 
insensitivity in these cells. It is possible and predictable that the impact of ATR and 
PCNT deficiency on mTOR signaling could be mechanistically different, albeit with 
a similar outcome. 
 
 
4.2.2. Insulin- dependent activation of mTOR signaling pathway 
components in ATR-S and PCNT-S cells 
Because of the known role of insulin signaling in development and growth, I 
looked at insulin-dependent mTOR pathway signaling in primary fibroblasts derived 
from Seckel Syndrome patients, both ATR-defective  (FO2-92), as well as PCNT-
defective (ASB) cells.  
To minimize the contribution of serum-derived insulin, the cells were serum-
starved for 72h prior to re-addiction of serum and/or insulin. Activation of the mTOR 
pathway was investigated after re-introduction to normal growing media (15% FBS) 
or insulin alone. Importantly, physiologically relevant concentrations of insulin 
(200nM) were used in this study. mTOR pathway signaling response was assessed 
by looking at the phosphorylation status of a number of components of the pathway. 
In particular, phosphorylation of S6K is a convenient measure of the activity of 
mTORC1 branch, and phospho-AKT levels can inform on mTORC2 function. 
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Figure 4.2.2. Activation of PI3K/AKT/mTOR signaling pathway components following 
serum/insulin stimulation. 
WT, ATR-S and PCNT-S primary cells were serum starved for 72h and reintroduced to complete 
medium (15%FCS) or 200nM insulin for 2h. Protein extracts were analyzed by Western-blot using 
phospho-specific antibodies. β-tubulin expression was used as protein loading control. 
 
AKT activation is triggered by phosphorylation at two key residues: Thr308 
by PDK1, and Ser473 by mTORC2. Serum starved cells showed efficient 
inactivation of AKT, as expected. Following stimulation, Thr308 and Ser473 
phosphorylation on AKT was attenuated after insulin when compared to serum 
stimulation, the latter being the result of an array of other serum components and 
growth factors found in the growth media that are also able to induce AKT 
activation. AKT was efficiently activated in serum deprived cells when reintroduced 
to full-serum media. Looking at insulin stimulation alone, both WT as well as ATR-
S and PCNT-S cells respond to insulin by phosphorylating AKT and the pattern of 
activation was the same at both phosphorylation sites. However, looking further 
a) 
b) 
100 
 
downstream at p70S6 kinase (S6K) phosphorylation, a problem involving insulin -
dependent S6K regulation in the ATR-S cells becomes evident as they do not 
respond to insulin specifically (Figure 4.2.2.). Insulin stimulation in the WT cells 
results in evident S6K phosphorylation, and to a lower extent also in PCNT-S cells, 
but fails to stimulate S6K activation in the ATR-S cells. In addition, some 
phosphorylated S6K was still detected in the growth arrested ATR-S cells.  
Hyper or prolonged S6K activation results in a negative feedback in the 
insulin receptor by inhibition of IRS-1 (O'Reilly et al. 2006). This result implies a 
problem in the mTOR pathway regulation in response to insulin signaling in SS cells, 
which may lie at the level of the insulin receptor itself or be the result of a break 
elsewhere in the signal transduction pathway.  
Activated mTORC1 phosphorylates 4E-BP1 leading to its release from elf4E, 
which allows it to form initiation factor complexes and thus activate protein 
synthesis (Hay and Sonenberg 2004). Interestingly, 4EBP1 is also an ATR/ATM 
target for phosphorylation following DNA damage (Matsuoka et al. 2007). 4E-BP1 
phosphorylation in ATR-S cells seemed to follow a normal induction pattern.  
Paradoxically, 4E-BP1 and S6Kinase phosphorylation seemed to be 
differently affected/deregulated between the ATR and PCNT deficient cells even 
though they are both the downstream targets of mTORC1 activation. Studies have 
shown that mTORC1 can have different outputs to S6K and 4EBP1 (X. Wang et al. 
2005).   
Two different ribosomal S6 kinases, S6K1 and S6K2 act downstream of 
mTORC1 and phosphorylate the 40s ribosomal subunit S6 (Phin et al. 2003). S6K1 
has been associated with cell size regulation (Derheimer and Kastan 2010; Fingar et 
al. 2002). Interestingly, S6K2 has been found to localize to the pericentriolar area of 
the centrosome (Burma and Chen 2004; Rossi et al. 2007). Potential disturbance of 
S6K subcellular localization in pericentrin deficient cells could be involved in its 
deregulation.  
In order to identify where in the insulin/mTOR pathway the signaling cascade 
is being deregulated, I looked at the activation of a number of key components of this 
pathway. 
PDK1 acts downstream from PI3K, which is recruited to the IRS and 
activated following insulin stimulation, in a PI3K dependent manner (Bakkenist et al. 
2003; Vanhaesebroeck et al. 2000). In both WT and ATR-S cells serum/insulin 
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stimulation results in PDK1 phosphorylation on Ser241, a necessary step for PDK1 
activity. In PCNT-deficient cells, PDK1 is activated in the presence of serum, but 
less efficient after insulin stimulation. This suggests a problem in an early signaling 
event in this pathway, in PCNT-S cells specifically. 
The protein and lipid phosphatase PTEN (Phosphatase and Tensin Homolog 
Deleted on Chromosome 10) is a negative regulator of the PI3K/AKT pathway, 
opposing PI3K-derived PIP3 accumulation. Phosphorylation at Ser380 promotes 
PTEN stabilization, while inhibiting its phosphatase activity (O'Driscoll et al. 2006; 
Yang et al. 2012).  
PTEN phosphorylation is not induced in PCNT-S cells, following insulin. 
Under these conditions, in PCNT-deficient cells, PTEN is abnormally active, which 
may result in suppression of the pathway downstream. Conversely, PTEN 
inactivation would result in constitutive activation of the PI3K/AKT pathway. This 
continued effect could eventually lead to insulin insensitivity due to the feedback 
inhibition of IRS-1 by active S6K. Interestingly, PTEN can localize to the 
centrosome where it is involved in chromosome stability, DNA repair and cell cycle 
arrest (down-regulation of cyclin D1) (Riballo et al. 2004; Planchon et al. 2008). The 
phosphorylation status of PTEN at different sites seems to affect its subcellular 
localization.  
The glycogen synthase kinase 3 (GSK3β) is negatively regulated by insulin 
signaling. AKT activation mediated by the IRS-1/PI3K axis leads to phosphorylation 
of GSK3β resulting in its inactivation (Grimes et al. 2001). GSK3β inactivation is 
impaired in PCNT-S cells following insulin. GSK3β also directly phosphorylates 
IRS-1 and impairs insulin signaling and is involved in development of insulin 
resistance (Kaidanovich et al. 2002). Additionally, GSK3β was recently found to be 
a potential regulator of CDC25A (Kang et al. 2008), establishing a direct link to the 
DNA damage response/cell cycle-regulation machinery. 
The tuberous sclerosis complex (TSC1-2) is a negative regulator of mTORC1 
(Huang et al. 2008). In response to insulin, activated AKT phosphorylates TSC2 on 
Thr1462, and inactivates TSC1/TSC2, releasing its inhibition of Rheb, which in turn 
activates mTORC1. TSC2 inactivation was defective after serum stimulation as well 
as insulin in both Seckel patient lines.  TSC2 can also be phosphorylated by AMPK 
in response to low intracellular ATP and/or hypoxia (Murga et al. 2009; Inoki et al. 
2006; O'Driscoll et al. 2003; Ruzankina et al. 2007; Brugarolas et al. 2004). 
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Additionally, ERK signaling activates mTORC1, involving TSC1-TSC2 complex 
phosphorylation by RSK. RSK is also able to phosphorylate TSC2 on the AKT 
conserved sites, as well as at a novel site (Ser 1798). Interestingly, TSC2 is also an 
ATR-ATM substrate after DNA damage (Murga et al. 2009; Matsuoka et al. 2007). 
c-RAF (or Raf-1) is a serine/threonine kinase mainly implicated in the 
induction of proliferation via the Ras/MEK/ERK pathway. An inhibitory binding site 
on c-Raf (Ser259) can be directly phosphorylated by AKT (Murga et al. 2009; 
Moelling et al. 2002). C-Raf is phosphorylated and inactivated in serum-deprived 
cells, resulting in proliferation arrest. The AKT-dependent inhibition of c-Raf 
following serum-deprivation was sustained in WT cells after 2 hours of re-
introduction to serum/insulin. Remarkably, serum-starvation did not result in AKT-
dependent inactivation of c-Raf in both Seckel cell lines (Figure 4.2.2b). PCNT-S 
cells failed to inactivate c-Raf after insulin. Interestingly, c-Raf is also an ATR/ATM 
substrate after DNA damage (Lee et al. 2012; Matsuoka et al. 2007). These results 
seem to point to another important signal deregulation in Seckel Syndrome cells 
involving a different signaling cascade. 
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4.2.3. ATR knockdown results in inhibited insulin-dependent 
activation of AKT and S6K. 
 A knockdown of ATR in an independent cell line, the MG63 osteosarcoma, 
was used to further investigate the impact of ATR deficiency specifically on aspects 
of mTOR pathway signaling, and to corroborate the phenotypes observed in the 
patient cell lines. PI3K and PDK1-dependent phosphorylation of AKT on Thr308 did 
not occur specifically in ATR depleted cells, in response to insulin stimulation 
(Figure 4.2.3.). Correspondingly, phosphorylation of S6K downstream of mTORC1 
was also defective in the ATR knockdown cells, under the same conditions, when 
compared to control cells. These results further strengthen the observation that ATR 
deficiency is associated with impairment of insulin-dependent mTOR signal 
transduction.  
 
 
Figure 4.2.3. ATR knockdown in MG63 cells inhibits insulin-dependent activation of AKT and 
p70S6K. Control (WT) and ATR knockdown (ATR siRNA) cells were serum starved for 72h and 
reintroduced to complete medium (15% FBS) or insulin (200nM) for 2h. ATR siRNA cells failed to 
efficiently activate AKT, as well as S6K following insulin stimulation. Protein extracts were analyzed 
by Western-blot using phospho-specific antibodies. β-tubulin was used as a control for protein 
loading. 
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4.2.4. Insulin-dependent activation of PDK1 is reduced also in a 
PCNT-defective lymphoblastoid cell line 
An independent PCNT-S lymphoblast cell line (CV1559; affected 
Seckel/MDPII PCNT 658G>T; p.E220X) was used to investigate aspects of mTOR 
signaling and confirm some of the observations made using the PCNT-S fibroblast 
line. These cells also show some level of deregulation in the mTOR pathway, as the 
PCNT-S lymphoblasts also failed to specifically activate PDK1 following insulin 
stimulation, thus confirming the previous observations in the fibroblast cells. In 
PCNT-S cells, the AKT and PDK1 activation profiles suggest deregulation in early 
events in the insulin/ mTOR signaling cascade (Figure 4.2.4). 
Collectively, the phenotypes observed in both Seckel patient derived cells, as 
well as following ATR knockdown point to an association between defective 
ATR/PCNT and deregulation of the insulin/ mTOR pathway, a key signaling cascade 
involved in regulation of cell and organism growth. These novel findings shed new 
light into the potential contribution of defects in the PI3K-AKT-mTOR pathway to 
the clinical presentation of these patients. In fact, subsequent careful clinical 
evaluation of PCNT-defective individuals has shown that they all develop a 
pronounced insulin-resistant form of diabetes (Huang-Doran et al., 2011). 
 
 
Figure 4.2.4. Insulin stimulation results in PDK1 phosphorylation in control but not in PCNT-S  
LBLs. 
Exponentially growing (exp) control (WT) and PCNT-S (CV1559) lymphoblast cell lines we serum 
starved for 72h (NS) and reintroduced to complete growing medium (FS) or 200nM insulin (ins) for 
2h. Insulin stimulation failed to induce PDK1 phosphorylation in PCNT-S cells, unlike the WT. the 
pattern of AKT phosphorylation on Thr308 was comparable between WT and PCNT-S lines. Protein 
extracts were analyzed by Western-blot using phosphor-specific antibodies. β-tubulin was used as a 
control for protein loading. 
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4.2.5. PI3K activation is compromised in PCNT-S cells 
The PI3K pathway mediates the mTOR response to growth factors. Insulin or 
insulin-like growth factors (IGFs) binding to their receptors leads to recruitment and 
activation of PI3K by the insulin receptor substrate (IRS) (Whitehead et al. 2000). 
IRS-bound PI3K converts phosphatidylinositol-4,5-phosphate (PIP2) to 
phosphatidylinositol-3,4,5-phosphate (PIP3). The subsequent PIP3 accumulation  
results in the phosphorylation and activation of PDK1, which in turns phophorylates 
AKT on Thr308. Activated AKT can positively regulate mTORC1 activation by 
phosphorylating and suppressing TSC1-TSC2, and thus removing its inhibitory 
effect over mTORC1 (Rokutanda et al. 2009). PI3K activation is therefore an 
important step in this signal transduction, and therefore represents a key step in the 
regulation of these phosphorylation events. 
 
 
Figure 4.2.5 Insulin/serum stimulation results in PI3K phosphorylation in WT and ATR-S cells, 
but fails to induce PI3K activation specifically in PCNT-S cells, which showed also reduced 
levels of PI3K. 
WT, ATR-S and PCNT-S fibroblasts were serum starved for 72h and reintroduced to complete 
medium (15% FBS) or 200nM insulin for 2h. Protein extracts were analyzed by Western-blot using 
specific antibodies. β-tubulin was used as protein loading control. 
 
 
 
 
Strikingly, both serum as well as insulin stimulation failed to activate PI3K in 
PCNT-deficient cells, following serum deprivation (Figure 4.2.5). This result was 
further confirmed in an independent PCNT-defective fibroblast line (data not 
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shown). Moreover, endogenous levels of PI3K appeared abnormally low in these 
cells. Comparatively, efficient PI3K activation in response to insulin was observed in 
the ATR-S line investigated, comparative to WT cells. 
A fraction of PI3K has been found to localize to the centrosome (Kumar et al. 
2010). At least one study reports a potential association between PI3K and 
pericentrin, as the PI3K-dependent kinase activity was found to immunoprecipitate 
with PCNT antibodies in response to insulin (Kapeller et al. 1995). 
I wanted to investigate if PI3K is being recruited to the centrosome in PCNT-
defective Seckel cells and whether PI3K cellular localization is altered in response to 
insulin stimulation. Visualization of PI3K by immunofluorescence in the cells did 
not reveal any change in PI3K localization after induction with both serum and 
insulin alone (data not shown), which was observed mainly in the cytoplasm, as 
expected.  
 
 
Figure 4.2.6. Subcellular localization of PI3K in WT and PCNT-S primary fibroblast analyzed 
by immunofluorescence. 
Cultured WT and PCNT-S fibroblast cells were fixed, permeabilized and immunostained with the 
anti-p85PI3K antibody and a FITC conjugated secondary antibody (green). DAPI counterstain (blue) 
provides nuclear staining. 400X magnification. PI3K is mainly distributed in the cytoplasm. PCNT-S 
cells show reduced levels of PI3K when compared to WT cells. 
However, what was striking in all conditions was the reduced overall level of 
PI3K detected in the PCNT-S cell line (Figure 4.2.6) when compared to PI3K levels 
in control WT cells. This could represent a serious defect with potential impact not 
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only on regulation of mTOR signaling as well as other signaling cascades that 
operate downstream from PI3K. 
To confirm the previously described pericentrin-PI3K interaction, and to 
investigate this association in the context of pericentrin deficiency, I used a PCNT-S 
lymphoblast cell line. WT and PCNT-S cells were lysed and immunoprecipitated 
with either PCNT or PI3K antibodies (p85 and p110α PI3K subunits). The 
immunoprecipitates were then analyzed for the presence of PI3K and pericentrin, 
respectively, by immunoblotting. PCNT was detected in PI3K immunoprecipitates 
from WT (AG87) cells, thus confirming the interaction between these two proteins 
(Figure 4.2.7a). As expected, PCNT was not detected in PI3K-immunoprecipitates 
from the PCNT-S line (CV1559).  
 
 
   
Figure 4.2.7. PCNT immunoprecipitates with PI3K. 
a) PCNT detected by western-blot analysis in immunoprecipitates using an anti-p85PI3K antibody in 
control (AG87) but not in PCNT-S (CV1559) LBLs. b) serum-starvation in does not affect PCNT-
PI3K interaction in WT LBLs. 
 
Serum-deprivation, and subsequent stimulation with complete medium or 
insulin did not seem to affect PCNT-PI3K interaction (Figure 4.2.7.b). However, I 
was not successful in confirming this interaction in the reverse IP, as we failed to 
detect PI3K in PCNT immunoprecipitates (Figure 4.2.9). This could be due to 
different antibody efficiencies for immunoprecipitation, or the fact that only a small 
fraction of PI3K interacts with PCNT at centrosomes at any one time.  
 
a) b) 
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Figure 4.2.8. p85 PI3K is not detected in PCNT immunoprecipitates. 
a) p85PI3K not detected by western-blot analysis in immunoprecipitates using an anti-PCNT antibody 
in control (AG87) and PCNT-S (CV1559) LBLs, both in exponentially growing cells or b) following 
serum-starvation and re-stimulation with serum/insulin. Imput (WCE) represents 1/10 of the amount 
used for the IP. 
 
4.2.5 PI3K levels are reduced following siRNA-mediated PCNT 
knockdown 
To confirm that the signaling defects observed were a direct result of pericentrin 
depletion in the cell lines investigated, a transient siRNA-mediated PCNT 
knockdown was introduced in C2C12 cells, a mouse myoblast line frequently 
employed in mTOR pathway evaluations. PCNT expression was successfully 
reduced to undetectable levels in this cell line (Figure 4.2.7.).  
 
Figure 4.2.9. p85 PI3K is depleted in C2C12 mouse myoblasts after PCNT knockdown. 
C2C12 cells were transfected with PCNT siRNA (Dharmacon SMARTpool siRNA). PCNT, p85PI3K 
and phospho-PI3K (p55/p85) levels in cell lysates were examined by western-blot at 24h after 
transfection. PCNT knockdown resulted in reduced levels of p85 PI3K, and consequently of PI3K 
phosphorylation. β-tubulin was used as a control for protein loading. 
 
a) b) 
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Importantly, I found p85PI3K levels simultaneously downregulated following 
PCNT inhibition, suggesting the proteins co stabilize. PI3K downregulation after 
PCNT depletion is also reflected in decreased PI3K activation as determined by 
levels of phosphorylated p55(Tyr199)PI3K. I will now use this system to try and 
confirm the phenotypes observed in the patient cells. These results establish a 
possible interplay between pericentrin function and PI3K-associated signaling 
networks, such as the mTOR pathway.  
 
 
4.3 Summary 
MPD, including Seckel syndrome, is a rare disorder defined by extreme 
growth restriction and severe microcephaly, which has been associated with impaired 
ATR-pathway function. RTK signaling via the PI3K-AKT-mTOR pathway is 
essential for cell and organismal growth, promoting ribosome biogenesis and protein 
translation, and mutations in components of this pathway are linked to growth 
deregulation (e.g. S6K1 knockout mice show reduced body and cell size). 
Interestingly, ATR/ATM phosphorylate a number of components of the 
insulin/mTOR network in response to DNA damage. Moreover, acanthosis 
nigricans, commonly caused by insulin resistance, has been observed in SS, and the 
ATR-Seckel mouse also exhibits a supressed growth hormone--insulin-like growth 
factor 1 axis.  
In this chapter I found deregulation of the insulin-dependent PI3K-AKT-
mTOR signal transduction in ATR-defective and PCNT-defective Seckel Syndrome 
cell lines. S6K levels were endogenously elevated in ATR and PCNT-S cells, and 
irresponsive to rapamycin inhibition. Furthermore, examination specifically of the 
insulin-dependent signal transduction in these cells revealed 
impairment/unresponsiveness at various levels. These defects were also observed 
following ATR knockdown, and in a separate, patient-derived PCNT-S LBL. 
Importantly, PI3K activation is specifically compromised in PCNT-S cells. the 
interaction between PI3K and PCNT was confirmed by immunoprecipitation. A 
compromised insulin-mTOR signal transduction in ATR and PCNT defective cells, 
could underlie the severe dwarfism observed in these patients. 
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4.4 Discussion 
 
 Microcephalic primordial dwarfism (MPD) is a disorder characterized by 
severe growth impairment and disproportionate microcephaly. Causative mutations 
for MPD include the DDR apical kinase ATR, and the centrosomal protein 
pericentrin (PCNT). ATR pathway function is required for stable DNA replication 
fork progression and efficient DDR response, including G2/M cell cycle checkpoint 
control. Defects in centrosomal proteins can result in supernumerary centrosomes, 
spindle abnormalities, impaired mitotic progression and genomic instability. 
Symmetric cell divisions are required for stem cell self-renewal. Aberrant spindle 
orientation could result in an imbalance between symmetric vs asymetric divisions 
and thus impair the balance of progenitor cells/differentiating cells. Not only the 
deregulation of assymetric divisions in the neuroepithelion could contribute to the 
observed microcephaly, but the reduced total cellularity could also explain the short 
stature observed in primordial dwarfism. Notably, both ATR and PCNT defective 
MPD patient cells exhibit impaired ATR-pathway function. It is therefore likely that 
these defects should impact specifically on cells and tissues with a high replicative 
rate, e.g. during neurogenesis. 
 ATR knockout in the mouse is embryonic lethal. A transgenic mouse model, 
incorporating the Seckel syndrome hypomorphic ATR-splicing mutation (O'Driscoll 
et al. 2003) faithfully mimics the Seckel syndrome/MPD human phenotype (Murga 
et al. 2009). Elevated embryonic replicative stress is seen in the ATR-S mouse, 
resulting in elevated apoptosis, which could account for the striking growth defect. 
 However, interestingly, a suppressed insulin-like growth factor-1 (IGF-1) and 
growth hormone (GH) axis was also observed in the ATR-S mouse model. 
Additionally, acanthosis nigricans, a hyperpigmentation of the skin commonly 
caused by insulin resistance, has been observed in Seckel syndrome patients, and 
PCNT-defective MDP exhibit severe insulin resistance and diabetes (Huang-Doran 
et al. 2011). These observations could have implications for the intrauterine and 
postnatal growth retardation observed in MDP/Seckel syndrome. 
 
 Defects in the insulin-AKT-mTOR axis have been known to underlie major 
growth defects. Impairment of insulin signaling is particularly important during 
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development. A severe growth phenotype is seen in Igf-1 and Irs mutant mice, 
associated with insulin resistance (Tamemoto et al. 1994; DeChiara et al. 1990). As 
mentioned in the previous chapter, insulin-PI3K-AKT signaling plays a pivotal role 
in the processes of endochondral ossification and skeletal growth. The association 
between mTOR pathway dysfunction and growth defects has been well established. 
AKT is an important mediator of insulin metabolism. Akt1/Akt2 double KO in mice 
results in dwarfism and skeletal muscle atrophy (Peng et al. 2003). The mTORC1 
substrate S6K1 has been associated with cell size regulation, and S6k deletion also 
results in small sized mice (Shima et al. 1998).  
 
 A number of components of the insulin-mTOR pathway are novel substrates 
for ATR and ATM phosphorylation in response to types of DNA damage, although 
the biological significance of these interactions is yet unknown (Matsuoka et al. 
2007). 
 In view of these observations, and because of the level of cross-talk now 
anticipated between the DDR and the mTOR network, I investigated the PI3K-AKT-
mTOR signaling in response to insulin in ATR and PCNT defective MPD cell lines, 
to determine whether defects in this pathway could contribute to the severe growth 
phenotype that results from ATR and PCNT mutations. 
Surprisingly, I found evidence of deregulation of the insulin-dependent-
PI3K-AKT-mTOR signal transduction in ATR and PCNT defective MDP lines. 
Rapamycin inhibition of mTORC1 should result in rapid loss of S6K 
phosphorylation, and activation of AKT via an S6K-IRS-PI3K-dependent feedback 
mechanism. S6K levels were endogenously elevated and not inhibited by rapamycin 
in ATR and PCNT deficient cells, in contrast to WT cells. Examination specifically 
of the insulin-dependent signal transduction in these mutant cells revealed 
impairment/unresponsiveness at several points (Figure 4.4.1).  
Specifically, insulin-stimulation, after serum-starvation, failed to induce S6K 
phosphorylation in both ATR-S and PCNT-S cells, suggesting an important problem 
in the response to insulin in these cells, which could lie at the level of the insulin 
receptor itself of be the result of a break elsewhere in the signal transduction cascade. 
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Figure 4.4.1. Schematization of the PI3K-AKT-mTOR pathway activation in response to insulin 
in WT, ATR-S and PCNT-S cells. 
Further interrogation of the pathway by looking at the activation status of key 
components, suggests that different mechanisms could account for the defect in the 
insulin response in the ATR and PCNT defective cells. 
In the context of ATR deficiency, the TSC1-TSC2 complex is not efficiently 
inhibited in response to insulin. TSC1-TSC2 is the main upstream negative regulator 
of mTORC1 function, and hyperactivity of the TSC1-TSC2 complex would result in 
reduced mTORC1 activation, which seems to be the case in ATR-S cells, indicated 
by non-responsiveness of S6K to insulin stimulation, and lower phosphorylation of 
4E-BP1. S6K phosphorylation was still detected in the growth arrested ATR-S cells 
(Figure 4.2.2a), and seems to be endogenously elevated in these cells (Figure 4.2.1).  
Hyper or prolonged activation of S6K can negatively impact insulin signaling 
by inhibition of the insulin receptor substrate. 
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In PCNT-deficient cells, the activation profile of the pathway in response to 
insulin stimulation is distinct. Insulin addition results in a lower level of activation of 
S6K in PCNT-S cells, compared to WT. PI3K activation is specifically compromised 
in PCNT-defective cells, which results also in reduced PDK1 activation. 
Furthermore, activation of the PTEN phosphatase, which negatively regulates PI3K 
activity, was also not induced in PCNT-S cells. Phosphorylation, and inactivation, of 
GSK-3β is also impaired in PCNT-deficient cells. Interestingly, GSK-3β directly 
phosphorylates and inhibits IRS-1 and PTEN, and has been involved in the 
development of insulin resistance. This suggests an upstream, problem in the 
regulation of insulin response in PCNT deficient MPD cells, compared to ATR-
mutated SS cells. 
Furthermore, expression of PI3K expression is significantly reduced in PCNT 
MPD fibroblasts, as observed by anti- p85PI3K immunofluorescence, when 
compared to control levels in WT cells (Figure 4.2.6). This could represent a serious 
defect that could also impact on other signaling cascades operating downstream from 
PI3K. An association between PCNT and PI3K has been reported in the literature. I 
confirmed the PI3K-PCNT interaction by immunoprecipitation in a WT LBL (Figure 
4.2.7). Furthermore, siRNA-mediated PCNT knockdown resulted in reduced PI3K 
expression (Figure 4.2.9). This represents an important association that could be 
responsible for the PI3K-dependent signaling defect in PCNT-mutated cells. This 
could also contribute to the insulin-resistance phenotype, and diabetes, manifested in 
PCNT-MPD patients. 
Insulin-dependent signaling defects were also observed following ATR 
knockdown in an independent cell line (MG63 osteosarcoma); and also in a distinct 
patient-derived PCNT lymphoblastoid line, confirming some of the initial 
observations in ATR and PCNT deficient MPD patient fibroblasts.  Interestingly, 
inhibition of the ATR-related ATM-kinase results in decreased IGF-IR (insulin like 
growth factor- I receptor) expression, and IGF-IR cDNA expression restores normal 
radioresistance in AT cells (Peretz et al. 2001).  
A compromised insulin-mTOR signal transduction in ATR and PCNT-
defective cells could underlie/contribute to the severe dwarfism observed in these 
patients, and thus constitute a novel pathomechanism for ATR+PCNT-defective 
MDP. 
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Chapter Five 
Results III: Defective ATR-dependent DNA 
Damage Response in cells from individuals with 
primary defects in mTOR pathway function 
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5.1 Introduction 
In the last chapter I provided evidence of deregulation of insulin-dependent 
PI3K/AKT/mTOR signal transduction in patient-derived cell lines defective in ATR 
signaling, establishing a previously uncharacterized relationship between these 
pathways. Similarly, I demonstrated that ATR defective/impaired signaling 
compromises such distinct processes as differentiation (namely chondrogenesis, 
Chapter 3) and insulin/mTOR signaling events at various levels (Chapter 4).  
PCNT-defective forms of osteodysplastic primordial dwarfism have been 
associated with diabetes and insulin resistance (Huang-doran 2011) and early-onset 
diabetes and acanthosis nigricans have been reported in MOPDII patients. 
Additionally, the ATR-Seckel syndrome mouse exhibits a suppressed Insulin-like 
Growth Factor-1/Growth Hormone (IGF1–GH) somatotrophic axis (Murga et al. 
2009; O'Driscoll 2009) These observations are particularly relevant since several 
members of the insulin/AKT/mTOR network were recently identified as ATM/ATR 
substrates in response to DNA damage (Matsuoka et al. 2007), although the 
significance of this is yet unclear. Nevertheless, this implies that there is an extensive 
level of crosstalk between these pathways (Figure 5.1.1). 
Collectively, these novel findings have implications to the understanding of 
the particular set of clinical manifestations seen in Seckel syndrome/MOPDII, whose 
overt clinical features are severe microcephaly and dwarfism.  
A role for AKT on cell cycle regulation and checkpoint signaling is already 
well established (Kandel et al. 2002; Shtivelman, Sussman, and Stokoe 2002; N. Xu 
et al. 2010). AKT modulates the function of a number of factors involved in normal 
cell cycle progression, such as increasing activation of c-Myc, Cdk2, and CDC25 
phosphatase B, as well as inactivation of the CDK inhibitors p21
Cip1
 and p27
Kip1
 (Xu, 
2012 for review) (Figure 5.1.2). 
Additionally, the PI3K/PTEN/AKT also has a role in the cellular response to 
DNA damage. The DDR kinases DNA-PK, ATM and ATR can activate AKT in 
response to different genotoxic stresses (Lu et al. 2006; Viniegra et al. 2005; 
Caporali et al. 2008). AKT activation, or constitutively active/overexpression of 
AKT have been shown to surpass cell cycle checkpoints and promote mitosis in the 
presence of DNA damage (Kandel et al. 2002). These cells continue to divide despite 
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exposure to mutagenic agents, and are prone to accumulate mutations (N. Xu et al. 
2010), that can lead to neoplastic transformation. 
 
Figure 5.1.1. Insulin-AKT-mTOR pathway signal transduction. 
Highlighted in red are some of the novel ATM/ATR substrates identified following DNA damage 
(Matsuoka et al. 2011). 
 
Figure 5.1.2. Involvement of AKT in cell cycle progression. 
The AKT kinase modulates the activity of proteins associated with cell cycle regulation. (adapted 
from Xu et al.2012)  
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 The checkpoint kinase CHK1, an essential regulator of the G2/M transition, 
is directly phosphorylated by AKT on Ser280, resulting in increased cytoplasmic 
localization of CHK1. This effect results in inhibition of the checkpoint, and has 
been observed in breast cancers associated with increased AKT activation and 
reduced PTEN (Puc et al. 2005; Barré and Perkins 2007). Importantly, AKT 
activating and/or PTEN inactivating mutations are frequently found in a number of 
cancers, promoting tumor proliferation and survival. Specifically, AKT3 mutations 
are very common in malignant melanoma and PTEN mutations in breast and ovarian 
cancers. Furthermore, activation of AKT has been associated with resistance to 
chemotherapy in breast and ovarian cancers. 
 
Microcephalic primordial dwarfism, including Seckel Syndrome and MOPD 
typeII are associated with profound growth retardation and microcephaly. 
Interestingly, these clinical features are also seen in disorders of the mTOR pathway, 
an example of which is Donohue Syndrome (DS). To further probe the functional 
relationship between the ATR-DDR and mTOR pathway function, I examined lines 
from DS patients and other mTOR conditions.  
 
5.1.1 INSR and Donohue syndrome  
The human insulin receptor (INSR) is formed of two α subunits 
(extracellular, that bind insulin) and two β subunits (with intracellular receptor 
tyrosine kinase (RTK) domain), both coded by a single gene INSR on chromosome 
19.  
Donohue syndrome (DS; OMIM 246200), Rabson-Mendenhall syndrome 
(OMIM 262190) and type A insulin resistance (OMIM 610549) are examples of 
insulin-resistant syndromes resulting of INSR mutations associated with differing 
levels of residual activity. The one with the most severe clinical presentation is DS, 
initially referred to as Leprechaunism (William Donohue, 1948), which represents 
also the first INSR mutation found in a human disorder. DS is a rare autosomal 
recessive condition (estimated 1 in 4 million live births (Taylor et al. 1992), 
characterized by severe intrauterine and post-natal growth retardation, characteristic 
small “elfin-like” facies (Figure 5.1.3), insulin-resistant diabetes mellitus, acanthosis 
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nigricans, hyperinsulinemia, failure to thrive, and early death. See Table 5.1.1 for a 
list of DS clinical manifestations. 
 
 
Table 5.1.1. Clinical manifestations associated with Donohue syndrome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Donohue‟s syndrome patients display dismorphic 
facies, including large low set ears, saddle nose 
deformity, but also hirsutism and hypertrichosis, 
reduced subcutaneous fat, acanthosis nigricans, 
low birth weight. (Diabetes mellitus: a fundamental 
and clinical text, Derek leRoith et al. 3
rd
 3d, 2004 
by Lippincott Williams & Wilkins; Principles of 
Diabetes mellitus, Leonid Poretsky, 2002, Kluwer 
Academic Publishers) 
 
 
Clinical features associated 
with Donohue syndrome 
Hyperthrichosis 
Pachyderma 
Acanthosis nigricans 
Prominent genitalia with hypertrophy 
Mammary hyperplasia 
“Elfin-like” facial features 
               Prominent eyes with hypertelorism 
               Broad nose with wide nostrils 
               Thick lips 
               Large low set ears 
Hirsutism 
Poor muscular development 
Low birth weight 
Reduced fat stores/ lipoatrophy 
Neonatal growth retardation 
Dysplastic nails 
Hyperplasia and rugation 
Joint laxity 
Metabolic dysfunction 
Endocrine dysfunction 
Failure to thrive 
Figure 5.1.3. Characteristic facial features and 
clinical presentation of Donohue syndrome 
patients. 
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Donohue syndrome patient-derived cells present with extremely reduced 
insulin binding capacity or receptor autophosphorylation/kinase activity (D'Ercole et 
al. 1979; Kobayashi et al. 1978). INSR knockout in the mouse results in only slight 
prenatal growth retardation, quickly developing postnatal diabetes followed by early 
death due to ketoacidosis (Kitamura et al.2003). The differences found between the 
mouse model and humans lacking INSR, were attributed to distinct development 
timing and compensatory effect of Igf1 receptor signaling in mice (Kitamura et al. 
2003). 
 
5.1.2 PTEN and Cowden’s disease 
Cowden‟s disease (CD: OMIM 158350) is a rare autosomal dominant 
syndrome characterized by multiple hamartomas (Lloyd and Dennis 1963). The main 
features of the disease include macrocephaly, multiple hamartomatous lesions in 
various tissues (such as skin, gastrointestinal tract, brain, endometrium, breast), mild 
to moderate mental retardation, and developmental delay. Importantly, CD is 
associated with increased risk of developing breast, thyroid, and endometrial cancers. 
Cowden‟s disease results of germline mutations in PTEN (Phosphatase and 
tensin homolog) a phosphatidylinositol-3,4,5-trisphosphate (PIP3) phosphatase that 
negatively regulates PIP3 intracellular levels. PTEN functions as a tumor suppressor 
by negatively regulating PI3K/AKT signaling. PTEN germline mutations are found 
in a group of disorders known as the PTEN hamartomatous tumor syndromes 
(PHTS), which also include the Lhermite-Duclos disease (OMIM 158350), 
Bannayan-Riley-Ruvalcaba syndrome (OMIM 153480) and Proteus syndrome 
(OMIM 176920) (Liaw et al. 1997). PTEN null mice die during embryogenesis. 
Mice heterozygous for PTEN develop tumors in several tissues, including breast, 
colon and endometrium (Stambolic et al. 2000).  
PTEN has been implicated in regulation of genomic stability. PTEN 
upregulates the DSB repair protein, RAD51 (Shen et al. 2007); and is involved in 
modulation of the G2/M checkpoint, whereby PTEN loss can result in AKT-
mediated inhibition of CHK1 function (Puc et al. 2005; Puc and Parsons 2005). 
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ATR-function defective cells, such as Seckel syndrome, are compromised in 
insulin/AKT/mTOR signaling (Chapter 4). In this chapter I set out to investigate if, 
conversely, specific primary defects in mTOR signaling impact on the DNA damage 
response, and If so by what/which mechanism(s), and what could be the 
consequences at the human syndromal level. 
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5.2 Results 
5.2.1 Donohue’s syndrome and Cowden’s disease patient cells 
exhibit defective ATR-dependent G2/M checkpoint arrest 
To determine whether primary defects in the insulin/PI3K/mTOR axis could 
manifest with DNA damage response defects, thereby phenocopying ATR-defective 
Seckel syndrome, I analyzed INSR-defective Donohue syndrome (GM16378, 
CAO133) and PTEN-defective Cowden disease (GM10080) cell lines for their 
ability to respond to DNA damage caused by UV and IR.  
The G2/M checkpoint prevents cells from entering mitosis harboring DNA 
damage, and can be activated by either ATM or ATR, depending on the type of DNA 
damage incurred (Sancar et al. 2004) (see Introduction). To analyze the early G2/M 
checkpoint, the cells were irradiated with either 7J UV or 3Gy IR, incubated with the 
microtubule-depolymerizing drug, colcemid and the percentage of mitotic cells 
assessed after 4 hours. In control (WT) cells, the mitotic cell population significantly 
decreases when exposed to UV radiation. By contrast, ATR-defective Seckel 
syndrome cells (ATR-S) are defective in the activation of this checkpoint and a 
significant population of cells enters mitosis prematurely after UV treatment.  
Surprisingly, both DS and CD patient-derived LBLs showed inefficient UV 
radiation-induced G2/M checkpoint arrest (Figure 5.2.1.) suggesting impairment of 
the ATR-regulated DNA damage response pathway. In contrast, all cell lines 
efficiently arrested after exposure to gamma radiation, which induces the ATM-
dependent DDR. This suggests the checkpoint impairment observed in DS and CD 
cells to be specific to ATR (but not ATM)-dependent signaling. Furthermore, DS and 
CD patient-derived cells similarly failed to arrest proliferation up to 24hrs following 
UV irradiation (data not shown), when compared to control LBLs. 
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Figure 5.2.1.  Donohue’s syndrome and Cowden’s disease patient cells exhibit defective ATR-
dependent G2/M checkpoint arrest. 
Control (WT=AG87), ATR-defective (ATR-S), Donohue syndrome (DS1=GM16378; DS2= 
CAO133) and Cowden disease (CD=GM10080) cells were irradiated with either 7Jm
-2
 or 3Gy IR, in 
the presence of colcemid, and the number of mitotic cells assessed 4hrs later. ATR-S, and both DS 
and CD patient derived cells failed to efficiently activate the ATR-dependent G2/M checkpoint arrest, 
compared to control cells. By contrast, the IR-induced (ATM dependent) checkpoint was efficiently 
activated under these conditions. Data represents the mean±SD from 3 separate experiments. 
 
5.2.2 Insulin receptor knockdown results in defective ATR-
dependent G2/M arrest 
 To confirm that the striking checkpoint phenotype observed in Donohue 
syndrome patient cells was due to Insulin receptor deficiency, I inhibited the INSR by 
siRNA in MG63 osteosarcoma cells (Figure 5.2.2a) and analyzed the checkpoint 
proficiency of these cells. siRNA against the INSR resulted in a less eficcient 
induction of the G2/M checkpoint arrest in response to UV treatment, when 
compared to WT cells (Figure 5.2.2b). Significantly, this defect was again restricted 
to treatment with UV, but not IR. This result reinforces the checkpoint defect data on 
the Donohue syndrome patient cells, suggesting impairment of the ATR-dependent 
DNA damage response specifically in cells compromised in insulin receptor 
signaling. 
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Figure 5.2.2. Insulin receptor knockdown results in defective ATR-dependent, but not ATM-
dependent, G2/M DNA damage checkpoint. 
a) siRNA mediated INSR knockdown in MG63 osteosarcoma cells was confirmed by western blot. β-
tubulin levels were used for protein loading. b) 48h after siRNA, the cells were irradiated with either 
7Jm
-2
 or 3Gy IR, in the presence of colcemid, and number of mitotic cells assessed 4hrs later. After 
INSR knockdown, the cells fail to activate the UV-induced G2/M checkpoint arrest as efficiently, 
when compared to control (mock). INSR siRNA cells exhibit IR-induced checkpoint arrest. Data 
represents the mean±SD from 3 separate experiments. 
 
5.2.3 ATR-dependent 53BP1 foci formation is less efficient in 
Donohue syndrome and Cowden disease LBLs. 
Following DNA damage, 53BP1 is phosphorylated and rapidly localizes to 
nuclear foci. The precise role of 53BP1 in the DNA damage response remains 
unclear but it has been implicated in the regulation of G2/M checkpoint activation 
(B. Wang et al. 2002) Inhibition of DNA replication by the ribonucleotide reductase 
inhibitor, hydroxyurea (HU) also induces 53BP1 foci formation, specifically in an 
ATR and CHK1-dependent fashion, at the arrested replication fork in S phase cells 
(Sengupta et al. 2004; Stiff et al. 2006). 
I looked at the formation of HU-induced 53BP1 foci in Cowden and Donohue 
syndrome cells, one of the earlier observed DNA damage response events (Anderson 
et al. 2001). Both DS and CD cells formed lower amounts of HU-induced 53BP1 
foci (Figure 5.2.3) when compared to control cells (WT), although the level of 
induction was similar to WT cells, particularly for the CD cells.   
This data suggests that aspects of the ATR-dependent DDR may be less 
efficient in DS and CD cells. PTEN deficiency has previously been linked to CHK1 
a) b) 
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dysfunction (Puc et al. 2005; Puc and Parsons 2005), therefore I decided to 
concentrate on further characterizing the novel ATR-pathway defect in Donohue 
syndrome. 
 
 
 
Figure 5.2.3. ATR-dependent 53BP1 foci formation is impaired in Donohue syndrome and 
Cowden disease LBLs. 
 Donohue syndrome (DS) and Cowden disease (CD) LBLs are less efficient in forming 53BP1 foci , 
when compared to control (WT) cells. All LBLs were treated with 5mM HU for2 hrs. Positive cells 
were scored as those with more than 5 foci, as determined by immunofluorescence against 53BP1. 
Data represents the mean±SD from 3 separate experiments. 
 
 
 
5.2.4 Activation of ATR-dependent substrates in Donohue syndrome 
cells after treatment with DNA damaging agents.  
The G2/M cell cycle arrest is strongly dependent on CHK1-mediated 
signaling, which leads to suppression of CDK1-CyclinB1 activity via CDC25A. 
CDC25A phosphatase is a positive regulator of cell cycle transitions, specifically at 
the G2/M border where it removes the inhibitory T14 and Y15 phosphorylation on 
CDK1 to allow activation of CyclinB-CDK1 complex which controls progression 
from G2 into M (Nyberg et al. 2002; Sancar et al. 2004) (Figure 5.2.4).  
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Figure 5.2.4. Model for CDC25A regulation involving the DNA damage response pathway and 
the AKT pathway. 
Checkpoint-deficient ATR-Seckel syndrome cells fail to activate CHK1 via 
phosphorylation at Ser345 following HU treatment. DS cells however, showed 
proficient HU-induced phosphorylation of CHK1 on Ser345 (Figure 5.2.5a). This 
observation suggests that the checkpoint impairment observed in these cells likely 
lies downstream of CHK1 activation by ATR. 
CHK1 is also directly phosphorylated at Ser280 by AKT, a modification that 
is associated with increased CHK1 cytoplasmic localization, and is thought to inhibit 
checkpoint activation (King et al. 2004; Puc and Parsons 2005; Shtivelman et al. 
2002). CHK1 phosphorylation at Ser280 in response to HU was also normal in DS 
cells (Figure 5.2.5.a), compared to WT cells. Interestingly, ATR-S cells failed to 
induce Ser289 CHK1 phosphorylation under the same conditions.  
In checkpoint proficient cells (WT), UV-induced DNA damage results in 
inactivation and downregulation of CDC25A levels via βTrCP mediated 
ubiquitination, via a CHK1-dependent process delaying mitotic entry (Figure 5.2.5b) 
(Deng 2009; Busino et al. 2003; Ahel et al. 2009). Significantly, CDC25A inhibition 
is less sustained in DS patient cells. CDC25A overexpression has been reported in a 
number of cancers where it is associated with poor prognosis (Harvard et al. 2011; 
Kristjánsdóttir et al. 2004). 
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Figure 5.2.5. Activation of ATR-dependent substrates in Donohue syndrome cells after 
treatment with DNA damaging agents. 
a) Phosphorylation of CHK1 at S345 and S280 after 5mM HU, 2hrs, is not defective in Donohue 
syndrome (DS) patients cells, similar to control (WT) cells and by contrast to ATR-S cells. CHK1 
levels are not reduced in DS cells. b) DS (GM16378) LBLs show increased levels of CDC25A 
phosphatase 4h after 7Jm
-2
UV, when compared to WT cells. c) Correspondingly, DS cells exhibited 
reduced levels of p-Y15 CDK1 after UV (but not IR), when compared to control (WT). WT and DS 
LBLs were irradiated with 10Jm
–2 
UV or 3Gy ionizing radiation, incubated for 4h and analyzed by 
Western-blot using specific antibodies. β-tubulin levels were used as control for protein loading. 
 
 Correspondingly, the inhibitory phosphorylation of CDK1 was reduced in 
DS cells, at 4h after UV (but not IR) treatment, when compared to WT (Figure 
5.2.5c). This suggests an impact specifically on the ATR-dependent checkpoint. 
Inefficient CDC25A inhibition, and consequently increased activation of the 
CDK1/CyclinB complexes in Donohue syndrome would lead the cells prematurely 
into mitosis.  
 
 
 
 
 
a) 
b) c) 
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5.2.4 Increased phosphorylation of AKT and GSK-3β in response to 
UV in DS cells 
Due to the known role of AKT in the checkpoint response, I looked at AKT 
activation in INSR-defective DS cells after UV-induced DNA damage. AKT is 
activated by phosphorylation on Thr308 and Ser473. AKT is phosphorylated on 
Thr308 by PDK1, downstream of insulin/PI3K signaling. 
I found increased basal level of activated Thr308 AKT in DS cells, compared 
to control cells (Figure 5.2.6) likely a consequence of compensatory signaling via 
PDK1/PDK2 due to the InsR defect. Studies have shown that AKT activity is 
elevated in the G2/M phase (B. B. Kahn et al. 2005; Shtivelman, Sussman, and 
Stokoe 2002) and activation of AKT has been shown to overcome G2 arrest in 
response to ionizing radiation (Young 2009; Kandel et al. 2002) and other forms of 
DNA damage inducing agents (B. B. Kahn et al. 2005; Hirose et al. 2005). This 
suggests that AKT signaling is able to influence the outcome of this checkpoint 
regardless of which checkpoint signaling pathway is being activated. The level of 
AKT activation is likely to have a role in how AKT can affect the regulation of these 
checkpoint responses. The activity of a number of proteins involved in cell cycle 
regulation can be modulated by AKT, such as CHK1 (S280) and TopBP1 (S1159) 
(Garelick and Kennedy 2011; N. Xu et al. 2012). 
 
 
 
 
Figure 5.2.6. UV-induced AKT and GSk3β phosphorylation in INSR-defective DS cells. 
Basal levels of phosphorylated AKT at Thr308 are elevated in Donoue syndrome (DS) patient-derived 
cells when compared to WT cells. p-Thr308 AKT levels are maintained after UV irradiation, for the 
conditions tested (7Jm
-2UV, up to 4hrs). GSK3β phosphorylation (and inactivation) increases in 
response to UV treatment in both WT and DS cells. Additionally, levels are higher in DS LBLs show 
increased levels of p-Ser9 GSK3β, when compared to WT cells, both at the basal level as well as after 
UV induction. β-tubulin levels were used as control for protein loading.  
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However, my data suggests that the putative site of action of AKT in 
mediating the G2/M checkpoint defect in DS cells is likely to act downstream or 
parallel to CHK1 activation (Figure 5.2.4). 
An interesting recently found link between insulin signaling and cell 
cycle/checkpoint regulation involves the glycogen synthase kinase-3β (GSK-3β), 
which is directly phosphorylated by AKT on Ser9, resulting in GSK-3β inhibition. 
GSK-3β directly phosphorylates CDC25A on S76 and targets it for proteolysis 
(Young 2009; Kang et al. 2008) (Figure 5.2.6b).  
I found GSK-3β is phosphorylated, and thus inactivated, in response to DNA 
damage (10J UV) in normal cells. Remarkably, GSK-3β pS9 levels were further 
elevated in Donohue Syndrome cells when compared to WT levels (Figure 5.2.6). 
This result suggests that GSK-3β inhibition may affect the total levels of CDC25A 
present in these cells, independently of CHK1 activity, and thus influence the 
checkpoint response at the G2/M transition.   
 
 
5.2.6  GSK-3 inhibition results in defective ATR-dependent G2/M 
arrest. 
To further characterize the potential effect of GSK-3β on the ATR-dependent 
checkpoint defect observed in Donohue syndrome, I introduced a siRNA-mediated 
knockdown of GSK-3β in MG63 osteosarcoma cells (Figure 5.2.7a). GSK-3β 
knockdown cells maintained a high mitotic index in response to DNA damage 
caused by UV irradiation, but efficiently arrested following gamma irradiation 
(Figure 5.2.7b). This data suggests that GSK-3β is a regulator of the ATR-dependent 
G2/M checkpoint specifically, suggesting a mechanism for the checkpoint defect 
observed in DS patient cells. 
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Figure 5.2.7.  GSK-3β knockdown results in defective ATR-dependent, but not ATM-dependent, 
G2/M DNA damage checkpoint. 
a) siRNA mediated GSK-3β knockdown in MG63 osteosarcoma cells was confirmed by western blot. 
β-tubulin levels were used for protein loading. b) 48h after siRNA, these cells were irradiated with 
either 7Jm
-2
 or 3Gy IR, in the presence of colcemid, and number of mitotic cells assessed 4hrs later. 
After GSK-3β knockdown, the cells fail to activate the UV-induced G2/M checkpoint arrest as 
efficiently, when compared to control (mock). GSK-3β siRNA cells exhibit IR-induced checkpoint 
arrest. Data represents the mean±SD from 3 separate experiments. 
 
Figure 5.2.8. GSK-3β inhibition results in defective ATR-dependent, but not ATM-dependent, 
G2/M DNA damage checkpoint 
 Treatment with GSK-3β inhibitors a) lithium chloride (LiCL), and b) 1-AZKP results in failure to 
activate the G2/M checkpoint in response to UV irradiation. The WT LBLs were irradiated with either 
7Jm
-2
 or 3Gy IR, in the presence of colcemid, and number of mitotic cells assessed 4hrs later. GSK-3β 
inhibition does not compromise the IR-induced checkpoint arrest. Data represents the mean±SD from 
3 separate experiments. 
 
a) b) 
a) 
b) 
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Moreover, this data was also supported by the use of GSK-3β kinase 
inhibitors. Lithium is a crude GSK-3β inhibitor that has been extensively 
investigated for the treatment of neuropathologies and neurodegenerative disorders, 
such as schizophrenia and Alzheimer‟s disease, which are associated with increased 
activation/over-expression of GSK-3β. Lithium is thought to compete directly with 
magnesium at the cationic binding site in GSK-3β, inhibiting its catalytic activity. 
Reports suggest also a potential indirect inhibitory effect of lithium over GSK-3β by 
activating AKT (Young 2009; Chalecka-Franaszek et al. 1999; Zhang et al. 2003) or 
by reducing GSK-3β mRNA levels (Young 2009; Mendes et al. 2009). I found 
lithium treatment of WT LBLs resulted in failure to arrest cell proliferation in 
response to UV, though the cells remained proficient in activating the checkpoint 
response to DNA double strand breaks caused by IR. 1-azakenpaullone (1-AKP) is 
among the most potent and selective small molecule GSK-3β inhibitors that have 
since been developed. Treatment with 1-AKP also resulted in defective ATR-
dependent G2/M checkpoint (Figure 5.2.8). Collectively, this data indicates that the 
kinase activity of GSK-3β is required for the regulation of this checkpoint. 
 
5.2.7  UV induced G2/M checkpoint after AKT inhibition 
 Several upstream kinases other than AKT are able to inhibit GSK3β by 
phosphorylation on Ser9. These include protein kinases A (PKA) and C (PKC), p90 
ribosomal S6 kinase (p90RSK) and p70 ribosomal S6 kinase (p70S6K) (Fang et al. 
2000; Kim et al. 2007; Stambolic et al. 1994, Sutherland et al. 1993). 
I used an AKT inhibitor to determine whether the checkpoint defect observed 
in DS is AKT-dependent. AKT inhibition by treatment with 1.5 μM of AKT 
inhibitor IV (InSolution™ AKT Inhibitor IV, cat.124015, Calbiochem) was 
confirmed by looking downstream at GSK3β phosphorylation by western blotting 
(Figure 5.2.9a). Some residual GSK3β inhibition was still observed in DS cells, as 
well as PCNT-S cells after treatment with the inhibitor, upon UV irradiation. In 
chapter 4 I showed that PCNT-deficient cells are compromised in the PI3K-
dependent response to insulin, and the data also suggested increased activation of 
AKT in those cells.  
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Figure 5.2.9 AKT inhibition rescues the ATR-dependent G2/M DNA damage checkpoint defect 
in Donohue syndrome. 
a) AKT inhibition on WT, DS, PCNT-S LBLs using 1.5µM of AKT inhibitor (InSolution™ AKT 
Inhibitor IV, cat.124015, Calbiochem) results in decreased phosphorylation of GSK3β on Serine 9, 
confirmed by western blot. Total GSK-3β levels were used for loading control. b) Treatment with 
AKT inhibitor results in efficient G2/M arrest after UV treatment in Donohue syndrome patient cells, 
thereby rescuing the checkpoint defect in these cells. Under these conditions, AKT inhibition resulted 
in decreased cell proliferation in both WT, as well as ATR-S, even in un-irradiated cells. Interestingly,  
the use of AKT inhibitor also rescued the G2/M checkpoint defect in PCNT-deficient cells (PCNT-
S).The cells were irradiated with either 7Jm
-2
 or 3Gy IR, in the presence of colcemid, and number of 
mitotic cells assessed 4hrs later. AKT inhibition did not impact the IR-induced checkpoint arrest, 
under these conditions. Data represents the mean±SD from 3 separate experiments. 
 
 
 
 
 
a) 
b) 
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At this concentration, AKT inhibitor IV is known to block cell proliferation, 
and indeed control (WT) LBLs showed a drastically reduced mitotic index upon 
AKT inhibitor IV treatment (Figure 5.2.9.b). However, DS cells are resistant to 
inhibition of proliferation by AKT IV under the same conditions, which supports the 
observation that AKT is hyperactive in these cells. Strikingly, treatment with AKT 
inhibitor rescues the G2/M checkpoint defect in DS cells, which indicates that AKT 
plays a role in the modulation of this checkpoint. 
Interestingly, AKT inhibition also rescued the ATR-dependent G2/M 
checkpoint defect in PCNT-S, but not in ATR-S patient derived cells suggesting that 
different mechanisms are behind the DDR defect in these cells. This observation is 
consistent with a defect in PCNT-S cells affecting a more upstream point in the 
insulin-PI3K-AKT cascade, likely the PI3-kinase itself. Conversely, the defect in 
ATR-S would impact on the insulin pathway downstream of AKT activation, and 
therefore not benefit from AKT inhibition.  
 AKT inhibition did not affect other aspects of the DDR. 53BP1 foci 
formation was not altered by treatment with the AKT inhibitor, both in DS as well as 
PCNT-S cells (Figure 5.2.10) further suggesting that this influence is downstream of 
CHK1 activation. 
 
Figure 5.2.10. AKT inhibition does not affect 53BP1 foci formation in Donohue syndrome. 
a) AKT inhibition using 1.5µM of AKT inhibitor (InSolution™ AKT Inhibitor IV, Calbiochem) does 
not increase the number of 53BP1 foci formed in response to HU-treatment, to levels comparable to 
WT cells. the same is also true for PCNT-S cells. Donohue syndrome (DS) and PCNT-defective 
MPDII (PCNT-S) LBLs were treated with 5mM HU for2 hrs. Positive cells were scored as those with 
more than 5 foci, as determined by immunofluorescence against 53BP1. Data represents the mean±SD 
from 3 separate experiments. 
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5.3 Summary 
The overlap/interplay between the DDR and the insulin-AKT-mTOR 
pathway has been previously described. In the previous chapter I described defects in 
insulin/mTOR pathway signaling in cells derived from ATR and PCNT defective 
Seckel syndrome patients, both manifesting defects in the ATR response. Severe 
microcephaly and growth retardation are clinical features of SS, which are also 
observed in Donohue syndrome, caused by a mutation in the insulin receptor. In this 
chapter I set out to investigate if primary defects in a metabolic disorder, harboring 
mutation in the insulin/mTOR pathway, such as Donohue syndrome, could also 
impact on the DNA damage response.  
I found INSR-defective DS cells (and PTEN-defective Cowden‟s disease 
cells) exhibit defective ATR-dependent G2/M activation. This defect was also 
observed following siRNA-mediated INSR knockdown. Activation of ATR-
dependent substrates was also evaluated, and DS cells exhibited elevated levels of 
CDC25A, and reduced phosphorylation of Y15-CDK1, in response to UV irradiation 
specifically. Additionally, increased phosphorylation of AKT and GSK-3β was also 
observed in DS cells under the same conditions. Surprisingly, the ATR-dependent 
G2/M checkpoint defect in DS was rescued by GSK-3β inhibition, mediated by 
GSK-3β siRNA or by use of specific GSK-3β kinase inhibitors. Furthermore, AKT 
inhibition also rescued the checkpoint defect in DS  (and PCNT-S cells). This data 
suggests that both GSK-3β and AKT play a role in modulation of this checkpoint. 
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5.4 Discussion 
Patient-derived cell lines from two distinct human disorders caused by 
primary defects in mTOR pathway, Donohue syndrome and Cowden‟s disease, have 
been examined for the ability to effect aspects of the DNA damage response. These 
disorders, particularly DS, display a set of clinical features that in some aspects 
relates to Seckel syndrome/MOPD-type II. Both INSR-defective DS cells and 
PTEN-defective CD cells show defective UV-induced G2/M checkpoint activation. 
Both cell lines efficiently activated the checkpoint in response to IR, suggesting a 
problem specific in the ATR-regulated branch of the DNA damage response. A role 
for PTEN in checkpoint regulation has previously been established. Interestingly, 
PTEN null ES cells were shown to have a deficient IR-induced G2/M arrest (Kandel, 
2002). I present here the first association of an ATR-dependent checkpoint defect in 
a human disorder caused by PTEN deficiency. Loss of checkpoint proficiency could 
be a source of genomic instability in these cells, with implications for the high cancer 
predisposition observed in CD patients. 
The association of an INSR-defect with a DNA damage response defect is 
novel. A knockdown of INSR in an independent cell line confirmed the checkpoint 
defect identified in the two Donohue syndrome patient cell lines. 
In order to identify a possible mechanism behind this checkpoint defect, other 
aspects of the signaling response downstream of ATR were examined. Both DS and 
CD cells showed reduced, but not altogether defective, HU-induced formation of 
53BP1 foci. Phosphorylation of S345-CHK1 after treatment with HU was normal in 
DS and CD cells, an ATR-dependent event. This contradicts previous observations 
of diminished CHK1 S345 phosphorylation in PTEN
-/-
 cells, associated with elevated 
p-S473 AKT (Xu et al. 2010). An AKT–mediated regulation of CHK1 function has 
been suggested, involving direct phosphorylation of CHK1 on S280 by AKT. 
Phosphorylated S280-CHK1 levels in DS, in response to HU, were also comparable 
to WT levels. In response to UV-induced DNA damage, CHK1 mediates the 
downregulation of CDC25A phosphatase to delay entry into mitosis. Importantly, 
CDC25A is not efficiently inhibited in Donohue syndrome patient cells in response 
to UV irradiation.  This results in sustained de-phosphorylation of CDK1, meaning 
activation of the CDK1/Cyclin B complexes inappropriately, which drive the cell 
cycle into mitosis, and can account for the leaky checkpoint observed in these cells. 
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AKT is activated by phosphorylation on T308, mediated by the PDK1 kinase, in 
response to insulin/PI3K signaling. Impaired AKT activation is known to override 
cell cycle checkpoints and promote cell proliferation in the presence of DNA 
damage.  
Significantly, levels of p-T308 AKT are higher in DS cells when compared to 
control cells, even prior to DNA damage.  This could be related to lack of INSR-
mediated feedback inhibition of this pathway and/or compensatory phosphorylation 
of PDK1 from PI3K. AKT activation has been shown to bypass the ATM-dependent 
G2/M checkpoint following gamma irradiation (Kandel et al. 2002). Donohue 
syndrome patient cells however, efficiently activate this checkpoint when treated 
with IR. It is possible that the level of basal AKT activation is important in 
modulating this response, and that the levels of activated AKT in Donohue syndrome 
are not high enough to surpass the ATM-dependent DNA damage response signal, 
which is activated in response to extensive double strand break –inducing DNA 
damage. 
 Because CHK1 phosphorylation is normal in DS, the putative target for an 
AKT-mediated checkpoint defect should lie downstream or parallel to CHK1 
activation by ATR. The glycogen synthase kinase 3β  (GSK-3β) is phosphorylated 
directly by AKT on serine9, resulting in its inhibition. Notably, GSK-3β can directly 
phosphorylate CDC25A and target the phosphatase for degradation (Kim et al. 2002; 
Kang et al. 2008). Levels of CDC25 phosphatases are carefully regulated during the 
cell cycle. CHK1 and GSK-3β would then cooperate to regulate CDC25A 
proteolysis.  
 I found GSK-3β inhibitory phosphorylation on serine 9 is induced by 
treatment with UV. Notably, GSK-3β inhibition is more pronounced in DS when 
compared to control cells. By introducing a GSK-3β knockdown in an independent 
cells system, and treating the cells with specific GSK-3β inhibitors, I confirmed that 
GSK-3β is a regulator of this checkpoint. Moreover, in DS cells this effect is 
dependent of AKT, as treatment with a specific AKT inhibitor rescues the 
checkpoint defect, in both DS but also in PCNT-S cells, and unlike the ATR-S cells. 
This data further suggests that different mechanisms underlie the DDR defect in 
ATR and PCNT-defective SS/MOPDII cells. Furthermore, this is consistent with a 
defect in PCNT-S cells affecting a more upstream point in the insulin-PI3K-AKT 
cascade, likely the PI3-kinase itself, as suggested in chapter 4. 
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Other mechanisms cannot be ruled out, that could potentially affect the 
checkpoint defect observed. For example, activated AKT is also able to 
phosphorylate and inhibit the nuclear kinase Wee1A, on Ser642 (Katayama, 2005). 
Wee1A also catalyzes the inhibitory phosphorylation on Y15-CDK1, resulting in 
activation of the CDK1/Cyclin complex. These findings contribute to understanding 
the mechanisms by which AKT modulates DNA damage signaling, which could 
have broader implications, since impaired checkpoint proficiency can be a cause for 
genomic instability in cells with elevated AKT activity. AKT misregulation is a 
known cause of enhanced proliferation and survival in tumor cells. 
 
According to this model, impaired regulation of the insulin/AKT pathway, 
such as seen in DS, can result in deregulation of GSK-3β activity, thus affecting the 
net balance of CDC25A regulatory events. Sustained levels of CDC25A in these 
cells would enforce the continued activation of the CDK-Cyclin complexes, leading 
the cells through the G2/M border in an untimely manner (Figure 5.3.1).  
 
 
Figure 5.3.1. Model for G2/M checkpoint deficiency in Donohue syndrome. 
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However, other not necessarily mutually exclusive mechanisms may be at 
play that account for the clinical presentation of Donohue syndrome. One study 
showed downregulation of genes involved in cell growth and differentiation in 
patients with DS (Leick et al. 2010; Melis et al. 2003). 
The Wnt inhibitor, Dickkopf 1 (DKK1) is overexpressed in DS patients, 
which also have compromised Wnt signaling, important during development. Kahn 
et al. 2005; Metcalfe et al. 2011) Binding of Wnt leads to GSK-3β inactivation (Park 
et al. 2010). 
 
 
 
The data presented in this chapter proposes that the AKT/GSK-3β signaling 
pathway mediates an enhancement of the ATR/CHK1-dependent activation of the 
G2/M cell cycle checkpoint. This effect likely contributes to the specific checkpoint 
defect identified in two human disorders harboring mutations in the PI3K/AKT 
pathway, specifically Donohue syndrome. I identify novel routes to the manipulation 
of this cell cycle checkpoint in WT cells (GSK-3βi) and even in patient-derived cells 
(AKTi). Whether the latter would be of benefit in the management of these 
conditions is worthy of further investigation. Investigation of the links between 
defects in insulin/mTOR pathway function with deregulation of the DNA damage 
response, should contribute to our increased understanding of the mechanisms and 
factors that modulate cell cycle checkpoints, as well as the clinical consequences of 
defects in these pathways and their particular manifestations in human disease. 
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Chapter Six 
Results IV: Microcephaly - Capillary 
Malformation syndrome is caused by mutations in 
STAMBP resulting in aberrant RAS-MAPK and 
RTK-PI3K-AKT signaling  
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6.1 Introduction 
 
In this chapter I will characterize molecular aspects of a newly reported 
microcephalic disorder that combines a number of features, such as severe 
microcephaly and growth delay that overlap with Seckel syndrome/MOPDII. 
The Microcephaly-Capillary Malformation (MIC-CAP; OMIM 614261) 
Syndrome was first described in 2011. MIC-CAP patients exhibit severe congenital 
microcephaly (head circumference 3SD or more below mean) with progressive 
cortical atrophy, intractable epilepsy and multiple small capillary malformations 
(CMs) on the skin (Carter et al. 2011) (Mirzaa et al. 2011) (Isidor et al. 2011). Other 
clinical features include profound developmental delay, facial dysmorphism, small 
stature, spastic quadriparesis, and hypoplastic distal phalanges (Table 6.1.1; Figure 
6.1.1).  
One outstanding feature of all MIC-CAP patients is the presence, at birth, of 
numerous generalized capillary malformations on the skin also known as “port-wine 
stains” (Figure 6.1.1 F, G, H). These are cutaneous vascular abnormalities frequently 
observed in a class of developmental disorders associated with dysregulation of the 
RAS-MAPK (RAS-mitogen activated protein kinase) pathway, collectively referred 
to as RASopathies (Eerola et al. 2003). The RAS-MAPK signal transduction pathway 
is an important regulator of vascularization, cell growth and proliferation. The 
phenotypic features characteristic of RASopathies include cardiovascular anomalies, 
facial dysmorphia, skeletal and cutaneous abnormalities, neurocognitive delays and 
cancer, as exemplified by Noonan, LEOPARD (lentigines, ECG conduction 
abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, 
retardation of growth, sensorineural deafness), and Costello syndromes (Tidyman 
and Rauen 2009). 
 
A defect in RASA1 is known to cause a congenital capillary disorder called 
Capillary Malformation-Arteriovenous Malformation (CM-AVM;OMIM 608354) 
(Eerola et al. 2003) (Boon et al. 2005). The capillary lesions seen in CV-AVM 
patients are similar to those seen in MIC-CAP. The RASA-1 gene codes for a protein 
with Ras-GAP (GTPase activating protein) activity, a negative regulator of the RAS-
MAPK pathway (Ronnett et al. 2009; Bernards et al. 2004). This defect results in 
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chronically active RAS signalling due to a failure to generate  (recycle) 
GDP
RAS 
from 
GTP
RAS. 
 
 
 
Table 6.1.1. Clinical features and molecular findings of MIC-CAP patients included in this 
study. 
Patient P1.2 P3.1 P5.1 P7.1 
Exome Sequencing + + + – 
Validated Mutations
b 
(protein (cDNA)) 
p.Glu42Gly 
(c.125A>G) 
p.Phe100Tyr 
(c.299T>A ) 
nd p.Arg38Cys 
(c.112C>T ) 
p.Arg178* 
(c.532C>T) 
p.Arg424* 
(c.1270C>T ) 
nd nd 
Gender M M F F 
Age at assessment 9m 2y 5y4m 28m 
Ethnicity African-American Caucasian Caucasian Caucasian 
Gestational Age (weeks) 39 36 Term 37+2 
Progressive congenital MIC + + + + 
Small-for-gestational age + + – + 
Birth OFC  (SD) -4 -2 -1.8 -8 
Birth Weight (SD) -1.5 -2 +1.8 -4 
Birth Length (SD) – 2 nd 0 (mean) – 4 
Later age 9m 17m 2y10m 28m 
Later OFC - SD (age) – 6 – 4 – 2.5 -8 
Later Weight (SD) – 4 – 1 to – 2 +2 – 2.5 
Later Length (SD) nd – 2 0 (mean) – 4 
Generalized CMs + + + + 
Early-onset intractable seizures + + + + 
Infantile spasms – – – nd 
Hypoplastic distal phalanges + + + + 
Global DD + + + + 
Spastic quadriparesis + + – + 
Myoclonus/clonus – + – + 
Optic atrophy + + nd + 
Simplified gyral pattern + + nd + 
Increased extra-axial space + + nd + 
Hippocampal hypoplasia + nd nd + 
Hypomyelination – + nd + 
This table summarizes the clinical findings in study participants, b. Numbering of mutations is 
relative to NM_006463 (gene) and NP_006454.1 (protein). Abbreviations: F: female; M: male; y: 
years; m: months; OFC: Occipito-frontal circumference; SD: values are shown by their s.d. value 
from the mean; ND: not determined; DD: developmental delay. 
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This condition establishes a biological precedent for hyperactive RAS signalling in a 
capillary abnormality (Turnley et al. 1999; Eerola et al. 2003). No RASA1 mutations 
were found in MIC-CAP patients (Mirzaa et al., 2011). 
 
 
Figure 6.1.1. Neuroimaging and clinical features of  MIC-CAP patients. 
Images of the brain (A-C), evidencing the low-sloping forehead, simplified gyral pattern, increased 
extra-axial space, diffuse hypomyelination, and hippocampal hypoplasia. (D-F) Photos of MIC-CAP 
Patient 1.2 in this study (subject LR07-155a2, described in Mirzaa, 2011) at 9 months of age, showing 
the severe microcephaly, bitemporal narrowing with a low-sloping forehead and capillary 
malformations. Photos of MIC-CAP patient at 3 weeks (d) and 18 months (e) showing generalized 
capillary malformations of variable sizes and hypoplastic toenails. 
 
 
6 MIC-CAP children, including 2 siblings, were reported in the initial clinical 
studies (Dasgupta and Milbrandt 2009; Carter et al. 2011; Mirzaa et al. 2011; Isidor 
et al. 2011). A total of 10 MIC-CAP patients were included in a study by our 
collaborators - Prof. W.B. Dobyns (Seattle, USA) and Dr. Kym Boycott (Ottawa, 
Canada) - who applied exome sequencing on 5 patients from unrelated families to 
identify the previously unknown MIC-CAP causative genetic defect(s). Novel 
recessive mutations were found in the gene STAMBP in MIC-CAP patients. 
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 STAMBP (STAM binding protein, or AMSH - associated molecule with the 
SH3 domain of STAM) is an endosome-associated Zn(2+)-dependent ubiquitin 
isopeptidase that belongs to the JAMM metalloprotease family (Ronnett et al. 2009; 
Sierra, Wright, and Nash 2010). In addition to the JAMM (JAB1/MPN/MOV34) 
motif, the ubiquitously expressed STAMBP contains a microtubule-interacting and 
transport (MIT) domain and an SH3 binding motif (Figure 6.1.2) (Kahn et al. 2005; 
Tsang et al. 2006). STAMBP plays an important role in endocytosis, regulating 
endosomal sorting of ubiquitinated cargo (Qi et al. 2010; McCullough et al. 2006; 
Mattson et al. 2008; Agromayor et al. 2006; Kim et al. 2006; Mizuno et al. 2006; 
Kyuuma et al. 2007). 
 
 
 
 
Figure 6.1.2 STAMBP protein structure showing the location of MIC-CAP causing mutations 
The 424 amino acid sequence of STAMBP consists of the microtubule-interacting and transport 
(MIT) domain, the SH3 binding motif (SBM) (PXV/ID/NRXXP), the JAMM 
(JAB1/MPN/MOV34) motif, the nuclear localization signal (NLS) and the distal ubiquitin recognition 
site (DUR). Five of the six missense mutations identified are located in the MIT domain, which is 
thought to be required for the interaction of STAMBP with CHMP3, an ESCRT-III subunit. In red are 
highlighted the mutations found in the MIC-CAP patient lines included in this study. 
 
 
Sorting and trafficking of cell surface receptors is a highly regulated process 
important for maintenance of cell homeostasis and adequate response to extracellular 
stimuli, and enabling processes such as autophagy. STAMBP is recruited to the 
endosomal complexes required for transport (ESCRTs), a group of distinct 
macromolecules that mediates the sorting and trafficking of ubiquitinated proteins 
from endosomes to lyososomes (Dasgupta and Milbrandt 2009; Raiborg and 
Stenmark 2009). The ESCRTs DUBs include STAMBP and USP8, which interact 
with STAM (both associate with the SH3 domain of STAM via the same binding 
motif (PXV/ID/NRXXKP) (Iascone et al. 2002; M. S. Kim et al. 2006). Together 
with Hrs, they form the ESCRT-0 complex, which recognizes and processes 
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ubiquitinated protein cargo at the early and sorting endosomes (O'Driscoll et al. 
2003; Kyuuma et al. 2007; Wright et al. 2011). Endocytosed receptor-ligand 
complexes are either recycled back to the cell membrane or sorted to lysosomes for 
degradation in a process mediated by reversible ubiquitination (Figure 6.1.3) 
(Griffith et al. 2008; Komada 2008; Provot and Schipani 2005; Murga et al. 2009; 
Ma et al. 2007). This is a fundamental cellular process that controls the duration and 
amplitude of cell surface receptor-mediated signaling in a controlled, dynamic and 
reversible fashion (Matsuoka et al. 2007; Karsenty 2008; Raiborg and Stenmark 
2009). STAMBP has also been reported to associate with CHMP proteins that 
interact with ESCRT-III (Ruzankina et al. 2007; Goldring et al. 2006; Tsang et al. 
2006). These multiple interactions allow the ESCRT-associated DUBs to regulate 
multiple steps during endocytosis. 
 
 
Figure 6.1.3 Model of STAMBP function in endocytosis. 
STAMBP functions as an important DUB protease, along with USP8, that controls the sorting and 
trafficking of endocytosed, ubiquitinated receptor tyrosine kinases and G-protein coupled receptors.  
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Receptor ubiquitination is an important step in sorting and directing the receptor for recycling or for 
proteasome-mediated degradation. Depending upon the pathway, receptor mediated signaling can be 
either maintained or down-regulated. STAMBP interacts with early endosome sorting machinery via 
STAM and ESCRT complex machinery such as the ESCRT-III complex. ESCRT-DUBs are also 
thought to have a role in autophagy, a parallel degradation system that involves regulation through the 
ESCRT machinery. 
 
Importantly, both ESCRT DUBs, STAMBP and UPS8 demonstrate distinct 
substrate preferences. STAMBP processes mainly K63-linked polyubiquitin 
(generally an activity modifying post-translational modifications), generating di-
ubiquitin, on the other hand USP8 preferentially breaks-down K48-linked chains 
(linked to proteasomal degradation) to component ubiquitin monomers (Schipani 
2006; Provot and Schipani 2007; McCullough, et al. 2004; Provot and Schipani 
2005; McCullough et al. 2006). The DUB activity at the endosome therefore also 
recycles ubiquitin, and is important for the maintenance of free ubiquitin in the cells. 
Expression of an inactive STAMBP mutant results in accumulation of ubiquitin at 
the endosomes (Faqeih, et al. 2005; Sierra, et al. 2010; McCullough, et al.2004). 
Other pertinent STAMBP interactants include the Grb2 adaptor and the PI3K 
class II kinase (Figure 6.1.4) (Kitamura, et al. 2003; Sowa et al. 2009). 
Interestingly, brain lesions containing ubiquitinated protein aggregates have 
been noted in Stambp
 
knockout mice (Shah, et al. 2004; Suzuki et al. 2011). 
STAMBP-deficient mice, which are neonatal lethal by ~ day 19, develop post natal 
growth retardation associated with severe neuronal apoptosis in the hippocampus and 
cerebral cortex atrophy (Matsuoka et al. 2007; Ishii et al. 2001). These findings 
suggest that STAMBP-deficiency has a particular and profound impact upon normal 
cortical structure and function. 
 
I examined a panel of LBLs derived from unrelated MIC-CAP patients for 
defects in STAMBP-associated cellular functions to try and identify novel cellular 
defects in this syndromal context that could help explain the clinical presentation of 
this disorder. In particular, loss of STAMBP in MIC-CAP resulted in accumulation 
of ubiquitin-conjugated protein aggregates and elevated apoptosis, which can be a 
mechanism influencing progressive neuronal loss, underlying microcephaly and 
severe neurodegeneration. Additionally, insensitive activation of the RAS-MAPK 
and RTK-PI3K-AKT-mTOR pathways in these cells can relate to the established 
association between these networks and capillary malformations, suggesting MIC-
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CAP can be regarded as a RASopathy, although the consequences of STAMBP-
deficiency are wider than the RAS-MAPK pathway alone. 
 
 
 
 
 
Figure 6.1.4. Schematic illustration of the RAS-MAPK and PI3K-AKT pathways. 
As well as interacting with the ESCRT machinery and STAM, STAMBP has been shown to interact 
with other important components of several signal transduction pathways including the Grb2 adaptor 
and the class II PI3-kinase catalytic subunit.  
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6.2 Results 
6.2.1 MIC-CAP patient cell lines exhibit low or absent 
STAMBP/AMSH protein expression  
The relative levels of STAMBP protein expression in exponentially growing 
wildtype and MIC-CM patient cells were determined by western blotting, using anti-
STAMBP (H-4) with an epitope directed to amino acids 131-270 (Santa Cruz 
Biotechnology).  
STAMBP expression was not detected in MIC-CAP patients 7.1 and 1.2 
(Figure 6.2.1a). In patient 7.1 only one mutation in STAMBP was identified, but 
analysis by western blot failed to detect STAMBP expression (Figure 6.2.1a) 
suggesting that P7.1 has MIC-CAP secondary to an undetected deletion or noncoding 
mutation. Patient 3.1 showed a reduced level of STAMBP expression compared to 
control cells, likely secondary to the Arg424* mutation being targeted for nonsense-
mediated decay. (Figure 6.2.1b) No coding mutations were found in patient 5.1 using 
exome sequencing. The depth of coverage across the exons of STAMBP did not 
suggest a deletion and analysis of SNP (single nucleotide polymorphism) data was 
normal according to Laura McDonald (Ottawa, Canada). However, Western blotting 
revealed a severe reduction in STAMBP expression, (Figure 6.1.2c) suggesting that 
P5.1 has MIC-CAP secondary to noncoding (likely intronic) mutation in STAMBP.  
 
 
 
Figure 6.2.1. AMSH/STAMBP protein expression in MIC-CAP patient cell lines 
Western blot analysis of whole cell extracts (WCE) from patient-derived LCLs P3.1, P5.1, P7.1 and 
P1.2, showing either a) equivocal (P3.1), b) reduced (P5.1) or c) absent STAMBP expression (P7.1, 
P1.2) when compared to WT cells. Increasing amounts of WCE (25g, 50g, 75g) were blotted for 
WT versus P3.1 and WT versus P5.1, whilst 100g of WCE were used to investigate STAMBP 
expression in P7.1 and P1.2. Expression of -tubulin or PCNA was used as a control for protein 
loading.  
 
a) b) c) 
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Notably, patients 1.2 and 7.1, where no detectable STAMBP expression was 
found, seem to be associated with higher severity of some of the MIC-CAP 
phenotypical traits, namely lowest birth OFC, lowest later OFC and lowest birth 
length (Table 6.1.1) when compared to MIC-CAP patients with reduced STAMBP 
expression. This may be reflective of hypomorphic defects in this disorder. 
 
 
6.2.2. STAMBP depletion results in accumulation of conjugated 
ubiquitin 
Impaired ESCRT function is associated with the intracellular accumulation of 
ubiquitinated proteins (Peretz et al. 2001; Agromayor and Martin-Serrano 2006). 
Specifically, overexpression of catalytically inactive STAMBP has been shown to 
cause accumulation of ubiquitin at the endosomes (McCullough, 2004). Importantly, 
brain lesions containing ubiquitinated protein aggregates have been noted in Stambp
-
/-
 mice, associated with severe atrophy of cerebral cortex and loss of hippocampal 
neurons (Huang-Doran et al. 2011; Suzuki et al. 2011; Ishii et al. 2001) 
Consistent with this, I observed elevated levels of conjugated-ubiquitin 
agregates following siRNA-mediated silencing of STAMBP in the human 
medullablastoma line T98G using indirect immunofluorescence (IF) with an 
antibody that specifically detects conjugated-ubiquitin (FK2) and not free ubiquitin 
(Figure 6.2.2). 
Strikingly, elevated levels of conjugated-ubiquitin aggregates were also 
observed in several STAMBP patient LCLs, compared to wild-type (WT) controls 
following serum starvation (Figure 6.2.3).   
Accumulation of ubiquitin aggregates as a result of loss of STAMBP function 
in neurons is likely a mechanism that could influence the development of 
microcephaly and its progression in MIC-CAP.  
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Figure 6.2.2. Elevated conjugated-ubiquitin protein aggregates were observed following siRNA-
mediated silencing of STAMBP. 
a) siRNA-mediated knockdown of STAMBP in T98G medullablastoma cells was confirmed by 
western-blot (unt = untransfected). b) 24h post-transfection, the cells were immunostained with anti-
FK2 antibody and a FITC conjugated secondary antibody (green) and ubiquitin aggregates visualized 
by indirect immunofluorescence (IF). DAPI counterstain (blue) provides nuclear staining. 100X 
magnification. STAMBP siRNA resulted in accumulation of ubiquitin aggregates in T98G cells. 
 
 
Figure 6.2.3. STAMBP-patient LCLs exhibit elevated levels of conjugated-ubiquitin protein 
aggregates. 
WT and MIC-CAP patient derived LBLs were immunostained with anti-FK2 antibody and a FITC 
conjugated secondary antibody (green) and ubiquitin aggregates visualized by indirect 
immunofluorescence (IF). DAPI counterstain (blue) provides nuclear staining. 100X magnification. IF 
using anti-FK2 showed elevated levels of ubiquitinated protein aggregates in LCLs from P7.1, P3.1 
and P1.1, compared to WT following 24hrs serum starvation. 
a) 
b) 
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6.2.3 MIC-CAP patient LBLs exhibit elevated autophagy flux 
Endocytic DUBs including STAMBP are associated with the regulation of 
autophagy (Puc et al. 2005; Kirkin, McEwan, et al. 2009; Korolchuk, et al.2009). 
Autophagosomes are formed as a catabolic response under conditions of nutrient 
limitation or for targeting expended/damaged cellular structures for lysosomal 
degradation. 
Post-translational modifications of cell proteins (such as ubiquitination) 
provide a selective degradation signal for the autophagy pathway (N. Xu et al. 2010; 
Kirkin, et al. 2009; N. Xu et al. 2012).  p62 and NBR1 (neighbor of BRCA1 gene 1) 
are autophagy receptors that bind both ubiquitin and autophagosome-specific 
modifiers LC3/GABARAP, and are thought to be involved in autophagy of 
ubiquitinated targets (Carter et al. 2011; Kirkin, et al. 2009; Isidor et al. 2011; 
Komatsu et al. 2007; Mirzaa et al. 2011).  
During starvation-induced autophagy, the cytosolic form of microtubule-
associated protein light chain 3 (LC3-I) is cleaved at its carboxy-terminal, and 
conjugated to phosphatidylethanolamine to form LC3-II. The lipid-conjugated form 
LC3II is associated to autophagosomal membranes (Kabeya et al. 2000). LC3 
immunofluorescence did not reveal a clear difference in LC3 subcellular 
distribution/levels between MIC-CAP LBLs and the control (WT) (Figure 6.2.4a). 
However, studies have shown that the total autophagic flux is better assessed by 
immunoblot analysis of the ratio between the two forms of LC3 (LC3-II/LC3-I) 
(Mizushima and Yoshimori 2007) which correlates with the number of 
autophagosomes. Bafilomycin A1 inhibites fusion between autophagosomes and 
lysosomes. I examined processing of the autophagy marker LC3-I to LC3-II to 
evaluate autophagosome formation in STAMBP-deficient MIC-CAP cell lines. 
Treatment with the autophagy inhibitor Bafilomycin A1 helps monitor the 
autophagic flux, evidenced by an increase in LC3-II isoform expression in all LBL 
lines. Calculation of the LC3-II/LC3-I (cleaved/full length LC3A) ratio suggests an 
accumulation of autophagosomes in MIC-CAP LBLs, compared to WT levels, even 
in the untreated as well as after BafA1 treatment. This indicates upregulated 
autophagosome formation STAMBP-deficient MIC-CAP LBLs.  
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Figure 6.2.4. MIC-CAP patient LBLs show upregulated autophagosome formation. 
The presence of LC3 in autophagosomes and the conversion of LC3 (ful length) to the lower 
migrating form LC3-II (cleaved) were investigated to evaluate autophagy in MIC-CAP LBLs. a) WT 
and MIC-CAP patient derived LBLs were serum-starved for 24h to induce autophagy, and 
immunostained with autophagosome marker anti-LC3A antibody and a rhodamine-conjugated 
secondary antibody (red). DAPI  counterstain (blue) provided nuclear staining. 100X magnification. 
Subcellular localization of LC3A by indirect immunofluorescence revealed a punctate cytoplasmic 
distribution, which did not visibly differ between WT and MIC-CAP cells. However, b) treatment 
with the autophagy inhibitor Bafilomycin A1 monitors autophagic flux, evidenced by an increase in 
LC3-II isoform expression in all LBL lines. WT and MIC-CAP LBLs were grown in the absence (-) 
or presence (+) of BafA1 for 2h, and cell lysates analyzed by western blot for the presence of LC3A. 
PCNA levels were used as a control for protein loading. c) calculation of the LC3-II/LC3-I 
(cleaved/full length LC3A) ratio reveals an accumulation of autophagosomes in MIC-CAP LBLs, 
compared to WT levels, even in the untreated as well as after BafA1 treatment. 
 
b) 
a) 
c) 
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6.2.4. MIC-CAP patient LBLs exhibit elevated apoptosis  
 Apoptosis has been shown to have an important role during normal 
mammalian brain development, namely involved in the regulation of forebrain size 
(Haydar et al. 1999). An increase in neuronal apoptosis has been linked to 
microcephaly in Mos
+/-
 mice (Silver et al. 2010; Schipani et al. 2001; Provot and 
Schipani 2007; Schipani 2006), whereas apoptosis-deficient Caspase 9 knockout 
mice exhibit increased brain size (Schipani et al. 2001; Kuida et al. 1998), implying 
that a carefully regulated level of apoptosis is important for normal neural 
development. Importantly, increased apoptotic cell death in the cerebral cortex has 
been observed in a human disorder characterized by microcephaly, epilepsy and 
infantile diabetes (MEDS; OMIM 614231). MEDS results from a homozygous 
mutation in the gene IER3IP1 (immediate early response 3 interacting protein 1), 
which codes for an endoplasmic reticulum stress response protein highly expressed 
in the fetal brain cortex (Poulton et al. 2011).  
 I assessed apoptosis in MIC-CAP patient LBLs, as a possible mechanism that 
could explain the severe microcephaly manifested in this disorder. Elevated levels of 
cleaved caspase-3, activated during the early stages of apoptosis, were observed 
specifically in the 3 MIC-CAP LBLs, by comparison to WT, upon 24h serum 
starvation-induced apoptosis (Figure 6.2.5a). Under the same conditions, a higher 
number of cells stained positively for annexin V in MIC-CAP patient LBLs, 
compared to WT (Figure 6.2.5c).  These results indicate elevated apoptosis in MIC-
CAP. Elevated ubiquitin-conjugated protein aggregation resulting from STAMBP 
deficiency could induce progressive apoptosis, and provide a potential underlying 
mechanism for microcephaly in this disorder. This would be consistent with brain 
imaging analysis of MIC-CAP (Carter et al. 2011), as well as Stambp 
-/- 
mouse 
model, which showed that STAMBP is required for survival of hippocampal and 
cerebral cortex neurons ( Lee et al. 2012; Ishii et al. 2001). 
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Figure 6.2.5. MIC-CAP patient LBLs exhibit elevated apoptosis. 
WT and MIC-CAP LBls were serum starved for 24h to induce apoptosis. a) western-blot analysis 
revealed an increased amount of (apoptotic marker) cleaved caspase 3 in LCLs from P7.1, P3.1 and 
P1.1, compared to WT, following 24hrs serum starvation, suggesting elevated apoptosis in MIC-CAP 
cells. Caspase 3 levels were used as loading control. Additionally, b) annexin V staining under the 
same conditions was also determined by flow cytometry (using the Single Channel Annexin V/Dead 
Cell Apoptosis Kit with AlexaFluor® 488 annexin V and SYTOX® Green for Flow Cytometry, by 
Invitrogen). Serum-starved cells showed a higher percentage of apoptotic cells than the basal level of 
apoptosis seen in the untreated. c) Moreover, MIC-CAP LBLs showed higher levels of annexin V 
staining, when compared to control (WT), in response to serum starvation. Unt; untreated, NS; no-
serum 24h. Average of 3 separate determinations ± SD. These results indicate that apoptosis is higher 
in STAMBP-defective MIC-CAP LBLs, when compared to WT levels. 
a) 
b) 
c) 
AnnexinV 
negative 
AnnexinV 
positive 
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6.2.5 Is MIC-CAP a RASopathy? 
When the MIC-CAP syndrome was first described, the authors postulated 
that “the causative gene for this new syndrome may have a dual role in signaling 
pathways related to vasculogenesis and neuronal survival” (Carter et al. 2011). 
Considering the established role of STAMBP in regulating receptor-mediated 
endocytosis, sorting and trafficking (Kyuuma et al. 2006; Clague et al. 2006) I 
investigated RAS-MAPK signal transduction in MIC-CAP LBLs, since mutations in 
components of this pathway are associated with congenital capillary malformation 
disorders (Chang et al. 2006; Zenker 2011; Tidyman et al. 2009). RAS-MAPK signal 
deregulation could help explain the capillary malformations observed in MIC-CAP 
patients. 
RAS is a small GTP-binding protein (GTPase) that cycles between an 
inactive (GDP-bound) and an active (GTP-bound) form to regulate signal 
transduction pathways (Chang et al. 2006; Zenker 2011). GTP-bound RAS binds 
RAF-1, leading to activation of the MAPK pathway. Therefore, RAF-1 can be used 
as an affinity ligand to selectively precipitate GTP-RAS. To examine the direct effect 
of STAMBP-deficiency on RAS-MAPK pathway activation, I used a RAS pull-
down assay to investigate the endogenous levels of active RAS in MIC-CAP LBLs 
relative to WT (Figure 6.2.6). Compared to WT levels, both P7.1 and P1.2 LBLs 
exhibited elevated levels of GTP-bound RAS. This suggests MIC-CAP syndrome is 
associated with hyperactive RAS. 
Additionally, I investigated RAS-dependent signaling to the MAPK pathway, 
to determine if RAS over activation translates into perturbed regulation of this 
signaling cascade in MIC-CAP. Serum starvation induced a significant reduction in 
C-RAF phosphorylation on serine 338 in WT LBLs, consistent with inhibition of C-
RAF activity under these conditions (Figure 6.2.7a). However, STAMBP-patient 
LBLs maintained pS338-C-RAF levels in the absence of serum indicating persistent 
activation and insensitivity of this pathway. 
Further evidence suggesting insensitive signal transduction in this pathway in 
STAMBP-mutated LBLs is indicated by the relative insensitivity of these cells to the 
MEK1/2 inhibitor U0126. Active C-RAF phosphorylates and activates MEK1/2 
kinase, which then phosphorylates and activates ERK1/2 (Figure 6.1.4). I repeatedly 
found elevated levels of phosphorylated ERK1/2 in exponentially growing 
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STAMBP-mutated LBLs compared to WT following a short treatment (1hr) with the 
MEK1/2 inhibitor U0126  (Figure 6.2.7b). Treatment with increasing doses of 
MEK1/2 inhibitor further confirmed this observation, revealing an increased residual 
level of phosphorylated ERK1/2 in MIC-CAP LBLs, when compared to control 
levels in the WT (Figure 6.2.7c). The excess of phosphorylated ERK1/2 in 
STAMBP-mutated LBLs under these robust inhibition conditions is consistent with 
hyperactive and insensitive RAS-MAPK pathway in these cells.   
 
 
 
 
 
 
 
 
Figure 6.2.6 MIC-CAP LCLs exhibit hyperactive RAS 
A RAS pull down assay was performed using the Ras Activation Assay Kit (Millipore). Briefly, WT 
and MIC-CAP LBLs lysates were incubated with RAF-1 RBD agarose to precipitate activated GTP-
bound RAS. a) Western blot analysis was performed using anti-RAS antibody. GDP-loaded samples 
were used as a negative control. b) Measurement of the band intensities using Image J showed 
significantly elevated active RAS in MIC-CAP LBLs (P7.1, P1.2).( a.u., arbitrary units). This 
suggests MIC-CAP syndrome is associated with hyperactive RAS signaling. 
 
 
 
 
 
 
 
 
 
b) 
a) 
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Figure 6.2.7 MIC-CAP LBLs exhibit active and insensitive RAS-MAPK signaling. 
a) WT and MIC-CAP LBLs were grown in the presence (+) or absence (-) of serum for 24h. Serum 
starvation inhibits C-RAF activation (pS338 C-RAF) in wild type (WT) LBLs. In contrast MIC-CAP 
LBLs show inappropriately active C-RAF following serum starvation. b) LBLs were either treated (+) 
or untreated (-) with 10M U0126, a potent and specific MEK1/2 inhibitor for 1hr. Cells were 
harvested and whole cell extracts were probed for phospho-ERK1/2 levels, which is mediated by 
MEK. MIC-CAP LCLs show residual pERK1/2 signal following MEK1/2 inhibition, reflecting an 
increased intensity of signal transduction from RAF to MEK to ERK. c) UO126 titration further 
confirms this phenotype, showing a residual pERK1/2 signal in MIC-CAP LBLs treated with 
increasing doses of inhibitor, when compared to WT levels. Collectively, these results indicate a 
greater strength RAS-MAPK signaling in MIC-CAP LBLs. 
 
The RAS-MAPK pathway regulates crucial cellular processes including cell 
growth, cell cycle progression and differentiation. Disorders characterized by 
hyperactivity of RAS-MAPK network, such as Noonan and Costello syndromes, also 
exhibit growth delay, another prominent feature of MIC-CAP, alongside the 
microcephaly and capillary malformation (Cancer Genome Atlas Research Network 
2008; Adams, et al. 2006; Tidyman et al. 2009). Considering the marked post-natal 
growth retardation and capillary abnormalities seen in MIC-CAP, hyperactive RAS-
MAPK signaling may represent a significant biological consequence induced by 
impaired STAMBP function in humans and suggests that STAMBP-mutated MIC-
CAP is a RASopathy. 
 
a) 
b) 
c) 
pC-RAF (S338) 
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6.2.6 MIC-CAP patient LBLs exhibit insensitive, elevated PI3K-
AKT signaling 
Chronically activated signaling via cell surface receptors (due to STAMP 
deficiency) would also be associated with chronically activated signaling through 
PI3K (phosphoinositol-3-kinase) and consequently through AKT. The PI3K-AKT 
pathway represents another crucial receptor-mediated signaling cascade controlling 
the cell‟s translational response to its environment (Lee et al. 2012; Gregory et al. 
2004; Laplante and Sabatini 2012). 
Here I showed direct evidence of spontaneously elevated PI3K activity in 
STAMBP-mutated LBLs that was not responsive to serum removal (NS) (Figure 
6.2.8a). Phosphorylated PI3Kinase signal decreased in the WT following serum 
removal consistent with shutting off this pathway. However, both the p55 and the 
p85 isoform of PI3K were hyperphosphorylated specifically in MIC-CAP cells 
compared to WT, suggesting chronic activation of receptor-mediated signaling. 
Consistently, I saw elevated levels of activated, phosphorylated AKT in MIC-CAP 
patient cell lines, under the same conditions (Figure 6.2.8b).  
Both the RAS-MAPK and PI3K-AKT pathways are interdependent 
(Lindhurst et al. 2012; Ruzankina et al. 2007; Castellano et al. 2010) and involve 
complex cross-talk between the networks at many levels, particularly at the 
RAF↔AKT interface (Figure 6.1.4.) ultimately converging on inhibition of the 
tuberous sclerosis complex (TSC1/2) via phosphorylation of tuberin (TSC2). The 
TSC1/2 complex is the principal negative regulator of mTORC1, which when active, 
enables ribosome biosynthesis and protein translation. I monitored the consequences 
of apparently increased signaling through the PI3K-AKT network by examining 
TSC2 phosphorylation on threonine-1462, which is an AKT-dependent inhibitory 
signal for the TSC1/2 complex. Under nutrient-limiting conditions, this site should 
be unphosphorylated, allowing active TSC1/2 to be able to inhibit mTOR function 
and thereby suppress protein translation. Consistent with this, pT1462-TSC2 levels 
are reduced in WT in no-serum conditions. In MIC-CAP cells, however, the TSC 
complex fails to be inactivated (Figure 6.2.8b). Maintenance of phosphorylated 
TSC2 under these conditions indicates inappropriate mTORC1 activation.  
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Figure 6.2.8. MIC-CAP LBLs exhibit insensitive, elevated PI3K-AKT signaling. 
WT and MIC-CAP LBLs were grown in the presence (+) or absence (-) of serum for 24h. a) MIC-
CAP LBLs from P7.1 and P1.2 exhibit elevated basal levels of active phosphorylated PI3K (p55-
pY199/p85-pY458) when cultured in complete medium (15% FCS), compared to WT levels. Upon 
serum starvation (-) a modest reduction in p85 and p55 phosphorylation was seen in WT LBLs, 
consistent with attenuation of PI3K-mediated signaling, whereas both MIC-CAP LBLs consistently 
exhibited elevated levels of phosphorylation indicative of insensitive, hyperactive PI3K. The lower 
panel shows a re-probe of the above blot using antibodies against the native p85 PI3K regulatory 
subunit. b) MIC-CAP LBLs from P7.1, P1.1 and P3.1 exhibit elevated active phosphorylated-AKT 
(pT308) following serum starvation, compared to wild-type cells (WT). Similarly elevated levels of 
inhibited, AKT-dependent phosphorylated-TSC2 (pT1462) are observed in MIC-CAP LBLs 
following serum starvation, in contrast to WT cells. These results point to an increased activation of 
the PI3K/AKT/mTOR signalling in MIC-CAP cell lines, which is further supported by c) elevated 
mTOR-dependent phosphorylation of S6 (pS240/pS244) in STAMBP-deficient cells, compared to 
WT levels. pS6 is also less efficiently inhibited in serum-deprived cultures, compared to WT. β-
tubulin levels were here used as a control for protein loading. 
 
 
c) 
b) 
a) 
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Moreover, in MIC-CAP LBLs, mTORC1-dependent phosphorylation of S6 
(S240/S244) is elevated when compared to WT (Figure 6.2.8c), and in response to 
serum-starvation STAMBP-deficient LBLs fail to efficiently inhibit S6 activation. 
Activated mTOR pathway is likely to have causal impacts on clinical features such 
as growth retardation, manifested in MIC-CAP syndrome.  
Collectively, these results indicate that MIC-CAP causative mutations in 
STAMBP are associated with insensitive, elevated signal transduction in both the 
RAS-MAPK and PI3K-AKT pathways in patient derived cells. 
 
6.2.7. STAMBP reintroduction rescues MIC-CAP cellular 
phenotypes. 
To demonstrate that the novel cellular phenotypes described here in MIC-
CAP patient LBLs are the direct consequence of STAMBP deficiency, I reintroduced 
STAMBP in MIC-CAP cells using a lentiviral vector-mediated approach (LentiORF, 
Thermo Scientific Open Biosystems). Transduced P1.2 LBLs, where previously no 
STAMBP protein was detected, successfully re-expressed STAMBP to levels 
comparable to WT LBLs (Figure 6.2.9a). This resulted in correction of several 
cellular MIC-CAP phenotypes. A reduction of ubiquitin conjugated protein 
aggregates was now observed in STAMBP-complemented P1.2, as visualized by 
FK2 immunofluorescence (Figure 6.2.9b). STAMBP complementation also rescued 
signaling defects observed in MIC-CAP. Namely, under nutrient limiting conditions, 
STAMBP-expressing P1.2 LBLs efficiently downregulate signaling through the 
RAS/MAPK - as evidenced by pS338-C-RAF reduction- as well as throught the 
AKT/mTOR pathway, suggested by dephosphorylation of pT1462 TSC2 as well as 
p240/244 S6, thus behaving like the control (WT) cells. This is in stark contrast to 
MIC-CAP response, which exhibits elevated, insensitive signaling via these 
pathways. STAMBP re-introduction also restored autophagosome levels in a MIC-
CAP LBL, indicated by the reduction in LC3II/LC3I ratio compared to WT (Figure 
6.2.9d).  
Expression of STAMBP in a MIC-CAP patient-derived LBL lead to 
correction of multiple cellular MIC-CAP phenotypes, indicating that these defects 
resulted from the absence of STAMBP in these cells 
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Figure 6.2.9. STAMBP-complementation rescues specific cellular MIC-CAP phenotype. 
a) STAMBP-complementation of a MIC-CAP LBL line (P1.2), where no STAMBP expression was 
originally detected, was confirmed by western blotting. Complemented LBLs express STAMBP to 
levels comparable to WT. b) STAMBP complementation rescued the accumulation of ubiquitin 
aggregates observed in MIC-CAP cells. Following 24hrs of serum starvation, P1.2 and 
P1.2+STAMBP LBLs were immunostained with anti-FK2 antibody and a FITC conjugated secondary 
antibody (green) and ubiquitin aggregates visualized by indirect immunofluorescence (IF). DAPI 
counterstain (blue) provided nuclear staining. 400X magnification. c) STAMBP complementation in 
P1.2 also rescued cell signaling defects observed in MIC-CAP cells. Intrinsically active and 
insensitive signaling via the PI3K-AKT and RAS-MAPK pathway pathways observed in MIC-CAP 
LBLs was rescued in P1.2 by complementation with STAMBP. Western blot analysis showed reduced 
phosphorylation of S6 (pS240/pS244), C-RAF (pS338) and TSC2 (pT1462) after 24h serum 
starvation in P1.2-STAMBP complemented cells, by contrast to parental P1.2, and similar to WT 
LBLs. d) Additionally, analysis of LC3A-II/LC3A-I ratio after Bafilomycin A treatment revealed also 
a reduction in autophagy flux after STAMBP complementation in P1.2 MIC-CAP LBLS. PCNA 
levels were used as control for protein loading. Collectively, this data indicates that the cellular 
defects observed in MIC-CAP patient derived LBLs are the result of STAMBP deficiency in these 
cells.  
a) 
b) 
c) d) 
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6.2.8 MIC-CAP patient derived LBLs show inefficient ATR-
dependent G2/M checkpoint. 
Microcephaly (and growth retardation) is a clinical feature often observed in 
human disorders that manifest with DNA damage response defects (Kurek et al. 
2012; French et al. 2004; O'Driscoll et al. 2008). Examples include Seckel Syndrome 
(OMIM 210600), Microcephalic Osteodysplastic Primordial Dwarfism type II 
(OMIM 210720), Primary Microcephaly and Meier-Gorlin Syndrome (OMIM 
224690). This suggests that efficient DNA damage response is important during 
normal brain development and can be an underlying aetiology of microcephaly. 
Additionally, increased AKT-dependent signaling (such as seen in MIC-CAP) has 
been shown to overcome cell cycle checkpoints and induce mitosis in the presence of 
DNA damage (Rios et al. 2012; French et al. 2004; Kandel et al. 2002); and in 
Chapter 5 I presented evidence of a microcephalic disorder, Donohue syndrome, 
associated with increased PI3K-AKT signaling which manifests with an ATR-
dependent cell cycle checkpoint defect. For these reasons, I investigated some basic 
aspects of the DNA damage response in MIC-CAP patient derived LBLs to 
determine whether there was any crosstalk between a defective endocytic DUB and a 
functional cell cycle checkpoint. 
Fascinatingly, I found that MIC-CAP LBLs fail to activate the ATR-
dependent G2/M cell cycle checkpoint in response to UV-induced damage (Figure 
6.2.10a), compared to WT. STAMBP-mutated LBLs efficiently induced the IR-
induced checkpoint arrest. This suggests impairment specifically of the ATR-related 
(but not ATM) G2/M checkpoint in MIC-CAP. However, and unlike in Donohue 
syndrome, treatment with different doses of a specific AKT inhibitor did not rescue 
the checkpoint defect in MIC-CAP LBLs (Figure 6.2.10b).  This suggests that the 
DDR defect in STAMBP-mutated cells does not derive from increased AKT 
activation in these cells. Nonetheless, the observation of a defective ATR-dependent 
G2/M checkpoint arrest in cells deficient in an endosome-associated DUB represents 
a novel functional association that warrants deeper investigation. 
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Figure 6.2.10. MIC-CAP patient LBLs present defective ATR-dependent G2/M checkpoint 
activation. 
a) Control (WT), ATR-defective (ATR-S) and MIC-CAP (P7.1, P1.2) LBLs were irradiated with 
either 7Jm
-2
 or 3Gy IR, in the presence of colcemid, and the number of mitotic cells assessed 4hrs 
later. ATR-S, and both MIC-CAP patient derived cells failed to efficiently activate the ATR-
dependent G2/M checkpoint arrest, compared to control cells. By contrast, the IR-induced (ATM 
dependent) checkpoint was efficiently activated under these conditions. Mean ± SD of 3 experiments. 
b) AKT inhibition does not rescue the ATR-dependent G2/M DNA damage checkpoint defect in 
MIC-CAP. Treatment with different doses of AKT inhibitor (InSolution™ AKT Inhibitor IV, 
cat.124015, Calbiochem resulted in decreased cell proliferation in both WT, as well as MIC-CAP 
(P1.2), even in un-irradiated cells. This suggests that the checkpoint defect observed in these patient 
cells is not due to the observed elevated levels of active AKT in MIC-CAP. Data represents a single 
determination. 
 
 
 
 
 
b) 
a) 
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6.3 Summary 
 In summary, STAMBP mutations were identified in MIC-CAP syndrome, a 
recently described severe developmental disorder characterized by microcephaly, 
growth retardation and capillary malformations. Analysis of MIC-CAP patient LBLs 
demonstrated elevated ubiquitin-conjugated protein aggregation and apoptosis 
activation. This data is consistent with elevated ubiquitin-conjugated protein 
aggregate induced progressive apoptosis as a potential underlying mechanism for 
microcephaly in this disorder. Furthermore, I observed active and insensitive RAS-
MAPK pathway and PI3K-AKT pathway signaling as a novel consequence of 
defective STAMBP, which could potentially contribute to the vasculature defects 
and growth characteristics of MIC-CAP syndrome. Finally, MIC-CAP patient 
derived LBLs exhibit defective ATR-dependent DDR, a common feature of 
microcephalic disorders, which could be an additional important contributor to the 
microcephaly in this syndrome, although the molecular basis of this defect is 
currently completely unclear. This work presents an example of a human disorder 
caused by a congenitally defective endosome-associated DUB, providing significant 
new insights into the pathophysiology of human microcephaly and capillary 
malformation. 
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6.4 Discussion 
 
 In this chapter I described the identification and functional characterization of 
novel STAMBP mutations in a cohort of children with a severe congenital 
developmental and neurodegenerative disorder: microcephaly-capillary 
malformation syndrome (MIC-CAP). Using Western blotting analysis I observed 
absent or severely reduced STAMBP expression in MIC-CAP patient derived LBLs. 
 STAMBP-mutated MIC-CAP syndrome is associated with severe microcephaly, 
intractable seizures, post-natal growth retardation and capillary malformations 
(Kandel et al. 2002; Matsubara et al. 1992; Mirzaa et al. 2011; Carter et al. 2011; 
Isidor et al. 2011). Interestingly, Stambp
-/-
 mice are viable and exhibit post-natal 
growth retardation with severe neurological impairment and death between post-
natal days 19-23 (O'Driscoll et al. 2007; Araldi and Schipani 2010; Suzuki et al. 
2011). The brain abnormalities in these mice are region specific, typified by cerebral 
neuron loss and degradation of the CA1 hippocampal layer with relative sparing of 
the cerebellar cortex and olfactory bulbs (Stankiewicz et al. 2010; Suzuki et al. 2011; 
Colnaghi et al. 2011; Ishii et al. 2001). This is in keeping with the diffuse cortical 
and hippocampal atrophy with cerebral sparing described in MIC-CAP patients 
(P1.2, P3.1 and P7.1 in Table 6.1.1; Figure 6.1.1a,c). 
 STAMBP encodes a deubiquitinating enzyme (DUB) that plays a central role in 
controlling the sorting and trafficking of ubiquitinated endocytosed protein cargo 
(Colnaghi et al. 2011; McCullough et al. 2006; McCullough, et al. 2004; Tanaka et 
al. 1999; Suzuki et al. 2011). Impaired endosomal sorting complex required for 
transport (ESCRT) function is associated with the intracellular accumulation of 
ubiquitinated proteins. Specifically, overexpression of catalytically inactive 
STAMBP has been shown to cause accumulation of ubiquitin at the endosomes 
(McCullough, et al. 2004) and brain lesions containing protein aggregates have been 
noted in STAMBP
-/- 
mice (Suzuki et al. 2011). 
 Here, I showed that siRNA-mediated knockdown of STAMBP resulted in 
accumulation of ubiquitin conjugated protein aggregates in T98G human 
medullablastoma cells. Strikingly, examination of MIC-CAP patient derived LBLs 
revealed elevated levels of ubiquitin-conjugated protein aggregates in these cells 
when compared to WT levels, following nutrient deprivation.  
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 Autophagy is a key mechanism required for the degradation of expended and/or 
damaged proteins/macromolecules, and is up-regulated to provide nutrients during 
starvation (Mizushima et al. 2007). Much of the endosomal machinery is also 
associated with autophagy and indeed autophagosomes can fuse with multivesicular 
bodies (MVBs) and are regulated by ESCRT components. Impaired autophagy has 
been associated with the intracellular accumulation of ubiquitinated proteins. 
Deficient autophagic degradation of protein aggregates has been also associated with 
neuropathologies such as Alzheimer‟s, Parkinson‟s and prion disease (Ventruti and 
Cuervo 2007). Autophagic clearance of accumulated protein aggregates is therefore 
an important mechanism in preventing disruption of neural function and 
neurodegeneration. 
 I found STAMBP deficiency caused increased accumulation of autophagosomes 
in MIC-CAP LBLs, when compared to WT levels. This is consistent with the 
observation that depletion of certain ESCRT components does not prevent 
autophagosome formation, but instead inhibits the autophagic flux towards the 
lysosome ( Lee et al. 2007; Rusten et al. 2008; Wright, et al. 2011). Interestingly, 
STAMBP interacts with a number of ESCRT-III components at late endosomal sub-
compartments (Agromayor and Martin-Serrano 2006). Mutations in the ESCRT-III 
subunit CHMP2B (charged multivesicular body protein 2B, also known as 
chromatin-modifying protein 2B)/Vps2B), were found in patients exhibiting 
frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). CHMP2B-
mutations inhibited autophagic degradation and accumulation of autophagosomes in 
mammalian cells, also associated with increased levels of ubiquitin-positive protein 
agregates (Stiehl et al. 2002; Rusten et al. 2008). The accumulation of  ubiquitinated 
protein aggregates in MIC-CAP could be associated with impaired ESCRT-III 
function due to lack of STAMBP at the late endosomal pathway, which would also 
compromise efficient  autophagy. 
  
Careful regulation of apoptosis is crucial during brain development (Haydar et al. 
1999), and its deregulation has been associated specifically with altered forebrain 
size. I observed elevated apoptosis in MIC-CAP LBLs under the same nutrient 
limiting conditions, when compared to control (WT) levels. Elevated apoptosis in 
neurons has been linked to microcephaly (Silver et al. 2010). Conversely, mice 
deficient in caspase 9 exhibit increased brain size (Kuida et al. 1998). Increased 
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apoptotic cell death in the cerebral cortex has also been observed in a distinct human 
disorder associated with microcephaly, epilepsy and infantile diabetes (Poulton et al. 
2011). Importantly, STAMBP has been shown to be required for survival of 
hippocampal and cerebral cortex neurons (Ishii et al. 2001). Elevated ubiquitinated 
protein aggregation resulting from STAMBP deficiency could induce progressive 
apoptosis in neuronal cells, and provide a potential underlying mechanism for the 
development of microcephaly and its progression in MIC-CAP.  
 
Endocytosis of activated cell surface receptors is a fundamental process 
controlling protein homeostasis and regulation of signal transduction duration and 
amplitude/magnitude (Raiborg et al. 2009). Considering the overt capillary defect 
seen in MIC-CAP patients, and the association between activating mutations in 
components of the RAS-MAPK pathway seen in related capillary disorders, I 
investigated RAS-MAPK pathway function in MIC-CAP. STAMBP-patient LBLs 
maintained pS338-C-RAF levels after serum starvation, indicating persistent 
activation and insensitivity of this pathway. Further evidence came from the relative 
insensitivity of MIC-CAP LBLs to the MEK1/2 inhibitor, U0126, which resulted in 
elevated levels of phosphorylated ERK1/2 in these cells, when compared to WT 
levels. STAMBP-mutated LBLs exhibit hyperactive RAS function, associated with 
active and insensitive RAS-MAPK signaling. The data presented here suggests that 
MIC-CAP is a novel RASopathy associated with progressive and pronounced 
neurodegeneration.  
 
Activating RAS mutations have been well documented to drive oncogenic 
transformation and are frequently found in human tumours, associated with 
hyperactivation of the RAS-MAPK pathway, an important regulator of cell 
proliferation (Zenker et al. 2011). Indeed oncogenic K-RAS mutations are found in 
about 30% of all tumours, most commonly present in pancreatic ductal 
adenocarcinoma and significantly high percentages of lung and colon tumors. 
Mutations in N-RAS are prevalent in leukemias, thyroid carcinomas, or malignant 
melanoma (Fernández-Medarde et al. 2011). The stable but discrete increase in RAS-
MAPK signaling observed in RASopathies (Tidyman et al. 2009) (Aoki et al. 2008) 
contrasts with the more aggressive, stronger and constitutively active signal 
produced by oncogenic RAS mutations. Still, RASopathies mediated by mutations in 
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components of the RAS-MAPK pathway are prone to developing tumors. For 
example, Noonan syndrome has been associated with K-RAS and N-RAS mutations 
(Schubbert et al. 2006; Cirstea et al. 2010). Activation of RAS-MAPK signal 
transduction resulting from these mutations is increased when compared to WT RAS 
activation, but to a lesser degree than observed in most cancers.  
It is possible that the STAMBP mutations found in MIC-CAP, resulting in 
hyperactivation of the RAS-MAPK pathway, could increase the susceptibility of 
MIC-CAP patients to developing tumors, but none have yet been identified, although 
the molecularly defined cohort is still simply too small to enable a definite 
conclusion to be drawn.  
 
Chronically activated signaling via cell surface receptors (due to STAMP 
deficiency) should also be associated with chronically activated signaling through 
PI3K (phosphoinositol-3-kinase) and consequently through AKT. I found evidence 
of hyperactive signaling in the PI3K-AKT pathway in MIC-CAP patient derived 
cells. The functional interplay between the RAS-MAPK and the PI3K-AKT 
pathways has been well established. Additionally, STAMBP interactants include key 
components of receptor signaling pathways including GRB2 and the Class II PI3-
kinase catalytic subunit (Arts et al. 2011; Sowa et al. 2009; Tsang et al. 2006). Yet 
how this contributes to MIC-CAP patient phenotypes is unclear. Interestingly, 
intractable epilepsy, a specific feature found in all MIC-CAP patients, has been 
associated with enhanced mTOR signaling (Farquharson et al. 2000; Crino 2009). 
K63-linked polyubiquitination of the AKT kinase has been shown to promote 
localization of AKT to the cell membrane, and subsequently activation of AKT 
(O'Driscoll et al. 2003; G. Wang et al. 2012). These non-proteolytic functions of 
ubiquitination, including kinase activation, are also likely to be affected be loss of 
STAMBP DUB function, which normally functions by removing specifically K63-
linked polyubiquitin chains. 
 
Syndromes with dramatic PI3K-AKT pathway hyperactivity such as 
Cowden‟s disease, tuberous sclerosis and Peutz-Jehgers syndromes, are often 
associated with cell or organism overgrowth. This is in contrast to disorders 
characterized by pure hyperactivity of the RAS-MAPK network, such as Noonan and 
Costello syndromes (Tidyman et al. 2008). Considering the marked post-natal 
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growth and capillary abnormalities seen in MIC-CAP, hyperactive RAS-MAPK 
signaling may represent the predominant biological consequence induced by 
STAMBP deficiency in humans. Nevertheless, elevated PI3K-AKT-mTOR has also 
been implicated in vascular abnormalities, so a contribution of this pathway cannot 
be formally excluded, or indeed must be included (Griffith et al. 2008; Castellano et 
al.2011; Karar et al. 2011). 
 
 The precise mechanism by which loss of STAMBP DUB function can result 
in increased receptor mediated signaling is yet to be elucidated. Indeed contradictory 
studies can be found in the literature. McCullough et al observed an increased rate of 
EGFR degradation in STAMBP knockdown cells ((McCullough et al. 2004) On the 
other hand, catalytically inactive STAMBP has been shown to inhibit degradation of 
endosomal cargo (Agromayor et al. 2006).  
Interestingly, inhibition of STAMBP targeting to endosomes has been shown 
to prevent degradation, but not internalization, of EGFR (Ma et al. 2007). It is 
increasingly clear that endocytosis and signal transduction cannot be viewed as 
separate processes but instead exhibit a great level of cross talk. The established view 
is that endocytosis terminates receptor mediated signaling by removing active 
receptors from the cell membrane. Internalized receptors and their factor are targeted 
to the MVBs and the lysosomal pathway for degradation (Williams et al. 2007); 
alternatively, endocytosed ubiquitinated receptors can be recycled back to the cell 
surface.  
Recently, endosomes have also been viewed as potential signaling platforms, 
maintaining or even promoting specific signals (Dobrowolski et al. 2012; Sorkin et 
al. 2009). Internalized receptors can remain active on the surface of early endosomes 
(signaling endosomes), potentially increasing the duration and intensity of receptor 
dependent signaling. This has been proposed for MAPK-mediated signaling since all 
components of this signaling cascade have been found in the endosome (Alderton et 
al. 2004; Sorkin et al. 2009). The net effect of endosomal signaling would be 
dependent of how rapidly or efficiently the activated receptors are sorted to the 
degradative compartments. In this model, slow or impaired receptor sorting at the 
endosome due to loss of STAMBP function could result in sustained or increased 
receptor-mediated signal transduction from the signaling endosome, aggregation of 
ubiquitinated cargo and subsequent apoptotic cell death. 
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 Finally, STAMBP-mutated MIC-CAP is also associated with defective ATR-
dependent G2/M checkpoint activation. Specifically, MIC-CAP patient derived 
LBLs show impaired ATR-dependent (but not ATM dependent) activation of the 
G2-M cell cycle checkpoint. Microcephaly is a feature commonly observed in human 
disorders associated with defective DNA damage response (Mochida et al. 2001; 
O'Driscoll et al. 2008), suggesting that the regulation of DNA damage response is 
essential for normal brain development, and therefore may play a role in the 
development of microcephaly also in MIC-CAP syndrome.  
 Moreover, increased AKT activation has also been reported to surpass cell cycle 
checkpoints and promote entering into mitosis following DNA-causing damage 
(Murga et al. 2009; Kandel et al. 2002). However, the mechanism underlying the 
checkpoint defect in MIC-CAP is not associated with hyperactive AKT observed in 
these cells, as treatment with a specific and potent AKT inhibitor failed to rescue the 
checkpoint defect. Similarly, RAS signalling has been is implicated in the DNA 
damage response (Ruzankina et al. 2007; Gladfelter 2010). But preliminary data 
using MEK inhibitor (not shown) doesn‟t seem to point to a hyperactive RAS-
MAPK mediated effect as the causative agent behind the defective checkpoint 
activation in MIC-CAP LBLs. Therefore, the mechanism of STAMBP-mediated 
checkpoint defect remains elusive but clearly suggests a previously unknown route to 
cell cycle dysfunction.  
 The role of STAMBP in endocytosis has been primarily researched however, 
STAMBP contains a functional NLS and a substantial STAMBP pool has been 
shown to localize to the nucleus. This suggests additional, yet unclear STAMBP 
functions in the nucleus, which can potentially be relevant for DNA repair pathways. 
Nevertheless, MIC-CAP syndrome potentially highlights an important functional 
interplay between RTK-mediated signal transduction-endocytosis and the ATR-
dependent DNA damage response. 
 In conclusion, the work described in this chapter is the first example of a human 
disorder caused by a congenitally defective DUB isopeptidase functioning in the 
endocytic pathway, providing significant new insights into the pathophysiology of 
human microcephaly and capillary malformation. 
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Chapter Seven 
Results V: Mutations in the PI3K/AKT pathway 
genes AKT3, PIK3R2 and PIK3CA cause a 
spectrum of related megalencephaly syndromes 
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7.1 Introduction 
 
To further investigate the role of PI3K-AKT signaling in brain, limb and 
vascular development, in this chapter I will characterize aspects of the PI3K-AKT-
mTOR function in two megalencephaly disorders harboring novel mutations in core 
components of this pathway. 
Megalencephaly-capillary malformation (MCAP; OMIM 602501) and 
megalencephaly-polymicrogiria-polydactyly-hidrocephalus (MPPH; OMIM 603387) 
syndromes are two recently described developmental disorders characterized by 
marked brain overgrowth. The anomalies observed in MCAP patients include 
primary megalencephaly - defined as more than 2 standard deviations above the 
mean for the patients age and gender (Matsuoka et al. 2007; DeMyer 1986), prenatal 
overgrowth, brain and body asymmetry, cutaneous vascular malformations, digital 
anomalies (syndactyly with or without postaxial polydactyly) and connective tissue 
dysplasia (Ruzankina et al. 2007; Mirzaa et al. 2012; Mirzaa et al. 2004). MPPH is 
distinguished from MCAP in that it lacks the vascular malformations, as well as 
syndactyly (Figure 7.1.1, Table 7.1.1). Common complications of both syndromes 
include hydrocephalus, seizures, and cerebellar tonsillar ectopia that may lead to 
Chiari malformation (abnormal lowering of cerebellar tonsils below the foramen 
magnum) with or without syringomyelia (development of a cyst in the spinal cord) 
(Karsenty 2008; Mirzaa et al. 2012). Additionally, the literature suggests a 
moderately higher incidence of cancer in MCAP and MPPH patients, as well as 
occurrence of benign tumors (Table 7.1.2). 
 
Detailed clinical analysis of 42 children with MCAP or MPPH revealed 
significant phenotypic overlap with Noonan, cardiofaciocutaneous and Costello 
syndromes (i.e. high incidence of relative macrocephaly, vascular malformations, 
connective tissue dysplasia), which are caused by dominant mutations in RAS 
pathway genes (Araldi and Schipani 2010; Mirzaa et al. 2012). This suggested that 
MCAP and MPPH may be associated with altered RAS pathway function.  
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Figure 7.1.1. Craniofacial appearance and magnetic resonance imaging (MRI) of 3 
megalencephaly subjects featured in this study. 
Photos of patients LR08-018 (a), LR00-016a1 (b) and LR09-006 (c) were taken at 11 months, 15 
years, and 5 months, respectively. Note the prominent forehead and apparent macrocephaly in all 
three patients, and a midline facial capillary malformation (or nevus flammeus) in LR09-006. On 
brain imaging, note a prominent forehead, increased cranium-to-face ratio, cerebellar tonsillar ectopia 
(arrow heads) and bilateral perisylvian polymicrogyria (arrows). Adapted from (Stiehl et al. 2002; 
Rivière et al. 2012) 
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Table 7.1.1. AKT3, PIK3R2 and PIK3CA mutations and clinical features of the megalencephaly 
patients featured in this study. 
Patient ID LR08-018 LR00-016a1 LR05-204 LR09-006 
Group Overlap MPPH MPPH MCAP 
Gene AKT3 PIK3R2 PIK3CA PIK3CA 
cDNA change c.1393C>T c.1117G>A c.1359_1361del c.2740G>A 
Amino acid change p.Arg465Trp p.Gly373Arg p.Glu453del p.Gly914Arg 
 
sex M M M M 
Age last assessed 11m 16y 4y 5y6m 
Last OFC-SD (age) +5.5 (7.5m) +5 (13y) +9-10 (4y) +9-10 (5y) 
OG/ASYM nd/- - +/- +/+ 
VM + - - + 
SYN - - - + 
POLY (hands/feet) - - - + 
CONN + - + + 
HYD/VMEG + + + + 
CBTE + + + + 
PMG + + + + 
 
Abbreviations: ASYM, asymmetry; CBTE, cerebellar tonsillar ectopia; CONN, connective tissue 
dysplasia (including skin laxity, joint hypermobility, thick subcutaneous tissue); HYD, 
hydrocephalus; nd, no data; OFC, occipito-frontal circumference; OG, overgrowth; PMG, 
polymicrogyria; POLY, polydactyly; SD, standard-deviations; SYN, syndactyly; VM, vascular 
malformations; VMEG, ventriculomegaly. (adapted from (Phornphutkul, Wu, and Gruppuso 2006; 
Rivière et al. 2012)) 
 
 
173 
 
 
 
 
 
Table 7.1.2 Reports of cancer in MCAP and MPPH 
Subject Syndrome sex age Cancer type Reference 
Malignant tumors  
Patient 2 MCAP F 10m Wilms tumor Lapunzina et al 
Patient 3 MCAP M 4y Wilms tumor Wright et al. 
Not stated MCAP U 18y Leukemia Moore et al 
Patient 2 MPPH M 2y Medulloblastoma Osterling et al. 
Notable benign tumors 
Not stated MCAP U 21m Meningioma  Moore et al. 
Patient 14 MCAP M 5y Meningioma Conway et al. 
Abbreviations: F, female: M, male; mo, months; U, unknown sex; y, years. 
 
 
 
Figure 7.1.2. Schematic illustration of the PI3K-AKT pathway. 
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Several components of the PI3K/AKT signal transduction pathway  (Figure 
7.1.2) have been previously implicated in human overgrowth syndromes. MPPH and 
MCAP share clinical features with Proteus syndrome, recently found to be caused by 
an activating AKT1 mosaic mutation (Marsh,  et al. 2011; Lindhurst et al. 2011). 
Conversely, in mice, Akt1 loss is associated with growth retardation and increased 
apoptosis (Cho et al. 2001). Also, a spectrum of related overgrowth disorders 
resulting from germline loss-of-function mutations in PTEN, a negative regulator of 
PI3K signaling, share several clinical features with MCAP and MPPH. These include 
Bannayan–Riley–Ruvalcaba syndrome, Cowden disease and autism with severe 
megalencephaly (Butler et al. 2005; Liaw et al. 1997; Marsh et al. 1998; Orrico et al. 
2009). 
In view of the phenotypic similarity between MCAP and MPPH, it was likely 
that the two disorders could be caused by mutations affecting the same pathway. 
Our collaborators, Prof. W. B. Dobyns (Seattle, USA) and Dr. Kim Boycott (Ottawa, 
Canada) used a combination of exome sequencing, Sanger sequencing, restriction 
fragment length polymorphism, and targeted ultra-deep sequencing in 50 families 
with MCAP or MPPH to identify the causative genetic defect. De novo germline or 
postzygotic mutations were identified in core components of the 
phosphatidylinositol-3-kinase (PI3K)/AKT pathway (Rivière et al. 2012) (Figure 
7.1.3).  
A de novo mutation in AKT3 was identified in a patient with clinical features 
overlapping MCAP and MPPH (subject LR08-018). Interestingly, AKT3 encodes a 
supposedly brain-predominant form of the AKT serine/threonine kinase, a major 
downstream mediator of PI3K signaling. Sanger sequencing revealed a second de 
novo mutation in AKT3 in a MPPH patient, suggesting that mutations in AKT3 are a 
rare cause of megalencephaly. Significantly, an activating mutation in the kinase 
domain of Akt3 (p.Asp219Val) has been associated with brain overgrowth and 
seizures in mice (Tokuda et al. 2011). 
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Figure 7.1.3. Distribution of AKT3, PIK3R2 and PIK3CA mutations found in MCAP and 
MPPH patients. 
The activating Akt3 mutation in mouse is indicated in grey (p.Asp219Val). For recurrent mutations, 
the number of occurrences in distinct patients is indicated in parentheses. PH: pleckstrin homology 
domain; C-terminal: carboxyl-terminal domain; SH2 and SH3: Src-homology-2 and -3 domains; Rho-
GAP: Rho GTPase-activating protein domain; p85-BD and RAS-BD: p85- and RAS-binding 
domains; C2: protein-kinase-C-homology-2 domain. The PIK3CA mutations affect a total of 15 
residues, mainly localized in the p85-binding, C2, and catalytic lipid kinase domains. Adapted from 
(Rivière et al. 2012). 
 
Furthermore, a recurrent mutation in PIK3R2, and multiple mostly 
postzygotic mutations in PIK3CA were further identified in MCAP and MPPH 
patients, which encode the p85β regulatory subunit and the p110α catalytic subunit 
of class IA PI3K, respectively. Mutations of all 3 genes led to pre and post-natal 
overgrowth of brain and variably other tissues (Rivière et al. 2012). 
I examined a panel of MCAP and MPPH cell lines (Table 7.1.1) harboring 
mutations in AKT3, PIK3CA and PIK3R2 for alterations in PI3K-AKT signaling that 
could help explain the clinical presentation of this disorder, and further our 
knowledge of the role of this signaling cascade in brain, limb and vascular 
development. Our working hypothesis based on the association of PIK3CA 
mutations in cancer was that all megalencephaly-causing mutations would result in 
increased activation of the PI3K-AKT-mTOR signal transduction pathway. To this 
end I designed functional assays to interrogate this possibility. 
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7.2 Results 
7.2.1.  Impact of AKT3, PIK3R2 and PIK3CA mutations on PI3K 
activity in MCAP and MPPH patient LBLs. 
Class IA PI3K dimers are composed of a p110 catalytic subunit and a p85 
regulatory subunit, each of which has three isoforms encoded by three genes (p110 
isoforms: PIK3CA, PIK3CB and PIK3CD; p85 isoforms: PIK3R1, PIK3R2 and 
PIK3R3) (Engelman, Luo, and Cantley 2006). Interestingly, activating mutations in 
five of these six genes, particularly PIK3CA and PIK3R1, have been observed in 
many human cancers (Cancer Genome Atlas Research Network 2008). The 
sequencing data for MCAP and MPPH patients show that mutations in the PI3K 
p85β (PIK3R2) regulatory and p110α (PIK3CA) catalytic subunits are a common 
cause of megalencephaly syndromes, albeit with a clear genotype-phenotype 
correlation with PIK3R2 and PIK3CA mutations being associated with MPPH and 
MCAP, respectively. The regulatory p85 subunits are known to stabilize the catalytic 
subunits, influence their localization and binding partners, and maintain them in a 
low activity state (Huang et al. 2007; Miled et al. 2007).  
I found the PIK3CA, PIK3R2 mutations in MCAP and MPPH patients do not 
result in significantly altered levels of protein expression for the different PI3K 
subunits (Figure 7.2.1.a,b) when compared to expression levels in the control (WT) 
LBL. 
                      
Figure 7.2.1. PI3K and AKT3 protein expression in different megalencephaly patient cell lines. 
Western blot analysis of whole cell extracts (WCE) from a) PIK3R2-mutated; b) PI3KCA-mutated 
and c) AKT3-mutated patient-derived LCLs. The mutations found in these megalencephaly patients do 
not result in changed levels of protein expression for the various PI3K subunits analyzed a) and b), as 
well as AKT3 isoform c), when compared to control (WT) levels. 
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Similarly, AKT3-mutated megalencephaly patient LBLs express AKT3 to 
levels comparable to those seen in wild type (WT) cells (Figure 7.2.1.c). 
Both PIK3R1 and PIK3R2 have oncogenic potential, and mutations including 
the glycine-to-arginine substitution of PIK3R2 found in MPPH (p.Gly373Arg) have 
been found in cancer (Cheung et al. 2011). Several of these mutations have been 
proposed to disrupt the inactive conformation of the PI3K dimer and maintain the 
catalytic subunit in a high activity state (Miled et al. 2007; Huang et al. 2007).  
Class I PI3Ks convert phosphatidylinositol-4,5-bisphosphate (PIP2) to 
phosphatidylinositol-4,5-trisphosphate (PIP3), resulting in activation of downstream 
signaling components, notably AKT (Vanhaesebroeck et al. 2001) (Figure 7.1.3). In 
order to assess the impact of AKT3, PIK3R2 and PIK3CA mutations on PI3K 
activity, I performed PIP3 immunostaining using a monoclonal antibody to 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) developed by Caltag-Medsystems in 
lymphoblastoid cell lines derived from four megalencephaly mutation carriers (AKT3 
p.Arg465Trp, PIK3R2 p.Gly373Arg, and PIK3CA p.Glu453del and p.Gly914Arg), 
and compared PIP3 levels to those in control (WT) cells and a Cowden‟s disease line 
mutant in PTEN (Figure 7.2.2.a). PTEN is a phosphatase that specifically catalyzes 
the de-phosphorylation of PIP3, counteracting the activity of PI3K, and therefore cells 
that are PTEN-deficient should have elevated levels of PIP3. Similar to PTEN loss 
and consistent with elevated PI3K activity, all three PIK3R2 or PIK3CA mutant lines 
showed significantly increased PIP3 levels compared to unaffected control cells 
(Figure 7.2.2.b). I found no evidence for increased PI3K lipid kinase activity in the 
AKT3 mutant line, which is consistent with a mutation affecting a downstream 
effector of PI3K. Decreased PIP3 levels in the PIK3CA p.Glu453del mutant line upon 
treatment with a PI3K specific inhibitor (PI-103) confirmed that these observations 
are PI3K-dependent (Figure 7.2.3.). This data strongly supports and demonstrates for 
the first time increased activation of PI3K activity in PIK3R2 and PIK3CA mutated 
megalencephaly patients. 
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Figure 7.2.2. PIP3 levels are elevated in PI3K-mutated LBLs derived from megalencephaly 
patients. 
Lymphoblastoid cell lines derived from an unaffected control (WT), a patient with Cowden disease 
(GM10080), and four megalencephaly patients. (a) Indirect immunofluorescence staining of PIP3 in 
exponentially growing lymphoblastoid cell lines using a mouse monoclonal anti-PIP3 antibody. (b) 
Per-cell quantification of PIP3 levels based on anti-PIP3 signal intensity (a.u., arbitrary units) using 
ImageJ`. Levels of PIP3 signal in control cells (WT) are comparable to those of LR08-018 (AKT3 
p.Arg465Trp). All other mutant cell lines show increased PIP3 signal compared to control cells. 
Elevated PIP3 signal is also evident in cells derived from the patient with Cowden disease (PTEN 
p.Glu261Ter), which served as positive control. DAPI counterstain (blue) provides nuclear staining. 
100X magnification. * Statistically significant difference compared to control cells (p<0.05 two-tailed 
t-test assuming unequal variance, n=30 to 50 cells per cell line). Error bars indicate standard 
deviation.  
 
 
Figure 7.2.3. Levels of PIP3 in PI3K-mutated LBLs can be reduced by treatment with the PI3K 
inhibitor, PI-103. 
Indirect immunofluorescence staining of PIP3 in exponentially growing lymphoblastoid cell lines 
using a mouse monoclonal anti-PIP3 antibody (green). Megalencephaly patient derived cells LR00-
016a1 (PIK3R2 p.Gly373Arg) and LR05-204 (PIK3CA p.Glu453del) were treated  with the PI3K-
inhibitor, PI-103 (5µM for 16 hours). DAPI counterstain (blue) provided nuclear staining. 100X 
magnification. PIP3 levels were efficiently reduced after treatment with the PI3K inhibitor, indicating 
that the PIP3 phenotype observed in these patient cells is PI3K-dependent. 
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7.2.2. PIK3R2 and PIK3CA-mutated LBLs exhibit increased 
membrane-localized activated PDK1.  
To further determine whether the PIK3R2 and PIK3CA mutations found in 
MCAP and MPPH patients result in increased PI3K signaling, I investigated the 
localization of active phosphoinositide-dependent kinase 1 (PDK1) in patient-derived 
LBLs.  
PDK1 interacts with membrane phospholipids such as PIP3, generated by 
PI3-kinases, which promote PDK1 recruitment to the cell membrane. Membrane 
localization of PDK1 is required for activation of AKT on Thr308, a key step in the 
PI3K downstream signal transduction (K. E. Anderson et al. 1998). In un-stimulated 
cells, active, phosphorylated PDK1 is mainly found in the cytosol (Bayascas 2010; 
Bayascas 2008).  
 Indirect immunofluorescence staining in MCAP and MPPH patient derived 
lymphoblastoid cells shows increased localization of active p-PDK1 Ser241 at the 
cell membrane, a PI3K-dependent event (Figure 7.2.4) when compared to control 
(WT) cells. This was observed in both PIK3CA and PIK3R3 mutated LBLs (LR00-
016a1 (PIK3R2 p.Gly373Arg), LR05-204 (PIK3CA p.Glu453del) and LR09-006 
(PIK3CA p.Gly914Arg)), but not in the AKT3-mutated megalencephaly cell line 
((LR08-018 p.Arg465Trp), which is consistent with a mutation occurring 
downstream of PI3K activation in AKT3-mutated cells. Increased membrane 
localized endogenous p-Ser241 in PI3K-mutated individuals further supports 
hyperactive PI3K activity in the PI3K-mutated MCAP and MPPH patient cell lines. 
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Figure 7.2.4. PIK3R2 and PIK3CA-mutated LBLs exhibit increased membrane-localized 
activated PDK1. 
Indirect immunofluorescence (IF) staining of active PDK1 in exponentially growing lymphoblastoid 
cell lines using an anti-PDK1-p Ser241 antibody and a rhodamine-conjugated secondary antibogy 
(red). Images were captured on the Zeiss AxioPlan platform using the same exposure times for each 
sample. Activated PDK1 is enriched at the cell membrane by binding to PIP3. Mutant lymphoblastoid 
cell lines derived from PI3K-mutated individuals LR00-016a1 (PIK3R2 p.Gly373Arg), LR05-204 
(PIK3CA p.Glu453del) and LR09-006 (PIK3CA p.Gly914Arg) all appear to exhibit increased 
membrane-localized endogenous PDK1-pSer241 compared to wild-type (WT) and AKT3 mutant 
(LR08-018 p.Arg465Trp) cells. This is consistent with elevated PI3K activity in these cells. DAPI 
counterstain (blue) provides nuclear staining. 100X magnification. 
PDK1-pS241 
DAPI 
PDK1-pS241 
DAPI 
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7.2.3. AKT3, PIK3R2 and PIK3CA mutant lymphoblastoid cells lines 
exhibit increased PI3K-AKT-mTOR pathway signaling: 
downstream from mTOR. 
Chronic activation of the PI3K-AKT-mTOR network can be monitored via 
phosphorylation levels of downstream targets, such as S6 ribosomal protein and 
eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) (Figure 7.1.3).  
Western blot analysis showed elevated endogenous levels of phosphorylated 
S6 protein and 4E-BP1 in all MCAP and MPPH mutant cell lines compared to 
control (WT) cells (Figure 7.2.5). Both PIK3CA, PIK3R2 as well the AKT3-mutated 
patient LBLs therefore exhibit endogenously hyperactive/sustained signal via the 
PI3K-AKT-mTOR signaling network. Elevated S6 phosphorylation was also 
observed in a cell line derived from a Cowden‟s disease patient, which exhibits 
increased PI3K-mTOR signaling as a result of PTEN deficiency, a negative regulator 
of this pathway.  
In order to determine if the increased mTOR-dependent signaling in MCAP 
and MPPH was a direct result of hyperactive PI3K, I treated MCAP and MPPH cells, 
mutant in PIK3CA, PIK3R2 and AKT3, with a PI3K specific inhibitor. Treatment 
with PI-103, reduced S6 and TSC2 phosphorylation levels in control and mutant 
lines, however, the latter exhibited relative resistance to PI3K inhibition, which is 
consistent with elevated signaling through the pathway (Figure 7.2.6).   
The precise structural mechanisms by which the different causative mutations 
result in increased PI3K activity (or AKT3) remain to be elucidated. However, the 
elevated levels of PIP3 and increased phosphorylation of downstream mTOR 
signaling targets in the lymphoblastoid cell line derived from patient LR00-016a1 
suggest that the PIK3R2 p.Gly373Arg mutation results in increased PI3K lipid 
kinase activity. Importantly, the interaction between the helical domain of p110 and 
the first SH2 domain of p85, which is the location of the p.Gly373Arg mutation in 
PIK3R2 (Figure 7.1.2), helps maintain the heterodimer in a low activity state. 
Although functional studies will be necessary to prove this pathogenic mechanism 
for p.Gly373Arg, this particular mutation is likely to result in increased PI3K activity 
by disrupting normal interaction with the catalytic subunit. 
Altogether, these observations clearly show that the megalencephaly-
associated mutations result in increased PI3K activity and PI3K-mTOR signaling, a 
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critical signal transduction pathway required for normal cell and organismal growth, 
representing a novel pathomechanism for these megalencephaly-related human 
disorders. 
 
 
 
 
Figure 7.2.5. AKT3 and PI3K mutant lymphoblastoid cells lines exhibit elevated levels of 
phosphorylated S6 and 4E-BP1. 
Western-blot analysis of phosphorylated S6 and 4E-BP1 in mutant and control (WT) LBLs.  
Endogenous levels of phosphorylated S6 and 4E-BP1 in differing amounts of whole cell extracts (5, 
10 and 25μg) using phospho-specific antisera against pSer240/244 S6 and Thr37/47 4E-BP1. All 
mutant LBLs exhibited elevated levels of phosphorylated S6 and 4E-BP1 compared to WT. Elevated 
pSer240/244 S6 was also evident in GM10080, a lymphoblastoid cell line from a patient with 
Cowden‟ disease which served as a positive control. β-tubulin levels were used as a control for protein 
loading. 
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Figure 7.2.6. Sustained phosphorylation of PI3K-AKT downstream targets in MCAP/MPPH 
LBLs following treatment with the PI3K inhibitor, PI-103. 
a) TSC2 and  S6 phosphorylation was reduced to a greater extent in control cells (WT) when 
compared to those with PIK3CA (LR05-204 p.Glu453del) or PIK3R2 (LR00-016 p.Gly373Arg) 
mutations upon exposure to increasing amounts of PI-103 (0, 50, 100, 200 nM) for 2 hours. b) 
Consistent with an AKT3 activating mutation, treatment with PI3K inhibitor PI-103 did not inhibit 
TSC2 phosphorylation in the AKT3-mutated megalencephaly patient derived line, under the same 
conditions. These results further reflect elevated PI3K-mTOR signaling in MCAP and MPPH cell 
lines. β-tubulin and tuberin levels were used as a control for protein loading. 
 
 
 
 
 
 
 
 
 
a) 
b) 
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7.2.4. MCAP and MPPH patient derived LBLs exhibit inefficient 
ATR-dependent G2/M checkpoint. 
 Efficient DNA damage response is essential during normal brain 
development. MCAP and MPPH syndrome share a number of clinical features, 
including brain overgrowth, with disorders associated with PTEN loss of function. 
Interestingly, in Chapter 5, I showed that PTEN-deficient cells derived from 
Cowden‟s disease patients exhibit inefficient ATR-dependent checkpoint response, 
associated with increased PI3K signaling.  
For this reason, I investigated aspects of the ATR-dependent DNA damage 
response in MCAP and MPPH patient derived LBLs, as a possible contributing 
mechanism underlying the megalencephaly in this disorder.  
I found that MCAP and MPPH LBLs showed a moderately attenuated 
activation of the ATR-dependent G2/M cell cycle checkpoint in response to UV-
induced damage (Figure 7.2.7) as efficiently as the control (WT) LBLs.  
 
Figure 7.2.7. ATR-dependent G2/M checkpoint activation less efficient in MCAP and MPPH 
patient LBLs. 
Control (WT), and megalencephaly patient LBLs were irradiated with either 7Jm
-2
 or 3Gy IR, in the 
presence of colcemid, and the number of mitotic cells assessed 4hrs later. Patient derived cells failed 
to efficiently activate the ATR-dependent G2/M checkpoint arrest, compared to control cells. By 
contrast, the IR-induced (ATM dependent) checkpoint was efficiently activated in all patient derived 
LBLs under these conditions. Average + SD of 3 experiments.  
 
This was particularly significant for the PIK3R2-mutated line. MCAP and 
MPHH mutant LBLs efficiently induced the IR-induced checkpoint arrest. This 
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suggests modest impairment specifically of the ATR-related (but not ATM) G2/M 
checkpoint in MCAP and MPPH. One possibility is that this could be the result of 
increased AKT activity in these cells, as increased AKT-dependent signaling has 
previously been known to overcome cell cycle checkpoints and induce mitosis in the 
presence of DNA damage (Kandel et al. 2002). Further work is required to 
interrogate this association. Nevertheless, my data point to a previously 
unappreciated association between attenuated ATR-dependent G2/M checkpoint 
proficiency with a megalencephaly disorder. 
7.3. Summary 
Megalencephaly-capillary malformation (MCAP) and Megalencephaly-
polymicrogiria-polydactyly-hydrocephalus (MPPH) syndromes are sporadic 
overgrowth conditions. De novo germline or postzygotic mutations in three core 
components of the PI3K-AKT pathway were identified in MCAP and MPPH 
patients, including two mutations in AKT3, a recurrent mutation in PIK3R2 and 
multiple mostly postzygotic mutations in PIK3CA (Figure 7.1.2).  
Analysis of MCAP and MPPH patient LBLs demonstrated perturbed, 
elevated PI3K-mTOR signaling. This was confirmed by the elevated levels of PIP3 
and activated membrane associated PDK1 in PIK3CA and PIK3R2-mutated LBLs. 
PI3K and AKT3 mutant LBLs also exhibited increased phosphorylation of 
downstream mTOR signaling targets, S6 and 4E-BP1, as well as relative insensitivity 
to PI3K inhibition. Finally, MCAP and MPPH patient cells also showed somewhat 
inefficient G2/M cell cycle checkpoint arrest, associated with the ATR-dependent 
DNA damage response. 
These results extend the list of human overgrowth syndromes associated with 
aberrant PI3K/AKT signaling and demonstrate that dysfunction of the PI3K/AKT 
pathway causes a constellation of developmental brain disorders including 
polymicrogyria, hydrocephalus, and cerebellar tonsillar ectopia including Chiari 
malformation with or without syringomyelia, as well as congenital vascular and limb 
malformations. The unanticipated association of inefficient ATR-dependent G2/M 
checkpoint control in this context may point to a dominant impact of spontaneously 
active AKT upon the DDR. 
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7.4. Discussion 
In this chapter I designed and conducted functional characterization of 
lymphoblastoid lines lines derived from two related megalencephaly disorders, 
recently found to harbor mutations in core components of the PI3K-AKT pathway. 
Megalencephaly-capillary malformation (MCAP) and megalencephaly-
polymicrogiria-polydactyly-hydrocephalus (MPPH) syndromes share a high number 
of clinical features, including primary megalencephaly, prenatal overgrowth, brain 
and body asymmetry, digital anomalies and connective tissue dysplasia. In addition, 
MCAP patients also exhibit cutaneous vascular malformations (Mirzaa et al. 2012; 
Mirzaa et al. 2004). The study of MCAP and MPPH patient derived cell lines aimed 
to further our knowledge of the role of PI3K-AKT signaling in brain, limb and 
vascular development. 
 
The PI3Ks are a highly conserved family of signaling enzymes that regulate a 
wide range of processes including cell growth, proliferation, survival, migration, 
metabolism, angiogenesis, apoptosis and brain development (Vanhaesebroeck et al. 
2001; Engelman, et al. 2006; Katso et al. 2001). The serine/threonine kinase AKT is 
the predominant downstream effector of PI3K signaling. De novo mutations in AKT3 
(a brain-predominant form of the AKT kinase), a recurrent mutation in PIK3R2, and 
multiple mostly postzygotic mutations in PIK3CA were identified in MCAP and 
MPPH patients (Rivière et al. 2012). PIK3R2 and PIK3CA encode the p85β 
regulatory subunit and the p110α catalytic subunit of class IA PI3K, respectively.  
 
To assess the impact of AKT3, PIK3R2 and PIK3CA mutations on PI3K 
activity, I used immunostaining to compare phosphatidylinositol-4,5-trisphosphate 
(PIP3) amounts in lymphoblastoid cell lines derived from four mutation carriers with 
megalencephaly to those in control and PTEN-mutant cells. Class IA PI3Ks convert 
phosphatidylinositol-4,5-bisphosphate (PIP2) to PIP3 in a reaction reversed by the 
tumor suppressor PTEN phosphatase (Figure 7.1.3). Strikingly, PIK3CA and PIK3R2 
mutated LBLs revealed significantly elevated levels of PIP3 compared to WT levels. 
This phenotype strongly suggest elevated PI3K activity in these cells, and treatment 
with a specific PI3K inhibitor efficiently reduced PIP3 levels in PI3K-mutated LBLs. 
Moreover, in MCAP and MPPH LBLs with PIK3CA and PIK3R2 mutations there 
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was accumulation of active, phosphorylated PDK1 at the cell membranes, a PI3K 
dependent event (Bayascas 2010). Consistent with a mutation affecting a 
downstream mediator of PI3K and PDK1 signaling, I found no evidence for 
increased PI3K signaling in the AKT3-mutant line. Chronic activation of the PI3K-
AKT-mTOR network can be monitored by examining the extent of phosphorylation 
of mTOR downstream targets, S6 ribosomal protein and eukaryotic translation 
initiation factor 4E binding protein 1 (4E-BP1). Protein blot analysis showed higher 
amounts of phosphorylated S6 protein and 4E-BP1 in all MCAP and MPPH LBLs 
compared to controls, indicating mTOR hyperactivity in these cells. The TSC1-TSC2 
complex is the main negative regulator of mTORC1, operating downstream of AKT 
(Huang et al. 2008). The AKT-dependent phosphorylation of TSC2 on threonine 
1462 was elevated in MCAP and MPPH LBLs, indicating stronger inhibition of the 
TSC1-TSC2 complex. This results in release of TSC1-TSC2 complex inhibition over 
mTORC1, promoting activation of mTORC1 downstream targets. Mutant lines were 
also relatively resistant to PI3K inhibition. TSC2 and S6 phosphorylation upon 
exposure to increasing amounts of PI3K inhibitor, PI-103, was less reduced in 
MCAP and MPPH LBLs, in comparison to WT cells. These combined results 
suggest that the megalencephaly-associated mutations result in robust aberrant 
activation of PI3K-AKT-mTOR signal. 
 
 Substantial human and mouse model studies have shown that loss- and gain-
of-function mutations in AKT isoforms lead to opposite phenotypes. The Akt1 null 
mouse displays brain and somatic growth delay (Cho, et al. 2001), whereas an AKT1 
activating mutation was recently found to underlie Proteus syndrome (Lindhurst et 
al. 2011), an overgrowth disorder that shares clinical features with MCAP and 
MPPH. Whereas AKT2 loss in the mouse and human causes insulin resistance and 
diabetes (Cho, Mu, et al. 2001; George et al. 2004), an activating AKT2 mutation was 
associated with severe hypoglycemia and asymmetrical growth in humans (Hussain 
et al. 2011). The role of AKT3 in controlling brain size has been well established. 
Akt3 knockout in the mouse, and heterozygous AKT3 loss in human have been 
associated with severe microcephaly (Ballif et al. 2012; Boland et al. 2007; Tschopp 
et al. 2005). On the contrary an activating mutation in the kinase domain of Akt3 
(p.Asp219Val) was shown to cause brain overgrowth and seizures in mice (Tokuda 
et al. 2011), a phenotype that resembles the clinical presentation of the 
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MCAP/MPPH AKT3 mutation carriers. This data combined with my observations of 
higher S6 and 4E-BP1 phosphorylation in a lymphoblastoid cell line harboring the 
AKT3 p.Arg465Trp alteration strongly suggests a gain-of-function mechanism 
resulting in enhanced AKT kinase activity for the two AKT3 mutations in 
MCAP/MPPH. This is consistent with a recent study where somatic activating AKT3 
mutations were found in patients with hemimegalencephaly (brain hemisphere 
overgrowth), associated with severe intractable epilepsy (Poduri et al. 2012). Many 
MCAP and MPPH subjects had asymmetric brain enlargement, and several were 
diagnosed with hemimegalencephaly (Mirzaa et al. 2012). The findings presented in 
this chapter further emphasize the essential role of AKT3 in regulating normal brain 
size, establish the association between brain overgrowth and increased AKT3-
dependent signaling in two human disorders, and thus highlight the central but 
distinct functions of AKT isoforms in growth regulation and development. 
 
Class IA PI3Ks are formed of a p110 catalytic and a p85 regulatory subunit. 
Each of these subunits has three isoforms encoded by three genes (p100 isoforms: 
PIK3CA, PIK3CB and PIK3CD; p85 isoforms: PIK3R1, PIK3R2 and PIK3R3) 
(Engelman, Luo, and Cantley 2006). Mutations in five of these six genes (PIK3CA, 
PIK3CB, PIK3CD, PIK3R1 and PIK3R2) have been observed in many human 
cancers (Cancer Genome Atlas Research Network 2008), but until now not in 
individuals with developmental disorders. The data presented in this chapter also 
shows that mutations in the PI3K p85β (PIK3R2) regulatory and p110α (PIK3CA) 
catalytic subunits resulting in aberrant activation of PI3K, are a common cause of 
megalencephaly.  
A small number of malignancies and benign tumors have been observed in 
some patients with MCAP and MPPH syndromes. Regarding MCAP, the literature 
documents two cases of Wilms‟ tumor (Lapunzina et al. 2004; D. R. Wright et al. 
2009), one of whom also experienced cutaneous dermatomyofibroma and lipomas of 
the foot. A patient from the original series by Moore et al. died of leukemia at age 18 
years (Moore et al. 1997). A single MPPH patient has been reported with a 
medulloblastoma (Osterling et al. 2011). Numerous benign growths have also been 
seen in MCAP, of which vascular growths are the most common (Mirzaa et al. 2012; 
Moore et al. 1997; Martínez-Glez et al. 2010; Clayton-Smith et al. 1997). 
Furthermore, in one patient a large tufted angioma of the shoulder led to Kasabach-
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Merritt syndrome during early infancy (Wright et al. 2009). The large cohort 
reported by Mirzaa et al. also described one patient with multiple lipomas but no 
other growths (Mirzaa et al. 2012). Finally, two patients have been described with 
pediatric meningioma, which are extremely rare tumors in children (Moore et al. 
1997; Conway et al. 2007). 
The regulatory p85 subunits are known to stabilize the catalytic subunits, 
influence their localization and binding partners, and maintain them in a low activity 
state (Miled et al. 2007; Chuan-Hsiang Huang et al. 2007). Importantly, the 
interaction between the helical domain of p110 and the first SH2 domain of p85, 
helps maintain the heterodimer in a low activity state. The p.Gly373Arg mutation in 
PIK3R2 found in MPPH is located in this region, and it has been found in cancer, 
suggesting that this particular mutation may result in increased PI3K activity by 
disrupting normal interaction with the catalytic subunit. Somatic activating mutations 
in PIK3CA are frequently observed in approximately 30% of colorectal, breast and 
endometrial cancers, and at a lower frequency in other tumor types such as 
glioblastoma multiforme and skin cancer (Samuels et al. 2004).  
 
Presently, new mosaic gain-of-function mutations in PIK3CA have also been 
implicated in other distinct overgrowth conditions. Mutations in PIK3CA, associated 
with enhanced activation of the PI3K-AKT-mTOR pathway, were identified in 
hemimegalencephaly patients (also mutations in mTOR and AKT3) (J. H. Lee et al. 
2012), mosaic overgrowth disorder with fibroadipose hyperplasia (Lindhurst et al. 
2012), congenital lipomatous overgrowth with vascular, epidermal, and skeletal 
anomalies (CLOVES) syndrome (Kurek et al. 2012) and macrodactyly (Rios et al. 
2012). Phenotypic differences observed among all these overgrowth disorders could 
be associated with the timing and occurrence of the different causative mutations 
during embryogenesis, as well as the degree of PI3K-dependent activation of 
common downstream pathways. 
 
MCAP and MPPH also share clinical features with a spectrum of overgrowth 
disorders caused by germline loss of function mutations in PTEN, a negative 
regulator of PI3K activity. These include Cowden disease, Bannayan-Riley-
Ruvalcaba syndrome and autism with severe megalencephaly (Butler et al. 2005; 
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Liaw et al. 1997; Marsh et al. 1998). Autism spectrum disorder can also be part of 
the neurocognitive phenotype of MCAP/MPPH subjects.  
Additionally, the PI3K/AKT pathway is a major downstream effector of RAS 
(Figure 7.2.8), and the interaction of RAS with class I PI3K isoforms is well 
documented (Castellano et al. 2010), which may explain the significant overlap 
between MCAP/MPPH and the group of disorders globally known as RASopathies. 
 
 
 
 
Figure 7.4.1 PI3K-AKT signaling pathway overview and the known overgrowth syndromes 
associated with mutations in components of this pathway. 
Activated receptor-tyrosine kinase leads to activation of PI3K family members, which in turn convert 
phosphatidylinositol-3,4-bisphosphate (PIP2) to the −3,4,5-triphosphate (PIP3),  a process that is 
antagonized by the PTEN phosphatase. At the plasma membrane, PIP3 facilitates recruitment and 
phosphorylation of PDK1. PDK1 then promotes the activating phosphorylation of AKT at Thr308. 
Activated AKT inhibits the main negative regulator of mTORC1, the TSC1-TSC2 complex, resulting 
in mTORC1 activation. PHTS: PTEN Hamartoma Tumor Syndrome; CLOVES: Congenital 
Lipomatous Overgrowth Vascular malformation Epidermal nevi, Skeletal/spinal anomalies. 
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Finally, the MCAP and MPPH patient LBLs analyzed here also exhibit an 
inefficient G2/M cell cycle checkpoint arrest, associated with the ATR-dependent 
(but not ATM) DNA damage response. Interestingly, PTEN-deficient cells have also 
been associated with defects specifically in the ATR-dependent G2/M checkpoint 
(see Chapter 5), and Cowden‟s disease and other disorders associated with PTEN 
deficiency, share clinical features with MCAP and MPPH, including brain 
overgrowth. It is possible that the checkpoint defect observed in these particular 
disorders could be associated with increased AKT-dependent signaling, which has 
been known to surpass cell cycle checkpoints and induce mitosis in the presence of 
types of DNA damage (Kandel et al. 2002). This data may further support the 
importance of an efficient DNA damage response during normal brain development.  
 
In conclusion, the data presented in this chapter extends the list of human 
overgrowth syndromes associated with aberrant PI3K/AKT signaling (Figure 7.4.1) 
and demonstrate that dysfunction of PI3K/AKT pathway signaling causes a 
constellation of brain, vascular and limb malformations. These findings combined 
with the development of inhibitors for PI3K, AKT or downstream targets such as 
mTORC1 (rapamycin treatment, for example, has been shown to benefit children 
with somatic PTEN deficiency (Marsh et al. 2008) could provide new therapeutic 
opportunities for megalencephaly as well as other developmental syndromes.  
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Chapter Eight 
Results VI: Characterization of aspects of mTOR 
pathway function in cells from a Genomic 
Disorder caused by copy-number variation of 
1q21.1 
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8.1 Introduction 
 
Copy Number Variations (CNVs) are structural genomic modifications that 
result in altered number of copies of one or more regions of the DNA. CNVs 
generally encompass large regions (>1Kb), and are an important contributor to 
normal genomic variation (Stankiewicz and Lupski 2010). Locus-specific rates of 
genomic CNVs occur at several orders of magnitude higher than SNPs (10
-6 
to 10
-4
, 
versus 10
-8
). Therefore, CNVs are likely a more frequent cause of human congenital 
disorder when compared to SNPs (Lupski et al. 2007). Region-specific low copy 
repeats (LCR) are susceptible for non-allelic homologous recombination (NAHR), 
which can result in modifications including deletions, duplications or complex 
rearrangements (inversions, translocations). Such structural alterations in the human 
genome are commonly found in cancers (Stankiewicz and Lupski 2010; Colnaghi et 
al. 2011). Additionally, CNVs can also result in congenital Genomic Disorders, often 
accompanied by complex phenotypic traits (Colnaghi et al. 2011). 
In this chapter I set out to understand the impact of CNV on gene expression 
and function of a particular gene, using cell lines from clinically well characterized 
patients with duplications or deletions in the 1q21.1 chromosomal region.  
 Copy number changes of 1q21.1 (deletion, OMIM 612474; duplication, OMIM 
612475) are associated with variable phenotypes. These include intellectual disability 
and/or autism (Brunetti-Pierri et al. 2008), schizophrenia (Stefansson et al. 2008; 
Shtivelman et al. 2002; Christiansen et al. 2004; Xu et al. 2010), congenital heart 
anomalies (Kandel et al. 2002; Mefford et al. 2008), dysmorphic features, including 
microcephaly/macrocephaly ( Xu et al. 2010; Brunetti-Pierri et al. 2008) (Figure 
8.1.1). My interest was to try and gain some understanding into why microcephaly 
was associated with 1q21.1 deletion and macrocephaly with 1q21.1 duplication. 
 The 1q21.1 critical region spans approximately 1.35 Mb (from 145 to 146.35 
Mb) and includes at least 12 genes (Mefford et al. 2008) (Figure 8.1.2). Functional 
consequences of genes integral to CNVs in cells/tissues from carriers are rarely 
studied, due to unavailability of appropriate human tissues and the rarity of patients 
with individual CNVs (O'Driscoll et al. 2007). For these reasons, the underlying 
genetics basis associating these phenotypes with 1q21.1 copy number variant (CNV) 
remains largely unknown.  
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Figure 8.1.1. Facial appearance of individuals with the 1q21.1 microdeletion/microduplication. 
Microcephaly and certain facial dysmorphic features such as frontal bossing, deep-set eyes and 
bulbous nose seem to be common in individuals with 1q21.1 microdeletion (top row); and 
macrocephaly, frontal bossing and hypertelorism in individuals with 1q21.1 microduplication (bottom 
row). Developmental delay and/or learning disabilities are reported in most cases, as well as 
behavioral abnormalities, including attention deficit hyperactivity disorder (ADHD), autism, 
anxiety/depression, antisocial behavior, aggression and even hallucinations (adapted from Brunetti-
Pierri et al.2008). 
 
 
 
 
 
 
 
Figure 8.1.2. Genes included in the 1q21.1 CNV critical region. Core genes seen in all subjects 
with a 1q21.1 CNV. Two of the genes that ranked highest in the expression/1q21.1 copy number 
correlation were studied (underlined). I investigated aspects of PRKAB2 function (in red), which 
encodes the β2 isoform of AMPK, in patient cells. (Harvard et al., 2011) 
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 Our collaborator, Evica Rajcan-Separovic‟s group (Vancouver, Canada) 
performed whole transcriptome expression analysis in subjects with 1q21.1 deletions 
and duplications and ranked the top genes whose expression correlated highest with 
the 1q1.1 copy number (Harvard et al. 2011). The impact of the 1q21.1 CNV on gene 
expression and function of two selected top genes within that region was then 
evaluated. 
 CHD1L, the gene which ranked first in the expression/copy number 
correlation, has been implicated in chromatin remodeling and relaxation as well as 
DNA repair (Deng et al. 2009; Ahel et al. 2009). A novel role for CHD1L in 
decatenation (chromatin untangling) checkpoint activation was identified, which was 
suspected based on its known chromatin remodeling function, and the defective Topo 
II decatenation checkpoint demonstrated in both the 1q21.1 deletion and duplication 
containing patient cell lines (Harvard et al. 2011). 
 PRKAB2, which encodes one of the AMP-activated protein kinase (AMPK) 
isoforms, is also found in the 1q21.1 critical region, and ranked 10
th
 in the correlation 
between expression/copy number analysis (Harvard et al. 2011).  
 AMPK is a highly conserved heterotrimeric kinase that plays a major role in 
sensing and responding to the cell‟s energy status (Kahn et al. 2005). AMPK is 
activated by the reduction in ATP levels, and the correspondingly reciprocal increase 
in AMP or ADP (Figure 8.1.3), which accompanies a variety of physiological 
processes, such as low nutrient availability, prolonged exercise or pharmacological 
agents. Conformational changes involving the autoinhibitory domain (AID) of 
AMPK, both promote and protect phosphorylation of the key residue Thr172 on the 
AMPK-α subunit, essential for AMPK activation (Young et al. 2009). The LKB1 
(liver kinase B1) kinase is an important mediator of AMPK-α Thr172 
phosphorylation. Additionally, AMPK can be activated in response to calcium 
influx, involving CaMKK (Calcium/calmodulin-dependent protein kinase kinase) 
(Kahn et al. 2005). AMPK controls a number of metabolic processes, including 
glucose uptake, fatty acid and glucose metabolism and mitochondria biogenesis. 
Moreover, the AMPK signal transduction pathway interacts with the 
PI3K/AKT/mTOR network to regulate cell growth, protein translation and autophagy 
in response to cellular stress (Garelick et al. 2011) (Figure 8.1.4). 
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Figure 8.1.3. AMPK activation model. 
The AMPK heterotrimeric complex is formed by the α catalytic subunit (green), which includes the 
kinase domain containing the key Thr172 residue and an autoinhibitory domain; the β subunit (blue) 
containing a glycogen binding domain and binding sites for both the α and γ subunits; and the γ 
subunit, which contains the nucleotide binding sites. When the AMP/ATP ratio increases, more AMP 
is bound to the γ subunit and the auto-inhibitory subunit releases from the hinge of the kinase domain, 
which then assumes its active more closed configuration. Access of protein phosphatases (PP2C) to 
Thr172 is limited, favoring the action of upstream kinases (LKB1 and CaMKK) resulting in a high 
phosphorylation state. (Adapted from Young et al. 2009). 
 
 
Figure 8.1.4.  Activated AMPK directly phosphorylates substrates involved in cell metabolism 
and growth. 
Phosphorylation and consequent inactivation of ACC by AMPK regulates fatty acid metabolism by 
reducing malonyl-CoA inhibitory effect on mitochondrial fatty acid oxidation. AMPK activation also 
promotes glucose metabolism and has an inhibitory effect on mTOR pathway via TSC2 activation and 
phosphorylation of RAPTOR, suppressing protein synthesis when cellular energy and nutrients 
become limiting. 
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 PRKAB2 encodes the β2 isoform of the AMPK (Young 2009). Since AMPK 
can influence mTOR function and because the mTOR pathway plays such a 
fundamental role in normal tissue and neuronal development and function, I set out 
to establish whether AMPK function was affected by PRKAB2 CNV in cells from 
1q21.1 CNV individuals. Importantly, I utilized cells bearing 1q21.1 deletion and 
duplication. 
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8.2 Results 
8.2.1. AMPK-2 and AMPK-1 expression levels in patient-derived 
LBLs with 1q21.1 CNV  
 AMP-activated protein kinase (AMPK) is a heterotrimeric protein complex 
formed of three subunits: a catalytic α-subunit, a regulatory β-subunit and an 
ATP/ADP-binding γ-subunit. These subunits can exist in different isoforms (α1, α2, 
β1, β2, γ1, γ2, γ3) (Young et al. 2009). PRKAB2, located within the 1q21.1 CNV 
region, encodes the β2 isoform of the AMPK.  
 AMPK-β2 expression, the protein product of PRKAB2, was reduced in the cell 
line with the 1q21.1 deletion (Del) and increased in the cell line with the 1q21.1 
duplication (Dup), by comparison to a control unaffected (WT) cell line (Figure 8.2.1 
a,b). By contrast, expression of the closely related β1 AMPK subunit was not altered 
in the Dup and Del lines, compared to WT levels (Figure 8.2.1c). Importantly, 
PRKAB1, the gene that codes for AMPK-β1, is located on chromosome 12q24.1, not 
within the 1q21.1 CNV. This data shows for the first time that protein levels of 
AMPK-β2 are altered in accordance with the 1q21.1 copy number state and 
expression levels of PRKAB2 (Harvard et al. 2011).  It was therefore plausible that 
AMPK function could be affected in 1q21.1 CNV cell lines as a result of altered 
expression of the AMPK-β2 subunit. 
 
8.2.2. AICAR-induced activation of AMPK kinase in patient-derived 
LBLs with 1q21.1 CNV 
AMPK is a key sensor and regulator of energy homeostasis in the cell, which 
is activated by an elevated AMP/ATP ratio. The nucleoside analogue AICAR (N1- 
(β -D- Ribofuranosyl)-5-aminoimidazole-4-carboxamide) is a cell permeable 
compound that mimics the effects of AMP on the allosteric activation of AMPK. To 
investigate the effect of increased and decreased expression of AMPK-β2 on AMPK 
activity, I treated patient-derived LBLs with AICAR and monitored activation of 
AMPK on threonine-172 (p-T172-AMPKα). This is an essential modification, 
required for and diagnostic of AMPK activity. 
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Figure 8.2.1. AMPK-β2 and AMPK-β1 expression levels in patient-derived LBLs with 1q21.1 
CNV. 
a) Titrated whole cell extracts were blotted for AMPK-2 (encoded by PRKAB2) in wild-type (WT), 
Del and Dup containing LBLs. The blots were re-probed with anti-ß-tubulin. b) Densiometric 
quantification of AMPK-β2 expression from titrated extracts, going from low (black bar), 
intermediate (white) to higher (grey) amounts of protein, normalized to β-tubulin loading, from three 
separate determinations (a.u. arbitrary units). p = 0.01 for Del and p < 0.005 for Dup LBCs compared 
to WT. c) AMPK subunit AMPK-1, encoded by the PRKAB1 gene on chromosome 12q24.1, shows 
equivalent expression in the wild-type (WT), Del and Dup containing LBCs. β-tubulin was used to 
confirm equal loading. 
 
 
 
 
 
 
 
 
 
 
a) 
c) 
b) 
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Figure 8.2.2. AICAR-induced activation of AMPK kinase in patient LBLs with 1q21.1 CNV. 
a) AICAR-induced (2mM) activation of AMPK kinase was monitored using phosphorylation of the 
AMPKα subunit on threonine 172 (p-T172-AMPKα). Dup and Del containing LBLs exhibited higher 
levels of p-T172-AMPKα at the 0 time (untreated), relative to wild-type (WT). Only the 1q21.1 Del 
containing LBLs appeared to be unresponsive to AICAR-treatment. Blots were re-probed with for 
native AMPKα to confirm loading. b) AICAR-induced (2 mM) activation of AMPK was evaluated by 
monitoring phosphorylation of the AMPK substrate Acetyl-CoA Carboxylase on serine 79 (p-S79-
ACC). Similar to p-T172-AMPKα, the Del containing LBCs appear unresponsive to the AICAR 
treatment. Blots re-probed for native ACC to confirm loading. c) AICAR-induced activation of 
AMPK was also evaluated by phosphorylation of the AMPK substrate RAPTOR on serine 792 (p-
S792-RAP) under identical conditions. Again, Del containing LBCs appeared somewhat unresponsive 
to AICAR. Blots were re-probed for MCM2 to confirm loading. 
a) 
b) 
c) 
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Interestingly, the 1q21.1 Dup and 1q21.1 Del containing cell lines exhibited 
slightly elevated basal levels of p-T172-AMPKα prior to treatment with AICAR, 
compared to control (WT) cells (Figure 8.2.2a). Within 5 minutes following AICAR 
treatment, increased phosphorylation of p-T172-AMPKα was induced in wild-type 
LBLs. Elevated AICAR-induced p-T172-AMPKα was also detected in the 1q21.1 
Dup containing cells. In comparison, the change in p-T172-AMPKα after 5 minutes 
AICAR induction was less apparent in the 1q21.1 Del containing line, and the 
activity remained constant at 15 minutes. In contrast, the AICAR-induced p-T172-
AMPKα activity of the WT and 1q21.1 Dup LBL was reduced after 15 minutes. This 
data suggests that reduced AMPK-β2 level is associated with somewhat 
unresponsive AMPK activation, while the 1q21.1 duplication-containing LBL 
showed similar pattern of responsiveness to WT cells under these conditions. 
To investigate the significance of these findings, I analyzed the AMPK-
mediated phosphorylation of two of its best known substrates, Acetyl-CoA 
Carboxylase (ACC) and RAPTOR. ACC is a key mediator of fatty acid (FA) 
synthesis. AMPK-induced phosphorylation of ACC on serine-79 (p-S79-ACC) 
inhibits ACC enzymatic activity thereby limiting FA synthesis under energy limiting 
conditions (i.e. high [AMP] and low [ATP]) (B. B. Kahn et al. 2005). Consistent 
with the findings with p-T172-AMPKα, I found efficient induction of p-S79-ACC in 
control (WT) and 1q21.1 Dup LBLs within 5 minutes of AICAR treatment (Figure 
8.2.2b). Significantly, the LBLs with 1q21.1 Del failed to exhibit significant levels of 
p-S79-ACC under the same conditions. This data supports the observation of sub-
optimal AMPK activity in the 1q21.1 deletion-containing cell line. 
RAPTOR is an important regulatory component of the mTOR containing 
complex 1 (mTORC1), required for optimal mTOR kinase activity (D.-H. Kim et al. 
2002). Under conditions when cellular energy is limiting, AMPK mediates 
phosphorylation of RAPTOR on serine-792 (p-S792-RAP), promoting inhibition of 
mTORC1 thereby limiting protein synthesis and inducing cell cycle arrest. 
Consistent with sub-optimal AMPK activity in the 1q21.1 Del containing LBLs, I 
found reduced AICAR-induced p-S792-RAPTOR in these cells in contrast to the 
1q21.1 Dup containing line and the WT control cells (Figure 8.2.2c). These results 
suggest that reduced expression of the AMPK-β2 subunit is associated with impaired 
AICAR-induced activation of AMPK. In contrast, duplication of PRKAB2 did not 
negatively impact on AMPK activity under these conditions. 
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8.2.3. Characterization of mitochondria activity in 1q21.1 CNV 
LBLs 
Activation of AMPK can promote mitochondrial biogenesis and function in 
order to increase cellular energy levels. AICAR stimulation of AMPK activity in rat 
quadriceps has been shown to result in increased expression of mitochondrial 
enzyme cytochrome c as well as the Glucose transporter type 4 (GLUT-4) (Leick et 
al. 2010). Inhibition of acetyl-CoA carboxylase (ACC), a major AMPK substrate, 
promotes mitochondrial fatty acid oxidation (Kahn et al. 2005). The peroxisome 
proliferator-activated receptor gamma coactivator-1-α (PGC-1α) is an important 
regulator of mitochondrial biogenesis which is activated by AMPK (Jäger et al. 
2007; Zong et al. 2002). Additionally, mitochondria function is important for 
synaptic plasticity and its deregulation has been associated with numerous 
neuropathologies Consequently, I investigated whether the neurological phenotype 
of 1q21.1 CNV carriers could be associated with abnormal mitochondrial function, at 
least for the Del LBL exhibiting compromised AMPK function. 
Interestingly, reduced mitochondrial content has been observed in AMPK β2 
deficiency mice (although more significantly so after β1 or combined β1β2 
knockdown) associated with reduced mitochondrial citrate synthase and cytochrome 
c oxidase activity (O'Neill et al. 2011).  
I used mitochondrion-specific fluorescent dyes (MitoTracker, Invitrogen) to 
characterize mitochondria function/status in LBLs with 1q21.1 Dup or Del, using 
flow cytometry. MitoTracker Red probe accumulation in the mitochondria of live 
cells is indicative of the status of the mitochondrial transmembrane electrical 
potential.  MitoSox dye selectively detects superoxide in the mitochondria, indicative 
of mitochondria-derived ROS generation as a by-product of oxidative 
phosphorylation.  MitoTracker Green FM Dye is used to determine mitochondrial 
mass (i.e. amount of mitochondria within the cells).  The intensity of MitoTracker 
Red and MitoSox fluorescence in both 1q21.1 Dup and 1q21.1 Del LBLs was 
comparable to control (WT) LBLs, suggesting normal mitochondria activity. This 
data does not suggest impaired mitochondria function in 1q21.1 CNV LBLs. 
However, the modest increased relative MitoGreen fluorescence in 1q21.1 Dup LBL, 
compared to WT levels, suggests a potential increase in total mitochondria mass in 
these cells, although the significance of this is yet not clear. However, importantly, 
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1q21.1 deletion does not seem to negatively impact on mitochondrial mass or 
function. 
 
 
      
 
    
 
Figure 8.2.3.  Characterization of mitochondria function in 1q21.1 Dup and Del LBLS. 
WT, 1q21.1 Dup and 1q21.1 Del LBLs were stained with different mitochondrion selective probes 
(MitoTracker®, Invitrogen). a) MitoTracker Red dye, which is sensitive to mitochondrial membrane 
potential; b) MitoSox, indicates intracellular superoxide formation and c) MitoGreen, associated with 
total mitochondria mass, and the fluorescence was determined by FACS analysis. d) relative 
fluorescence intensity for the different mitochondria staining dyes in control, 1q21.1 Dup and 1q21.1 
Del LBLs indicates normal mitochondrial function in these CNV carrier lines. 
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8.3 Summary 
 
1q21.1 Copy Number Variant (CNV) is associated with a highly variable 
phenotype. 1q21.1 CNV carriers exhibit learning problems/ intellectual disability 
(ID) of various degrees, congenital anomalies, dysmorphic features, making the 
clinical significance of this CNV difficult to evaluate.  
Here I describe the consequences of the 1q21.1 CNV on gene expression and 
function of a selected candidate gene within 1q21.1 (PRKAB2) using cell lines from 
clinically well described subjects. 
I show that the 1q21.1 CNV can not only cause changes in the expression of 
one of the genes within the CNV, but also results in changes in their known function, 
as exemplified by impaired AMPK activation in the 1q21.1 Del LBLs. 
Haploinsufficiency of PRKAB2 results in reduced expression of AMPK-β2, which is 
associated with impaired AICAR-induced AMPK activation. In contrast, duplication 
of PRKAB2 did not negatively impact on AMPK activity under these conditions. 
Preliminary data suggests mitochondria function is not impaired in 1q21.1 CNV 
carriers. These results support the use of patient lymphoblasts for dissecting the 
functional consequences of genes integral to CNVs in carrier cell lines, ultimately 
increasing understanding of biological processes which may contribute to the clinical 
phenotype. 
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8.4 Discussion 
 
Copy Number Variation of chromosomal region 1q21.1 is associated with a 
highly variable phenotype (Mefford et al. 2008). Learning difficulties and intellectual 
disability (ID) of various degrees are one of the most commonly observed features of 
1q21.1 CNV carriers. Congenital heart anomalies, developmental delay, dysmorphic 
features, schizophrenia, behavioral abnormalities or even a normal phenotype, have 
also been associated with 1q21 CNV (Christiansen et al. 2004; Brunet et al. 2009; 
Stefansson et al. 2008; Mefford et al. 2008). Additionally, microcephaly and 
macrocephaly have been observed in subjects carrying microdeletions or 
microduplications of this region, respectively (Brunetti-Pierri et al. 2008). The broad 
clinical presentation of 1q21.1 CNV carriers means that the biological consequences 
of 1q21.1 CNV have been difficult to establish. 
 Recently, whole transcriptome expression analysis was performed in carriers of 
1q21.1 deletion and 1q21.1 duplication (Harvard et al. 2008). This study allowed the 
identification of a core group of genes in the critical region, which could be ranked 
based on correlation of expression and 1q21.1 copy number change. 
 CHD1L was the gene that ranked highest in the expression/ 1q21.1 copy 
number correlation.  CHD1L/ALC1 is an enzyme involved in chromatin 
modification and the DNA damage response. Functional studies in 1q21.1 CNV 
LBLs established a new role for CHD1L in chromatin untangling (decatenation), 
whereby 1q21.1 Del and Dup containing patient cell lines exhibited a defective Topo 
II decatenation checkpoint (Harvard et al. 2008). Similar decatenation checkpoint 
defects have been observed in Werner syndrome (Franchitto et al. 2003). 
As part of that study (manuscript included in the Publications section), in this 
chapter I characterized aspects of AMPK functionality in cell lines from 1q21.1 
CNV carriers (deletion and duplication), whose critical region includes PRKAB2, the 
gene that codes for the β subunit of AMPK. PRKAB2 ranked 10th in the 
expression/1q21.1 copy number correlation (Harvard et al. 2008). 
 AMPK is a key regulator of cellular response to a large number of external 
stimuli, which modulates energy levels at the cellular and organism level. I found 
deregulation of AMPK-β2 expression in the 1q21.1 deletion and duplication carriers. 
Changes in levels of AMPK-β2 protein were observed, in keeping with the 1q21.1 
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copy number state and expression level of the PRKAB2 gene. Phosphorylation of 
AMPK-α on Thr172 is an essential modification required for AMPK activation 
(Young et al. 2009). Both 1q21.1 Del and Dup containing lines exhibit different 
basal levels of p-T172-AMPK-α in comparison to control (WT) cells. Furthermore, 
AICAR-induced phosphorylation of the AMPK substrates ACC and RAPTOR was 
sub-optimal, specifically in the 1q21.1 Del containing line. The last observation 
could be explained by the fact that AMPK, as a multi protein complex, may be 
sensitive to imbalances of its components and that reduced availability of a 
regulatory β-isoform, as occurs here, could impact on AMPK activity more than its 
over-abundance. Interestingly, reduced AMPK activity in the skeletal muscle was 
observed in AMPK-β2 knockout mice, associated with insensitivity to AICAR 
treatment (Dasgupta et al. 2012).  
 The multifaceted nature of AMPK role in brain function is of particular interest 
to the 1q21.1 phenotype, which most consistently includes some form of learning 
difficulty (Ronnett et al. 2009). Interestingly, the mouse AMPK-β2 subunit is 
moderately expressed by most neurons, with the exception of the cerebellar Purkinje 
cells which express very high levels of AMPK-β2 (Turnley et al. 1999). Previous 
studies showed that alternations of AMPK activity resulted in profound 
abnormalities of the central nervous system in AMPK-β1 knockout mice (Dasgupta 
et al. 2009), which had a reduction of AMPK activity, whereas the consequences of 
AMPK activation remain controversial as some groups have shown that AMPK 
activation is neuroprotective while others show that AMPK overactivation is 
detrimental (Ronnett et al. 2009). The essential role of AMPK in brain function is 
further supported by its inhibition of the mTOR pathway (Kahn et al. 2005), which is 
required for learning and memory . 
 AMPK has also an established role in modulation of aspects of mitochondria 
function and mitochondrial biogenesis, and abnormal mitochondria function has been 
observed in a number of neurological and psychiatric disorders (Qi et al. 2010; 
Mattson et al. 2008). Evaluation of mitochondria function in 1q21.1 CNV carriers 
using mitochondria-specific dyes suggests mitochondria function is not grossly 
impaired in LBL‟s from 1q21.1 CNV carriers: it would be very interesting to know if 
this was the case in patient‟s neurons. 
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 Our studies are the first to report that the function of two genes (CDH1L and 
PRKAB2) integral to 1q21.1 CNV are changed in patient lymphoblasts and that both 
genes are likely to be dosage sensitive. Both genes are expressed in multiple tissues, 
including brain (Dasgupta et al. 2009), which may explain the multi-systemic nature 
of the physical abnormalities, and the frequent involvement of learning difficulty 
albeit at a very variable levels. It remains uncertain as to the tissue-specific 
consequences of gene function changes in individuals with 1q21.1 CNV although 
AMPK is clearly involved in brain development and homeostasis.  
 
 The phenotypic variability for some CNVs has been traditionally explained by 
genetic and environmental factors (Iascone et al. 2002). In that respect it is of interest 
to note that CHD1L and PRKAB2 have a role in sensing and responding to genomic 
(chromosomal structure) and metabolic (energy level) stress and therefore their 
dysfunction may result in a more severe phenotype in individuals, which experienced 
more adverse environmental conditions during development. Sequence changes of 
other genes from the 1q21.1 region as well as other genes across the genome that 
impair their function cannot be ruled out as a source of variability at this time and the 
new whole genome sequencing technologies will no doubt become useful in future 
investigations of their contribution to the development of an abnormal phenotype. 
My findings could prompt the use of AMPK activity modify therapies in animal 
models of this CNV. For example the use of AMPK activators in the case of 
PRKAB2 deletion. 
 
In conclusion, I provided evidence of changes in the function of a gene from 
1q21.1 CNV in lymphoblasts from both deletion and duplication carriers. Deletions 
and duplications can have similar (e.g. CHD1L-associated DCC deficiency in 1q21.1 
Del and Dup containing LBCs) as well as differing functional consequences (e.g. 
PRKAB2-associated less responsive AICAR-induced AMPK activity in 1q21.1 Del 
containing LBLs) depending on the genes and pathways involved. These results 
support the use of patient lymphoblasts for dissecting the functional sequelae of 
genes integral to CNVs in carrier cell lines, ultimately enhancing understanding of 
biological processes, which may contribute to the clinical phenotype.  
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Chapter Nine 
Discussion: Understanding at the molecular level 
the clinical consequences of defective ATR 
function in humans 
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Discussion 
This thesis provided novel insights on how defective ATR function can 
manifest in the specific set of clinical features that are observed in some forms of 
microcephalic primordial dwarfism (MPD). 
A hypomorphic ATR-mutation causes a form of MPD classified as Seckel 
syndrome; which is linked to a defective ATR-dependent DNA damage response 
(O'Driscoll et al. 2003). Significantly, other forms of MPD have been associated with 
impaired ATR-dependent function, even when the causative mutation is not in ATR 
per se. This is observed for example in PCNT-mutated MOPDII (Griffith et al. 
2008), and ORC1-mutated MGS. Collectively, this signifies that compromised ATR 
function is linked to profound growth delay, severe microcephaly with mental 
retardation, and skeletal abnormalities. 
Atr depletion in mice results in replicative stress during embryogenesis, with 
accumulation of DNA damage and increased apoptosis (Murga et al. 2009). This 
could account for a considerable depletion of the stem cell pool, particularly during 
neurogenesis, as well as loss of total cellularity, which could underlie some of the 
clinical features seen in Seckel syndrome. However, the disproportionate impact on 
the skeletal tissue is not fully explained by this mechanism. Furthermore, recent 
studies have suggested an expansion of the ATR (and ATM) functional network 
beyond the DNA damage response (Matsuoka et al. 2007), which should prove of 
crucial interest for the understanding of all the signaling pathways involved. 
Therefore, and in order to investigate the genotype-to-phenotype relationship in 
MPD, I examined in particular whether ATR function is required specifically for 
skeletal development.  
In Chapter 3 I showed that ATR inhibition did not compromise initiation of 
osteogenesis in MG-63 osteosarcoma cells, but there was some indication that 
maintenance of the differentiated status was not fully supported in ATR deficient 
cells. This could be an interesting observation in the context of the osteoporosis 
condition, defined as pathological loss of bone mass, which was observed after 
conditional Atr knockdown in adult mice (Ruzankina et al. 2007). Still on chapter 3, 
I presented findings derived from an optimized chondroinduction model system that 
allowed de-differentiation of MPD-derived fibroblastic lines into chondrocytes. 
Analysis of several markers of chondrogenic differentiation suggested that ATR-S 
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and PCNT-S patient cells are not able to efficiently form chondrocytes, when 
compared to control fibroblasts. These observations were confirmed by ATR and 
PCNT knockdown in control cells.  
HIF-1α promotes chondrocyte survival in the hypoxic fetal growth plate 
(Schipani 2006), and its expression is induced under normoxic conditions in my 
chondroinduction system Significantly, both ATR-S and PCNT-S patient derived 
cells fail to adequately induce HIF-1α, and VEGF expression (required for 
recruitment of blood vessels to the growth plate). This data suggests a serious 
problem in the regulation of the hypoxia response in ATR-function deficient cells, 
and altogether an impact of ATR depletion in several aspects of cartilage 
differentiation. Additionally, I provided evidence for the first time suggesting that 
defective ORC1 function, seen in MGS; as well as impaired IFT43, in the context of 
Sensenbrenner syndrome, are also associated with aberrant chondroinduction. Since 
the majority of the bones in the skeleton are formed using a cartilage template, a 
defect specifically in chodrogenesis would effectively result also in compromised 
bone formation and skeletal abnormalities. Interestingly, some forms of MPD, 
namely Meier-Gorlin syndrome, exhibit distinguishing defects in cartilaginous 
tissues, such as the absence of ear lobes, hypoplastic ears and small and/or absent 
kneecaps (Faqeih et al. 2005). 
Importantly, all these phenotypes are disengaged from ATR‟s (as well as 
PCNT‟s and ORC1‟s) role during replication - since induction of chondro-
differentiation is accompanied by exit from the cell cycle - and are therefore not 
associated with replicative stress. 
My novel findings provide a cell-based model to help explain the origin of 
skeletal abnormalities in multiple MPD‟s, and establish a previously unsuspected 
role for ATR function in differentiation processes, specifically its involvement in 
skeletogenesis via chondrogenesis. 
 
RTK signaling via the PI3K-AKT-mTOR pathway is essential for regulation 
of cell and organismal growth, and mutations in some components of this pathway 
can also result in growth retardation or dwarfism. Interestingly, numerous novel 
substrates for ATR phosphorylation in response to DNA damage are components of 
the insulin-AKT-mTOR network, although the biological significance of these 
interactions is yet unknown. 
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Affected insulin/IGF-dependent signaling in the context of ATR depletion 
has been insinuated in the literature. The humanized ATR-Seckel mouse has a 
suppressed growth hormone-IGF1 axis, and acanthosis nigricans, linked to insulin 
resistance, has been reported in Seckel syndrome patients. Furthermore, in Chapter 3 
I showed that some crucial chondrogenic events are under PI3K/AKT regulation, and 
these are also being misregulated in ATR-S cells. Conversely, Igf-1 and Irs mutant 
mice exhibit a severe growth phenotype (Kitamura et al. 2003). 
 Analysis of insulin-dependent PI3K-AKT-mTOR signaling in ATR-defective 
and PCNT-defective lines (Chapter 4) revealed deregulation of this important signal 
transduction pathway in MPD. Defects in this pathway may also underlie some of the 
clinical features observed in these patients. Interestingly, the two MPD lines 
exhibited a distinct pattern of deregulation/unresponsiveness throughout the PI3K-
AKT-mTOR signal transduction, suggesting that different mechanisms could 
account for the defect in insulin response in ATR-S and PCNT-S. 
 In ATR-deficient cells, over-activation of the tuberous sclerosis complex 
(TSC1/TSC2), the principal negative regulator of mTORC1, results in unresponsive 
mTORC1-mediated phosphorylation of S6K. I also found evidence of endogenously 
elevated phosphorylation of S6K in ATR-S, which was not inhibited by short 
treatment with rapamycin under the conditions assessed, compared to control cells. 
Importantly, hyper or prolonged activation of S6K can result in inhibition of insulin-
receptor mediated signaling, and has been associated with insulin resistance in type 
II diabetes (Shah et al. 2004). Although a mechanism for how ATR signal 
impairment can result in TSC2/TSC1 over-activation is not proposed here, it is 
noteworthy that TSC1 was identified as a direct substrate for ATR phosphorylation 
in response to DNA damage (Matsuoka et al. 2007). This suggests a previously 
unsuspected link between these two molecules, and pathways, whose biological 
significance is yet unknown. Interestingly, at least one study has shown that 
inhibition of the ATR-related ATM kinase results in decreased IGF-1 receptor 
expression (Peretz et al. 2001). 
 With regards to PCNT-S, insulin-dependent signaling is specifically 
compromised by failure to activate PI3K. Furthermore immunofluorescence studies 
in these cells revealed significantly reduced levels of PI3K. This indicates a serious 
defect impacting on an upstream event in this signaling pathway, and which could 
also affect other signaling cascades that are PI3K-signaling dependent. I confirmed a 
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direct interaction between PCNT and PI3K, by immunoprecipitation, and observed 
also reduced PI3K expression following PCNT depletion in an independent cell line. 
Interestingly, PCNT-mutated MPD has been specifically associated with severe 
insulin-resistance and diabetes (Huang-Doran et al. 2011). Decreased levels of PI3K 
could contribute to the insulin-resistance and diabetes phenotype in these patients. 
 Altogether, impaired insulin-mTOR signaling in ATR and PCNT-defective 
cells constitute a novel pathomechanism for ATR and PCNT-defective MPD, which 
could contribute to the severe dwarfism as well as some of the other phenotypes 
observed in these patients, namely insulin resistance, and skeletal defects. 
Severe growth retardation, and microcephaly, the defining features of MPD, 
are also manifested at various levels in metabolic disorders of the mTOR pathway, 
such as Donohue syndrome (DS), which is caused by mutations in the insulin 
receptor (INSR). I analyzed cells derived from DS patients to further investigate the 
level of crosstalk and the functional relationship between the ATR-dependent DDR 
and mTOR pathway function (Chapter 5). 
 Surprisingly, INSR-mutant LBLs (and INSR-knockdown cells) are defective 
in the ATR-dependent activation of the G2/M checkpoint. This was also the case for 
PTEN-deficient Cowden‟s disease LBLs. PTEN has been shown to have a role in this 
checkpoint, whereby PTEN depletion results in cytoplasmic sequestration of CHK1, 
therefore impairing CHK1-mediated checkpoint activation (Puc et al. 2005). 
Importantly, loss of checkpoint proficiency could be a source of genomic instability 
in these cells, with implications for the high cancer predisposition observed in 
Cowden‟s disease and other PTEN-hamartoma diseases. 
 A novel mechanism for the regulation of the ATR-dependent G2/M 
checkpoint in INSR-defective cells was suggested here by my findings. I proposed 
that ATR/GSK-3β signaling mediates an enhancement of the ATR/CHK1-dependent 
activation of the G2/M cell cycle checkpoint, acting downstream or parallel to CHK1 
activation by ATR by directly phosphorylating CDC25A and targeting it for 
proteasomal degradation. Consequently, loss of the contributing effect of GSK-3β 
down-regulation of CDC25A levels results in increased activation of the 
CDK1/CyclinB complex and premature entry into mitosis. Furthermore, this was 
dependent on AKT increased activation in DS cells, either due to lack of INSR-
mediated feedback inhibition of the pathway, and/or via compensatory AKT 
phosphorylation from PDK1. I found AKT phosphorylation is induced in WT cells 
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following UV irradiation, which is translated in increased inhibition of its 
downstream target GSK-3β. Notably, in DS cells this effect is enhanced. Inhibition 
of GSK-3β (via siRNA, or use of specific inhibitors) replicated the checkpoint defect 
in control cells; and treatment with a specific AKT inhibitor rescued the checkpoint 
defect in INSR-defective cells.  
Surprisingly, AKT inhibition also rescued the ATR-dependent checkpoint 
defect in PCNT-S cells, but not in ATR-S cells. This data further suggested that 
different mechanisms underlie the DDR defect in ATR and PCNT-defective 
SS/MOPDII cells; and is consistent with a defect in PCNT-S cells affecting a more 
upstream point in the insulin-PI3K-AKT cascade, likely the PI3-kinase itself, as 
suggested in Chapter 4. 
AKT hyperactivation has been shown to override cell cycle checkpoints and 
promote cell proliferation in the presence of DNA damage (Xu et al. 2010; Xu et al. 
2012). It is likely that the level of basal AKT activation is important in modulating 
this response. It is possible that the levels of AKT activation in DS were not 
sufficient to surpass the ATM-dependent DDR signal, which is activated in response 
to extensive DSB-inducing DNA damage.  
 A clearer understanding of how AKT is able to modulate the DDR could 
have broader implications, as AKT activation has been associated with enhanced 
proliferation and survival in tumor cells, and genomic instability, which could also 
derive from impaired checkpoint proficiency. 
 
 A novel cellular defect has been linked to the particular clinical presentation 
of microcephaly and growth retardation in a syndromal context: a newly described 
microcephalic disorder caused by mutations affecting the endosome-associated 
deubiquitinating enzyme, STAMBP. Microcephaly-capillary malformation syndrome 
(MIC-CAP) patients exhibit severe microcephaly, intractable seizures, post-natal 
growth retardation and extensive vascular malformations (Carter et al. 2011; Isidor et 
al. 2011; Mirzaa et al. 2011) 
Functional analysis of cell lines derived from MIC-CAP individuals (Chapter 
6) revealed elevated ubiquitin-conjugated protein aggregation, increased 
autophagosome formation, and elevated apoptosis induced by nutrient depletion. 
Elevated apoptosis is a recognized cause of microcephaly (Kuida et al. 1998; Schmitt 
et al. 2006; Silver et al. 2010; Cox et al. 2006). Additionally, autophagic clearance of 
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accumulated protein aggregates is an important mechanism disrupted in 
neuropathologies and neurodegenerative conditions such as Alzheimer‟s, Parkinson‟s 
and prion disease (Ventrutti et al.2007). Therefore it is probable that these cellular 
phenotypes could cause progressive apoptosis in neuronal cells, and be important 
contributors to the microcephaly, mental retardation and seizure phenotype exhibited 
by MIC-CAP patients. 
Furthermore, active and insensitive RAS-MAPK and PI3K-AKT pathway 
signaling were also observed in STAMBP-mutated LBLs. These phenotypes could 
contribute to the vascular defects and growth delay in MIC-CAP, and justify the 
inclusion of MIC-CAP in the class of disorders known as RASopathies. Hyperactive 
RAS signaling is a known instigator of oncogenic transformation. Although the 
cancer susceptibility in MIC-CAP is not known, it is likely that the increase in RAS-
MAPK signaling is stable but discrete when compared to the more aggressive signal 
derived from oncogenic RAS mutations; and therefore more in keeping with the level 
of RAS activation in the other RASopathies. Nevertheless, increased tumor 
susceptibility is also a feature of most RASophaties, and therefore potentially of 
MIC-CAP as well. 
Chronically activated signaling via internalized cell surface receptors, due to 
lack of STAMBP function, could provide a mechanism to explain the elevated 
activation of these signaling pathways. 
 Surprisingly, MIC-CAP patient LBLs also exhibit defective ATR-dependent 
G2/M checkpoint activation, which was not in this case mediated by elevated AKT 
signaling, as indicated by inhibitor studies. It is possible that defective DDR response 
may have a role in the development of microcephaly also in MIC-CAP. The brain 
abnormalities in Stambp
-/-
 mice are region-specific, with marked cerebral neuron loss 
and degradation of the CA1 hippocampal layer, with relative sparing of other CNS 
tissues such as the hippocampus (Busino et al. 2003; Suzuki et al. 2011; Ishii et al. 
2001). In a recent study, conditional depletion of Atr throughout the mouse CNS 
revealed a relatively late and selective impact of ATR function during neurogenesis 
(Lee et al. 2012), involving only certain progenitor populations. The authors 
therefore refuted the suggestion that ATR‟s role in this process is the general 
prevention of replicative stress, but rather involves a regulated surveillance of 
genomic integrity in particular tissues and in a time-dependent manner. The 
mechanistic association between STAMBP-function and checkpoint activation 
216 
 
remains unclear, but it suggests a previously unknown route to cell cycle 
dysfunction. Importantly, a pool of STAMBP has been found to localize to the 
nucleus, suggesting additional and yet unknown functions for STAMBP at this site 
that could potentially be relevant for DNA repair pathways. 
This study expands the list of known microcephalic disorders associated with 
defective ATR-dependent DDR; presents the first example of a human disorder 
caused by congenitally-defective endosome-associated DUB; and highlights an 
important functional interplay between RTK-mediated signal transduction and the 
ATR-dependent DDR, which could provide significant new insights into the 
pathophysisology of human microcephaly. 
PI3K (PIK3CA; PIK3R2) and AKT3 mutations were recently found in two 
related megalencephaly disorders (MCAP and MPPH). This suggests a key function 
of the PI3K-AKT-mTOR signaling pathway in the regulation of brain abnormalities, 
but also limb and vascular defects. Indeed components of this pathway have been 
implicated in human overgrowth syndromes, such as Proteus syndrome (caused by 
an activating AKT1 mosaic mutation), the PTEN-hamartoma diseases, including 
Cowden‟s disease and autism with severe megalencephaly (Peng et al. 1997; 
Lindhurst et al. 2011; Cazales et al. 2005; Butler et al. 2005; Smith et al. 2009; 
Orrico et al. 2009).  
Analysis of a panel of PIK3CA, PIK3R2, and AKT3 mutated megalencephaly 
patient-derived LBLs (Chapter 7) established an association between brain 
overgrowth and increased activation of PI3K-AKT-mTOR signaling. Mutations in 
PI3K subunits (PIK3CA, PIK3CB, PIK3CD, PIK3R1 and PIK3R2) have been 
observed in many human cancers (Cancer Genome Atlas Research Network 2008), 
but until now not in individuals with developmental disorders. Presently however, 
new mosaic gain-of-function mutations in PIK3CA have also been implicated in 
other distinct overgrowth conditions: hemimegalencephaly patients (also mutations 
in mTOR and AKT3) (Lee et al. 2012), mosaic overgrowth disorder with fibroadipose 
hyperplasia (Lindhurst et al. 2012), congenital lipomatous overgrowth with vascular, 
epidermal, and skeletal anomalies (CLOVES) syndrome (Kurek et al. 2012) and 
macrodactyly (Rios et al. 2012). 
 
Interestingly, analysis of megalencepahly patient LBLs revealed also an 
inefficient ATR-dependent G2/M checkpoint activation. Cowden‟s disease and other 
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disorders associated with PTEN deficiency, share clinical features with MCAP and 
MPPH, including brain overgrowth, and have also been associated with defects 
specifically in the ATR-dependent G2/M checkpoint (see Chapter 5). It is possible 
that the checkpoint defect observed in these particular disorders could be linked to 
increased AKT activation, which has been known to surpass cell cycle checkpoints 
and induce mitosis in the presence of types of DNA damage (Kandel et al. 2002). 
The data presented in this thesis with regards to megalencephaly may further support 
the importance of an efficient DNA damage response during normal brain 
development.  Furthermore, it extends the list of human overgrowth syndromes 
associated with aberrant PI3K/AKT signaling, demonstrating that dysfunction of 
PI3K/AKT pathway signaling causes a constellation of brain, vascular and limb 
malformations. These findings combined with the development of inhibitors for 
PI3K, AKT or downstream targets such as mTORC1 could provide new therapeutic 
opportunities for megalencephaly as well as other developmental syndromes.  
 
Curiously, both brain reduction as well as brain overgrowth have been here 
associated with increased signaling via the PI3K/AKT pathway (MIC-CAP vs 
MCAP/MPPH). 
Syndromes with dramatic PI3K-AKT pathway hyperactivity are often 
associated with cell or organism overgrowth (e.g. Cowden‟s disease, tuberous 
sclerosis, Peutz-Jehgers syndromes). In contrast, disorders characterized by pure 
RAS-MAPK hyperactivity such as Noonan and Costello are associated with delayed 
development, short stature, and heart and vascular abnormalities. It is possible that 
the biological contribution of PI3K-AKT activation in MIC-CAP is counterbalanced  
by RAS-MAPK-dependent signaling, and importantly, by the elevated accumulation 
of ubiquitinated protein aggregates, defective ATR-dependent checkpoint activation,  
and resulting elevated apoptosis in STAMBP-deficient cells, which would be primary 
contributing factors to the clinical presentation of micro-(instead of macro)cephaly, 
growth retardation and vascular problems. Furthermore, a comparison between the 
levels of PI3K-AKT activation between microcephalic MIC-CAP and the 
megalencephaly disorders, might reveal another distinction between these disorders 
that could result in opposing phenotypes. Integration of all the inputs from the 
different intervening and interconnected signal transduction pathways, likely tips the 
phenotypic outcome in one direction vs another with respect to growth regulation.  
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ATR-dependent signaling is sensitive to haploinsufficiency for genes 
associated with ATR function (e.g. RPA, and ATR itself). This is seen in a set of 
happloinsufficient contiguous deletion disorders, such as Miller-Dieker lissencephaly 
and Williams-Beuren syndromes (O'Driscoll et al. 2007), which are also associated 
with microcephaly and growth retardation, among other distinctive features. 
Copy Number Variation of DNA sequences (generally encompassing large 
regions >1Kb) are common occurrences that contribute to normal genomic variation. 
Additionally, these structural alterations in the human genome are commonly found 
in cancers (Stankiewicz et al. 2010; Colnaghi et al. 2011), but also in congenital 
Genomic Disorders, often accompanied by complex phenotypic traits (Colnaghi et al. 
2011). Therefore the impact of CNV on dosage-sensitive pathways/processes, could 
also provide an important insight into the biological processes that contribute to 
particular clinical features. 
1q21.1 Copy Number Variant (CNV) is associated with a highly variable 
phenotype. 1q21.1 CNV carriers exhibit learning problems/ intellectual disability 
(ID) of various degrees, congenital anomalies, dysmorphic features, making the 
clinical significance of this CNV difficult to evaluate.  
In Chapter 8 I show that the 1q21.1 CNV can not only cause changes in the 
expression of one of the genes within the CNV, but also results in changes in their 
known function, as exemplified by impaired AMPK activation in the 1q21.1 Del 
LBLs. AMPK is involved in brain development and homeostasis and can impact on 
mTOR function. My findings could prompt the use of AMPK activity modify 
therapies in animal models of this CNV. For example the use of AMPK activators in 
the case of PRKAB2 deletion. Furthermore, this study supports the use of patient 
lymphoblasts for dissecting the functional consequences of genes integral to CNVs 
in carrier cell lines, ultimately increasing understanding of biological processes 
which may contribute to the clinical phenotype. 
 
 
The data provided in this thesis and ongoing research shows that the 
investigation of the basic mechanisms that regulate cell and organismal growth can 
benefit from studies of MPD and human overgrowth disorders. The re-evaluation of 
the roles of some of the MPD-causative genes at the cellular and developmental 
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levels was also proposed, exemplified by ATR‟s impact on specific differentiation 
processes (namely chondrogenesis) but also defects in fundamental replication 
proteins such as ORC1, which cause reduced growth and specific developmental 
abnormalities. Additionally, novel links were established between the DNA damage 
response and defects in such distinct proteins as the insulin receptor, and the 
endosome-associated deubiquitinase STAMBP, thereby implicating distinct cellular 
mechanisms and pathways in the regulation of these processes, with direct relevance 
to human health. 
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